



CASE  
COMPREHENSIVE  
CANCER CENTER



### American Society of Hematology (ASH) Annual Meeting

Dec 1-4, 2018

<http://www.hematology.org/Annual-Meeting/Program/>

\*\*Case CCC Members in **BOLD**; Presenter UNDERLINED\*\*

#### PRESENTATIONS/SESSION CHAIRS

##### **Matt Kalaycio, MD**

Case Comprehensive Cancer Center, Cleveland Clinic

Chair and Speaker, [\*Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies\*](#)

Friday, Nov 30, 2018, 7-11 am; Hyatt, Coronado Ballroom, A-C

##### **Hetty E. Carraway, MD, MBA**

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [\*Hematology Oncology Training Program Directors Workshop\*](#)

Friday, Nov 30, 2018, 11 am-2 pm; Petco Park, The Auditorium

Speaker, [\*Blood Drops: Career 101: Early career planning topics; Knocking Your Fellowship Interview Out of the Park: Tips to Make Sure Your Interview Day Is a Homerun\*](#)

Friday, Nov 30, 2018, 3:30-3:45 pm; Western Metal Concourse (Petco Park)

##### **Alok Khorana, MD**

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [\*What's New in VTE? Evaluating the Latest Evidence and Grades of Recommendation\*](#)

Friday, Nov 30, 2018, 12:30-4:30 pm; Hyatt, Coronado Ballroom, A-C

##### **Mikkael A. Sekeres, MD, MS**

Case Comprehensive Cancer Center, Cleveland Clinic

Co-Chair, Education Program

Speaker, [\*Blood Drops: Wellness: Topics to help your well-being; Telling It Like It Is: Essays About Medicine\*](#)

Friday, Nov 30, 2018, 1:30-1:45 pm; Western Metal Concourse (Petco Park)

Co-Chair, [\*Late-Breaking Abstracts Session\*](#)

Tuesday, Dec 4, 2018, 7:30-9:00 am; San Diego Convention Center, Hall AB

##### **Anne T Neff, MD**

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [\*Blood Drops: Hematology 201: A mid-level clinical topic\*](#)

Friday, Nov 30, 2018, 1:30-4:45 pm; Western Metal Concourse (Petco Park)

##### **Aziz Nazha, MD**

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [\*Blood Buddies/Mentor Session 1; Adult Clinical Malignant Hem\*](#)

Friday, Nov 30, 2018, 2:30-3:00 pm; Section 124 – The Porch (Petco Park)

Speaker, [Blood Buddies/Mentor Session 2; Adult Clinical Malignant Hem](#)

Friday, Nov 30, 2018, 3:30-4:00 pm; Section 124 – The Porch (Petco Park)

Speaker, [The MDS Genomics-Prognosis Symbiosis; The Molecular Maelstrom of Myelodysplastic Syndromes \(MDS\)](#)

Saturday, Dec 1, 2018, 4:00-5:30 pm; San Diego Convention Center, Room 6A

Sunday, Dec 2, 2018, 9:30-11 am; San Diego Convention Center, Room 6A

**Keith R. McCrae, MD**

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Blood Buddies/Mentor Session 1; Laboratory & Translational Hem](#) and [Adult Clinical Non-Malignant Hem](#)

Friday, Nov 30, 2018, 2:30-3:00pm; Section 124 – The Porch (Petco Park)

Speaker, [Blood Buddies/Mentor Session 2; Laboratory & Translational Hem](#) and [Adult Clinical Non-Malignant Hem](#)

Friday, Nov 30, 2018, 3:30-4:00pm; Section 124 – The Porch (Petco Park)

Chair, [Scientific Committee on Thrombosis and Vascular Biology: Microparticles and Exosomes: Ready for the Clinic?](#)

Saturday, Dec 1, 2018, 9:30-11:00 am; San Diego Convention Center, Room 24B

Saturday, Dec 1, 2018, 4:00-5:30 pm; San Diego Convention Center, Room 11B

Co-Chair and Speaker, [Special Symposium on the Basic Science of Hemostasis and Thrombosis; Best of ASH in Hemostasis and Thrombosis 2](#)

Monday, Dec 3, 2018, 4:30-6:30pm; San Diego Convention Center, Room 30D

**Navneet Majhail, MD**

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Career-Development Lunch Session Ballroom AB: Adult Clinical Malignant Hematology/BMT](#)

Saturday, Dec 1, 2018, 11:15 am-12:15 pm; Sapphire Ballroom AB (Hilton San Diego Bayfront)

**Alvin H. Schmaier, MD**

Case Comprehensive Cancer Center, Case Western Reserve University

Chair, [Scientific Committee on Hemostasis: Vascular Biology Components of Hemostasis](#)

Saturday, Dec 1, 2018, 2:00-3:30 pm; San Diego Convention Center, Room 31B

Sunday, Dec 2, 2018, 7:30-9:00 am; San Diego Convention Center, Room 31B

Co-Chair and Speaker, [Special Symposium on the Basic Science of Hemostasis and Thrombosis; Best of ASH in Hemostasis and Thrombosis 1](#)

Monday, Dec 3, 2018, 4:30-6:30pm; San Diego Convention Center, Room 30D

**Mukesh Jain, MD**

Case Comprehensive Cancer Center, University Hospitals, Case Western Reserve University

Speaker, [Scientific Committee on Hemostasis: Vascular Biology Components of Hemostasis; Krüppel-Like Factors in Thrombosis and Hemostasis](#)

Saturday, Dec 1, 2018, 2:00-3:30 pm; San Diego Convention Center, Room 31B

Sunday, Dec 2, 2018, 7:30-9:00 am; San Diego Convention Center, Room 31B

**Betty K. Hamilton, MD**

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Current Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation: Reining in Graft-Versus-Host Disease \(GVHD\) After Allogeneic Hematopoietic Cell Transplantation](#)

Sunday, Dec 2, 2018 7:30-9:00 am; Manchester Grand Hyatt San Diego, Grand Hall D  
Monday, Dec 3, 2018 10:30 am-12:00 pm; Manchester Grand Hyatt San Diego, Grand Hall D

**Aaron T. Gerds, MD, MS**

Case Comprehensive Cancer Center, Cleveland Clinic  
Chair, [Social Media for the Hematologist: Today and in the Future](#)

Sunday, Dec 2, 2018, 11:15-12:15 pm; San Diego Convention Center, Room 28D

**Sudipto Mukherjee, MD, PhD, MPH**

Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, [Population Risks of Developing Myeloid Malignancies; From Fat Man to Agent Orange and Beyond: When Myeloid Malignancies Strike](#)

Sunday, Dec 2, 2018, 4:30-6:00 pm; San Diego Convention Center, Room 11B

**Eric Kodish, MD**

Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, [Ethical Conundrums in Pediatric Genomics; Using Genomics to Risk Stratify and Treat Kids](#)  
Sunday, Dec 2, 2018, 9:30-11:00 am; Marriott Marquis San Diego Marina, San Diego Ballroom B  
Monday, Dec 3, 2018, 7:00-8:30 am; Marriott Marquis San Diego Marina, San Diego Ballroom 21

**ORAL ABSTRACTS – CASE CCC PRESENTER (with CASE CCC CO-AUTHORS)**

**[33 Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp \(Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine\) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia](#)**

Program: Oral and Poster Abstracts

Type: Oral

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Improving Frontline Therapy in ALL

Hematology Disease Topics & Pathways: antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Lymphoid Malignancies

Saturday, December 1, 2018: 8:00 AM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

**Anjali S. Advani, MD<sup>1</sup>, Anna Moseley, M.S.<sup>2\*</sup>, Kristen Marie O'Dwyer, MD<sup>3</sup>, Brent Wood, MD PhD<sup>4\*</sup>, Min Fang, MD, PhD<sup>5</sup>, Matthew J. Wieduwilt, MD, PhD<sup>6</sup>, Ibrahim Aldoss, MD<sup>7</sup>, Jae H. Park, MD<sup>8</sup>, Rebecca Klisovic, MD<sup>9\*</sup>, Maria R. Baer, MD<sup>10</sup>, Wendy Stock, MD<sup>11</sup>, Rupali Bhave, M.D.<sup>12\*</sup>, Megan Othus, PhD<sup>2</sup>, Mark R. Litzow, MD<sup>13</sup>, Richard M. Stone, MD<sup>14</sup> and Harry P. Erba, MD, PhD<sup>15</sup>**

<sup>1</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>SWOG Statistics and Data Management Center, Seattle, WA

<sup>3</sup>University of Rochester Medical Center, Rochester, NY

<sup>4</sup>Department of Laboratory Medicine and Division of Hematopathology, University of Washington, Seattle, WA

<sup>5</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>6</sup>University of California, San Diego, La Jolla, CA

<sup>7</sup>University of Southern California, Duarte, CA

<sup>8</sup>Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>9</sup>Ohio State University, Columbus, OH (past during conduct of trial)/ Emory University, Atlanta, GA

<sup>10</sup>University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

<sup>11</sup>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

<sup>12</sup>Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC

<sup>13</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>14</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>15</sup>University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL

**206 A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee**

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question

Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies

Saturday, December 1, 2018: 2:15 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

**Aziz Nazha, MD<sup>1</sup>, Zhen-Huan Hu, MPH<sup>2\*</sup>, Tao Wang, PhD<sup>2,3\*</sup>, Betty K. Hamilton, MD<sup>4</sup>, Navneet S.**

**Majhail, MD, MS<sup>5</sup>, R. Coleman Lindsley, M.D., Ph.D.<sup>6</sup>, Ronald Sobecks, MD<sup>5</sup>, Uday Popat, MD<sup>7</sup>, Bart L Scott, MD<sup>8</sup> and Wael Saber, MD, MS<sup>2\*</sup>**

<sup>1</sup>Cleveland Clinic, Cleveland, OH

<sup>2</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>3</sup>Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>7</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>8</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

**397 Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study**

Program: Oral and Poster Abstracts

Type: Oral

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents

Hematology Disease Topics & Pathways: Diseases, Biological, apoptosis, Adult, Therapies, Non-Biological, Non-Hodgkin Lymphoma, chemotherapy, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018: 12:00 PM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

**Paolo Caimi, MD<sup>1</sup>, Deepa Jagadeesh, MD, MPH<sup>2</sup>, Kirsten Marie Boughan, DO<sup>1</sup>, Robert M. Dean, MD<sup>2</sup>, Brenda Cooper, MD<sup>1</sup>, Brad Pohlman, MD<sup>3</sup>, Molly M Gallogly, MD, PhD<sup>1</sup>, Sarah L. Ondrejka, DO<sup>4</sup>, Erika Moore, MD<sup>5\*</sup>, Kwadwo Asare Oduro, MD, PhD<sup>5</sup>, Eric D. Hsi, MD<sup>4</sup>, Marcos de Lima, MD<sup>1</sup> and Brian T. Hill, MD, PhD<sup>6,7</sup>**

<sup>1</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>2</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

**466 PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis**

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics II

Hematology Disease Topics & Pathways: Diseases, antibodies, Biological, Therapies, MDS, checkpoint inhibitors, Myeloid Malignancies

Sunday, December 2, 2018: 5:15 PM; Grand Hall A (Manchester Grand Hyatt San Diego)

**Aaron T. Gerds, MD, MS<sup>1</sup>, Bart L Scott, MD<sup>2</sup>, Peter L Greenberg, M.D.<sup>3</sup>, Samer K. Khaled, MD<sup>4</sup>, Tara L Lin, MD<sup>5,6</sup>, Daniel A Pollyea, MD<sup>7</sup>, Amit Verma, MD<sup>8</sup>, Monique Dail<sup>9\*</sup>, Cherie Green<sup>9\*</sup>, Connie Ma<sup>9\*</sup>, Bruno C Medeiros<sup>9</sup>, Patrick Phuong<sup>9\*</sup>, Michael Wenger<sup>10</sup>, Mark Yan<sup>11\*</sup> and William B. Donnellan, MD<sup>12</sup>**

<sup>1</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>2</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>3</sup>Stanford University Cancer Center, Stanford, CA

<sup>4</sup>City of Hope, Duarte, CA

<sup>5</sup>University of Kansas Medical Center, Kansas City, KS

<sup>6</sup>Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS

<sup>7</sup>University of Colorado School of Medicine, Aurora, CO

<sup>8</sup>Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY

<sup>9</sup>Genentech Inc, South San Francisco, CA

<sup>10</sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland

<sup>11</sup>Hoffmann-La Roche Ltd, Mississauga, ON, Canada

<sup>12</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

## **793 A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes**

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Prognosis and Prediction

Hematology Disease Topics & Pathways: AML, Diseases, MDS, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS

Monday, December 3, 2018: 2:45 PM; Grand Hall A (Manchester Grand Hyatt San Diego)

**Aziz Nazha, MD<sup>1</sup>, Rami S. Komrokji, MD<sup>2</sup>, Manja Meggendorfer, PhD<sup>3</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>4</sup>, Najla Al Ali, M.Sc<sup>5</sup>, Wencke Walter, PhD<sup>3\*</sup>, Stephan Hutter, PhD<sup>3\*</sup>, Eric Padron, MD<sup>5</sup>, Yazan F. Madanat, MD<sup>6</sup>, David A Sallman, MD<sup>7</sup>, Teodora Kuzmanovic<sup>8\*</sup>, Cassandra M. Hirsch<sup>9\*</sup>, Vera Adema, PhD<sup>8\*</sup>, David P. Steensma, MD<sup>10</sup>, Amy E. DeZern, MD<sup>11</sup>, Gail J. Roboz, MD<sup>12</sup>, Guillermo Garcia-Manero, MD<sup>13</sup>, Alan F. List, MD<sup>14</sup>, Claudia Haferlach, MD<sup>3</sup>, Jaroslaw P. Maciejewski<sup>8</sup>, Torsten Haferlach, MD<sup>15</sup> and Mikael A. Sekeres, MD, MS<sup>16</sup>**

<sup>1</sup>Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

<sup>3</sup>MLL Munich Leukemia Laboratory, Munich, Germany

<sup>4</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

<sup>8</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>11</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>12</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>13</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>14</sup>H. Lee Moffitt Cancer Center, Tampa, FL

<sup>15</sup>MLL Munchner Leukemie Labor GmbH, Munchen, Germany

<sup>16</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute Taussig Cancer Institute, Cleveland, OH

## **ORAL ABSTRACTS – NON-CASE CCC PRESENTER (with CASE CCC/CLEVELAND CO-AUTHORS)**

### **1 The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions**

Program: General Sessions

Session: Plenary Scientific Session

Hematology Disease Topics & Pathways:

Biological, Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 2:00 PM-4:00 PM; Hall AB (San Diego Convention Center)

**Pierre Fenaux, MD, PhD<sup>1</sup>, Uwe Platzbecker, MD<sup>2</sup>, Ghulam J. Mufti<sup>3\*</sup>, Guillermo Garcia-Manero, MD<sup>4</sup>, Rena Buckstein, MD, FRCPC<sup>5</sup>, Valeria Santini<sup>6</sup>, María Díez-Campelo<sup>7\*</sup>, Carlo Finelli, MD<sup>8\*</sup>, Mario Cazzola<sup>9</sup>,**

*Osman Ilhan, MD<sup>10</sup>\*, Mikkael A. Sekeres, MD, MS<sup>11</sup>, José F. Falantes<sup>12</sup>\*, Beatriz Arrizabalaga, MD, PhD<sup>13</sup>\*, Flavia Salvi<sup>14</sup>\*, Valentina Giai<sup>14</sup>\*, Paresh Vyas, MRCP FRCP FRCPath<sup>15</sup>, David Bowen, MD<sup>16</sup>, Dominik Selleslag, MD<sup>17</sup>\*, Amy E. DeZern, MD<sup>18</sup>, Joseph G. Jurcic, MD<sup>19</sup>, Ulrich Germing, MD<sup>20</sup>\*, Katharina S. Götze, MD<sup>21</sup>, Bruno Quesnel<sup>22</sup>, Odile Beyne-Rauzy<sup>23</sup>\*, Thomas Cluzeau, MD, PhD<sup>24</sup>\*, Maria Teresa Voso<sup>25</sup>, Dominiek Mazure<sup>26</sup>\*, Edo Vellenga<sup>27</sup>, Peter L Greenberg, M.D.<sup>28</sup>, Eva Hellstrom Lindberg, MD, PhD<sup>29</sup>, Amer M. Zeidan, MBBS, MHS<sup>30</sup>\*, Abderrahmane Laadem, MD<sup>31</sup>, Aziz Benzohra<sup>32</sup>\*, Jennie Zhang<sup>31</sup>\*, Anita Rampersad<sup>31</sup>\*, Peter G. Linde<sup>33</sup>, Matthew L. Sherman<sup>33</sup>, Rami S. Komrokji, MD<sup>34</sup> and Alan F. List, MD<sup>34</sup>*

<sup>1</sup>Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France

<sup>2</sup>University Hospital Dresden, Dresden, Germany

<sup>3</sup>Department of Haemato-Oncology, King's College London, London, United Kingdom

<sup>4</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>5</sup>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

<sup>6</sup>MDS Unit, AOU Careggi, University of Florence, Florence, Italy

<sup>7</sup>Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain

<sup>8</sup>Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy

<sup>9</sup>University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

<sup>10</sup>Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey

<sup>11</sup>Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>12</sup>Unidad de Hematología, Hospital Universitario Virgen del Rocío, Seville, Spain

<sup>13</sup>Department of Hematology, Hospital Universitario Cruces, Vizcaya, Spain

<sup>14</sup>Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy

<sup>15</sup>Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

<sup>16</sup>Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom

<sup>17</sup>Department of Haematology, AZ Sint-Jan, Bruges, Belgium

<sup>18</sup>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

<sup>19</sup>Division of Hematology/Oncology, Columbia University Medical Center, New York, NY

<sup>20</sup>Klinik für Hämatologie, Onkologie and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany

<sup>21</sup>Department of Medicine III, Technical University of Munich, Munich, Germany

<sup>22</sup>Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, Lille, France

<sup>23</sup>Médecine Interne, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

<sup>24</sup>Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

<sup>25</sup>Dipartimento di Biopatologia e Diagnostica per Immagini, University of Rome Tor Vergata, Rome, Italy

<sup>26</sup>Universitair Ziekenhuis Gent, Ghent, Belgium

<sup>27</sup>Department of Hematology, University Medical Center Groningen, Groningen, Netherlands

<sup>28</sup>Stanford University Cancer Center, Stanford, CA

<sup>29</sup>Department of Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>30</sup>Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

<sup>31</sup>Celgene Corporation, Summit, NJ

<sup>32</sup>Celgene International, Boudry, Switzerland

<sup>33</sup>Acceleron Pharma, Cambridge, MA

<sup>34</sup>Moffitt Cancer Center, Tampa, FL

## **75 Neutrophil KLF2 Regulates Arterial and Venous Thrombosis**

Program: Oral and Poster Abstracts

Type: Oral

Session: 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Vascular Physiology and Thrombosis

Hematology Disease Topics & Pathways: Biological Processes, inflammation

Saturday, December 1, 2018: 10:00 AM; Room 28D (San Diego Convention Center)

*Lalitha V. Nayak, MD<sup>1</sup>, Stephanie Lapping, MS<sup>2</sup>\*, Andrei Maiseyev<sup>3</sup>\*, Alvin H. Schmaier, MD<sup>4</sup> and Mukesh Jain, MD<sup>2,5\*</sup>*

<sup>1</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>2</sup>Case Cardiovascular Research Institute, CWRU, Cleveland

<sup>3</sup>Case Cardiovascular Research Institute, Case Western Reserve University, Cleveland

<sup>4</sup>Case Western Reserve University, Cleveland, OH

<sup>5</sup>Case Western Reserve University / University Hospitals Health System, Cleveland, OH

## **91 Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience**

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting

Hematology Disease Topics & Pathways: Biological, Therapies, CAR-Ts

Saturday, December 1, 2018: 9:30 AM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

*Loretta J. Nastoupil, MD<sup>1</sup>, Michael D. Jain, MD, PhD<sup>2</sup>, Jay Y. Spiegel, MD, FRCPC<sup>3</sup>, Armin Ghobadi, MD<sup>4\*</sup>, Yi Lin, MD, PhD<sup>5</sup>, Saurabh Dahiya, MD<sup>6</sup>, Matthew A. Lunning, DO<sup>7</sup>, Lazaros J. Lekakis, MD<sup>8\*</sup>, Patrick M. Reagan, MD<sup>9</sup>, Olalekan O. Oluwole, MBBS, MPH<sup>10</sup>, Joseph P. McGuirk, DO<sup>11</sup>, Abhinav Deol, MD<sup>12</sup>, Alison R. Sehgal, MD<sup>13</sup>, Andre Goy, MD<sup>14</sup>, Brian T. Hill, MD, PhD<sup>15,16</sup>, Charalambos Andreadis, MD<sup>17,18</sup>, Javier Munoz, MD<sup>19</sup>, Jason R. Westin, MD<sup>20</sup>, Julio C. Chavez, MD<sup>21</sup>, Amanda F Cashen, MD<sup>22</sup>, Nora N Bennani, MD<sup>5</sup>, Aaron P. Rapoport, MD<sup>23</sup>, Julie M. Vose, MD, MBA<sup>7</sup>, David B. Miklos, MD, PhD<sup>24</sup>, Sattva S. Neelapu, MD<sup>25</sup> and Frederick L. Locke, MD<sup>26</sup>*

<sup>1</sup>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>2</sup>Moffitt Cancer Center, Tampa, FL

<sup>3</sup>Stanford University Medical Center, Stanford, CA

<sup>4</sup>Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

<sup>5</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>6</sup>University of Maryland School of Medicine, Baltimore, MD

<sup>7</sup>University of Nebraska Medical Center, Omaha, NE

<sup>8</sup>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

<sup>9</sup>Wilmett Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

<sup>10</sup>Vanderbilt-Ingram Cancer Center, Nashville, TN

<sup>11</sup>Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

<sup>12</sup>Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

<sup>13</sup>UPMC Hillman Cancer Center, Pittsburgh, PA

<sup>14</sup>John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

<sup>15</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>16</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>17</sup>Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA

<sup>18</sup>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

<sup>19</sup>Banner MD Anderson Cancer Center, Gilbert, AZ

<sup>20</sup>Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston

<sup>21</sup>H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

<sup>22</sup>Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

<sup>23</sup>University of Maryland Medical Center Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD

<sup>24</sup>Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA

<sup>25</sup>Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX

<sup>26</sup>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

**104 Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)**

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and Germline Predisposition

Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Biological Processes, Myeloid Malignancies, molecular interactions

Saturday, December 1, 2018: 9:45 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

*Yasunobu Nagata<sup>1\*</sup>, Hideki Makishima, MD, PhD<sup>2</sup>, Tetsuichi Yoshizato, MD, PhD<sup>2</sup>, Hiromichi Suzuki, M.D., Ph.D.<sup>2\*</sup>, Cassandra M. Hirsch<sup>3\*</sup>, Abhinav Goyal<sup>3\*</sup>, Hassan Awada, MD<sup>3</sup>, Mohammad Fahad B. Asad<sup>3</sup>, Teodora Kuzmanovic, BA<sup>3\*</sup>, Bartlomiej P. Przychodzen<sup>3\*</sup>, Kenichi Yoshida, MD, PhD<sup>2\*</sup>, Kenichi Chiba, PhD<sup>4\*</sup>, Hiroko Tanaka, BA<sup>4\*</sup>, Yuichi Shiraishi, PhD<sup>4\*</sup>, Satoru Miyano, PhD<sup>4\*</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>5</sup>, Tomas Radivoyevitch, PhD<sup>3\*</sup>, Thomas Laframboise, PhD<sup>6\*</sup>, Aziz Nazha, MD<sup>5</sup>, Mikkael A. Sekeres, MD, MS<sup>5</sup>, Torsten Haferlach, MD<sup>7</sup>, Seishi Ogawa, MD, PhD<sup>8</sup> and Jaroslaw P. Maciejewski<sup>3</sup>*

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

<sup>5</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

<sup>7</sup>MLL Munich Leukemia Laboratory, Munich, Germany

<sup>8</sup>Department of Pathology and Tumor Biology, Kyoto University, Graduate School of Medicine, Kyoto, Japan

## **107 SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition**

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and Germline Predisposition

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MDS, Technology and Procedures, Study Population, Myeloid Malignancies, inflammation

Saturday, December 1, 2018: 10:30 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Kathy L McGraw, Ph.D<sup>1</sup>, Chia-Ho Cheng, Ph.D.<sup>2\*</sup>, Y. Ann Chen, Ph.D.<sup>3\*</sup>, Hsin-An Hou, MD, PhD<sup>4\*</sup>, Guilio Genovese, Ph.D.<sup>5\*</sup>, Thomas Cluzeau, MD, PhD<sup>6\*</sup>, Andrea Pellaatti, PhD<sup>7\*</sup>, Bartłomiej Przychodzen<sup>8\*</sup>, Mar Mallo, Ph.D.<sup>9\*</sup>, Arenillas Leonor, MD, PhD<sup>10\*</sup>, Azim M. Mohamedali, Ph.D.<sup>11\*</sup>, Pierre Fenaux, MD<sup>12</sup>, David A Sallman, MD<sup>13</sup>, Eric Padron, MD<sup>14</sup>, Lubomir Sokol, MD, PhD<sup>15</sup>, Chimene Morelhon<sup>16\*</sup>, Sophie Raynaud, MD, PhD<sup>17\*</sup>, Bjorn Nilsson, PhD.<sup>18\*</sup>, Hwei-Fang Tien, M.D., PhD.<sup>19</sup>, Jacqueline Boulwood, PhD<sup>7</sup>, Benjamin L. Ebert, MD, PhD<sup>20</sup>, Francesc Sole, PhD<sup>21</sup>, Pierre Fenaux, MD, PhD<sup>22</sup>, Ghulam Mufti<sup>23\*</sup>, **Jaroslaw P. Maciejewski<sup>24</sup>**, **Peter Kanetsky, Ph.D.<sup>2\*</sup>** and **Alan F. List, MD<sup>2</sup>**

<sup>1</sup>Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

<sup>2</sup>H. Lee Moffitt Cancer Center, Tampa, FL

<sup>3</sup>H. Lee Moffitt Cancer Center, Tampa

<sup>4</sup>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan

<sup>5</sup>Broad Institute of the Massachusetts Institute of Technology, Cambridge, MA

<sup>6</sup>Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

<sup>7</sup>Bloodwise Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

<sup>8</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain

<sup>10</sup>Laboratori de Citologia Hematològica i Citogenètica, servei de Patologia, Hospital del Mar. GRETNHE- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain

<sup>11</sup>Kings College London, London, GBR

<sup>12</sup>INSERM UMR-S1131, Institut Universitaire d'Hématologie, Hôpital St Louis/ Paris 7 University, PARIS, France

<sup>13</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

<sup>14</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>15</sup>Moffitt Cancer Center, Tampa, FL

<sup>16</sup>CHU of Nice, Nice, France

<sup>17</sup>CHU de Nice, Onco-hematology Laboratory, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France

<sup>18</sup>Lund University, Lund, Sweden

<sup>19</sup>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

<sup>20</sup>Brigham and Women's Hospital, Harvard Medical School, Boston, MA

<sup>21</sup>MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

<sup>22</sup>INSERM UMR-S1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, Paris, France

<sup>23</sup>Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom

<sup>24</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

## **108 Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP)**

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and

## Germline Predisposition

Hematology Disease Topics & Pathways: Diseases, Adult, MDS, Biological Processes, Technology and Procedures, Study Population, Clinically relevant, genomics, Myeloid Malignancies, Quality Improvement , NGS

Saturday, December 1, 2018: 10:45 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

*Hideki Makishima, MD, PhD<sup>1</sup>, Tetsuichi Yoshizato, MD, PhD<sup>2</sup>, Yasuhito Nannya, MD, PhD<sup>3</sup>, Yasuhide Momozawa, PhD<sup>4\*</sup>, Yoshiko Atsuta, MD, PhD<sup>5\*</sup>, Yusuke Shiozawa, M.D., Ph.D.<sup>2\*</sup>, Yuka Iijima-Yamashita<sup>6\*</sup>, Kenichi Yoshida, MD, PhD<sup>2\*</sup>, Yuichi Shiraishi, PhD<sup>7\*</sup>, Hiromichi Suzuki, M.D. , Ph.D.<sup>2\*</sup>, June Takeda, MD<sup>8\*</sup>, Yasunobu Nagata<sup>9\*</sup>, Yusuke Sato<sup>10\*</sup>, Nobuyuki Kakiuchi, M.D.<sup>2\*</sup>, Makoto Onizuka, MD, PhD<sup>11</sup>, Keisuke Kataoka, MD, PhD<sup>2</sup>, Kenichi Chiba, PhD<sup>7\*</sup>, Hiroko Tanaka, BA<sup>7\*</sup>, Hiroo Ueno, MD<sup>2\*</sup>, Masahiro Marshall Nakagawa, MD, PhD<sup>12</sup>, Hidehiro Itonaga, M.D., Ph.D.<sup>13\*</sup>, Yoshinobu Kanda, MD, PhD<sup>14</sup>, Yasushi Miyazaki, MD, PhD<sup>15</sup>, Keizo Horibe, MD, PhD<sup>16\*</sup>, Masashi Sanada, MD, PhD<sup>16</sup>, Yoichiro Kamatani, MD, PhD<sup>17\*</sup>, Michiaki Kubo, MD, PhD<sup>17\*</sup>, Satoru Miyano, PhD<sup>18\*</sup> and Seishi Ogawa, MD, PhD<sup>19</sup>*

<sup>1</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan, Kyoto, Japan

<sup>2</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>3</sup>Tokyo University, Tokyo, Japan

<sup>4</sup>Center for Integrative Medical Sciences (IMS), RIKEN, Laboratory for Genotyping Development, Tsurumi, Japan

<sup>5</sup>Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

<sup>6</sup>Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan

<sup>7</sup>Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

<sup>8</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, KYO, Japan

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

<sup>11</sup>Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan

<sup>12</sup>Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>13</sup>Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

<sup>14</sup>Saitama Medical Ctr. Jichi Medical Univ., Saitama, Japan

<sup>15</sup>Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

<sup>16</sup>Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

<sup>17</sup>RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

<sup>18</sup>Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

<sup>19</sup>Department of Pathology and Tumor Biology, Kyoto University, Sakyoku, Japan

## 157 Outcomes and Healthcare Utilization of Children with Mucopolysaccharidosis with and without Hematopoietic Stem Cell Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Sickle Cell Disease and Mucopolysaccharidosis

Hematology Disease Topics & Pathways: Pediatric, Technology and Procedures, Study Population, Clinically relevant, newborn screening

Saturday, December 1, 2018: 12:00 PM; Room 24B (San Diego Convention Center)

*Cara E Carr, MD<sup>1\*</sup>, Nikita Goel, MD<sup>1\*</sup>, Nori Minich, BS<sup>2</sup>, Steven L Shein, MD<sup>1\*</sup> and Jignesh Dalal, MD<sup>1</sup>*

<sup>1</sup>Rainbow Babies & Children's Hospital, Cleveland, OH

<sup>2</sup>Case Western Reserve University, Cleveland, OH

## 158 Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the GRNDaD Registry

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Sickle Cell Disease and Mucopolysaccharidosis

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies

Saturday, December 1, 2018: 12:15 PM; Room 24B (San Diego Convention Center)

*Matthew Sears, PhD<sup>1</sup>, Sophie Lanzkron, MD, MHS<sup>2</sup>, Carolyn Hoppe, MD<sup>3</sup>, Joshua J. Field, MD<sup>4</sup>, Payal C Desai, MD<sup>5</sup>, Elizabeth Williams<sup>6\*</sup> and Jane Little, MD<sup>7,8</sup>*

<sup>1</sup>*Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA*

<sup>2</sup>*Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD*

<sup>3</sup>*UCSF Benioff Children's Hospital, Oakland, CA*

<sup>4</sup>*Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI*

<sup>5</sup>*Department of Hematology, The Ohio State University, Columbus, OH*

<sup>6</sup>*Johns Hopkins School of Medicine, Baltimore, MD*

<sup>7</sup>*CWRU School of Medicine, Cwru/University Hospitals, Cleveland, OH*

<sup>8</sup>*Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH*

**207 Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study**

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question

Hematology Disease Topics & Pathways: Adult, Biological, AML, Diseases, bone marrow, Therapies, Elderly, Study Population, Clinically relevant, Myeloid Malignancies, transplantation

Saturday, December 1, 2018: 2:30 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

*Mohamed L. Sorror, MD, MSc<sup>1,2</sup>, Barry E. Storer, PhD<sup>3,4\*</sup>, Aaron T. Gerds, MD, MS<sup>5</sup>, Bruno C. Medeiros, MD<sup>6</sup>, Paul J Shami, MD<sup>7</sup>, John P. Galvin, MD, MS, MPH<sup>8</sup>, Kehinde U. Adekola, MBBS, MS<sup>9</sup>, Selina Luger, MD<sup>10</sup>, Maria R. Baer, MD<sup>11</sup>, David A. Rizzieri, MD<sup>12</sup>, Tanya M. Wildes, MD, MSC<sup>13</sup>, Eunice S. Wang, MD<sup>14</sup>, Stefan Faderl, MD<sup>15</sup>, Jamie L. Koprivnikar, MD<sup>15</sup>, Mikael A. Sekeres, MD, MS<sup>5</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>5</sup>, Julie Smith, MD<sup>16\*</sup>, Mitchell Garrison, MD<sup>16\*</sup>, Kiarash Kojouri, MD<sup>17\*</sup>, Jennifer E. Nyland, PhD<sup>1\*</sup>, Rachelle R. Moore, BS<sup>1\*</sup>, Sophie L. Fleuret, BS<sup>1\*</sup>, Ylinne Lynch, MD<sup>1,18\*</sup>, Pamela S. Becker, MD<sup>1,19</sup>, Mary-Elizabeth M. Percival, MD, MS<sup>1,19</sup>, Brenda M. Sandmaier, MD<sup>1,2</sup>, Frederick R. Appelbaum, MD<sup>1,2</sup> and Elihu H. Estey, MD<sup>1,19</sup>*

<sup>1</sup>*Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA*

<sup>2</sup>*Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA*

<sup>3</sup>*Department of Biostatistics, University of Washington School of Public Health, Seattle, WA*

<sup>4</sup>*Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA*

<sup>5</sup>*Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH*

<sup>6</sup>*Department of Medicine, Division of Hematology, Stanford University, Palo Alto, CA*

<sup>7</sup>*Huntsman Cancer Institute, University of Utah, Salt Lake City, UT*

<sup>8</sup>*Feinberg School of Medicine, Northwestern University, Chicago, IL*

<sup>9</sup>*Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL*

<sup>10</sup>*Abramson Cancer Center at the University of Pennsylvania School of Medicine, Philadelphia, PA*

<sup>11</sup>*University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD*

<sup>12</sup>*Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC*

<sup>13</sup>*Division of Oncology, Washington University School of Medicine, St Louis, MO*

<sup>14</sup>*Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY*

<sup>15</sup>*John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ*

<sup>16</sup>*Confluence Health/Wenatchee Valley Hospital, Wenatchee, WA*

<sup>17</sup>*Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA*

<sup>18</sup>*Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA*

<sup>19</sup>*Division of Hematology, Department of Medicine, University of Washington, Seattle, WA*

**211 Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies**

Program: Oral and Poster Abstracts

Type: Oral

Session: 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development

Hematology Disease Topics & Pathways: Diseases, Therapies, Non-Biological, chemical interactions,

MDS, Biological Processes, Technology and Procedures, Clinically relevant, Myeloid Malignancies, genomics, RNA sequencing

Saturday, December 1, 2018: 2:00 PM; Room 7B (San Diego Convention Center)

*Valeria Visconte, PhD<sup>1</sup>, Bartłomiej P. Przychodzen<sup>1\*</sup>, Vera Adema, PhD<sup>1\*</sup>, Cassandra M. Hirsch<sup>2\*</sup>, Allison Noe<sup>2\*</sup>, Rachel Toth<sup>2\*</sup>, Christina Snider, BA<sup>2</sup>, Hassan Awada, MD<sup>1</sup>, Amy C Graham, BS, MS<sup>3\*</sup>, Yvonne Parker<sup>4\*</sup>, Yuriy Fedorov<sup>5\*</sup>, Drew Adams<sup>5\*</sup>, Hetty E. Carraway, MD, MBA<sup>6,7</sup>, Anjali S. Advani, MD<sup>8</sup>, Tomas Radivoyevitch<sup>2\*</sup>, Heesun J. Rogers, MD, PhD<sup>9</sup>, Kevin R Kelly, MD, PhD<sup>10\*</sup>, Steffan T. Nawrocki, PhD<sup>11</sup>, Jennifer S. Carew, PhD<sup>12</sup>, Daniel Lindner, MD, PhD<sup>2\*</sup>, Richard A Padgett<sup>13\*</sup>, Mikkael A. Sekeres, MD, MS<sup>14</sup>, James G Phillips, PhD<sup>1\*</sup> and Jaroslaw P. Maciejewski<sup>1</sup>*

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

<sup>3</sup>Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Department of Genetics and Genome Sciences, Small-Molecule Drug Development Core, Case Western Reserve University School of Medicine, Cleveland

<sup>6</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>8</sup>Leukemia Program, Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Department of Hematopathology, Cleveland Clinic, Cleveland

<sup>10</sup>Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA

<sup>11</sup>Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ

<sup>12</sup>The University of Arizona Cancer Center, Tucson, AZ

<sup>13</sup>Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>14</sup>Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, OH

## **216 A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis**

Program: Oral and Poster Abstracts

Type: Oral

Session: 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development

Hematology Disease Topics & Pathways: Non-Biological, Therapies, chemical interactions, Biological Processes, epigenetics

Saturday, December 1, 2018: 3:15 PM; Room 7B (San Diego Convention Center)

*Ashwin Kishtagari, MBBS, Kwok Peng Ng, PhD\*, Charlotte Jarman\*, Anand D. Tiwari, PhD\*, James G Phillips, PhD\*, Caroline Schuerger\*, Babal K. Jha\* and Yogenthiran Saunthararajah, MD*

*Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*

## **217 Hepatocyte-Derived Tissue Plasminogen Activator Regulates Systemic Fibrinolysis**

Program: Oral and Poster Abstracts

Type: Oral

Session: 321. Blood Coagulation and Fibrinolytic Factors: Animal Models and Therapeutic Targets in Thrombosis and Hemostasis

Hematology Disease Topics & Pathways: Diseases, Hemostasis, Bleeding and clotting, Biological Processes, Thrombosis

Saturday, December 1, 2018: 4:00 PM; Room 28D (San Diego Convention Center)

*Ze Zheng, MD, PhD<sup>1</sup>, Lalitha V. Nayak, MD<sup>2</sup>, Mukesh Jain, MD<sup>3\*</sup> and Ira Tabas, MD, PhD<sup>4\*</sup>*

<sup>1</sup>Department of Medicine, Columbia University, New York, NY

<sup>2</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>3</sup>Case Western Reserve University / University Hospitals Health System, Cleveland, OH

<sup>4</sup>Department of Medicine, Columbia University, New York City, NY

## **268 High Molecular Weight Kininogen Contributes to End-Organ Damage and Mortality in a Mouse Model of Sickle Cell Disease**

Program: Oral and Poster Abstracts

Type: Oral

Session: 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Sickle Cell Disease—Role of Coagulation and Inflammation in Pathophysiology

Hematology Disease Topics & Pathways: Sickle cell disease, Diseases, Animal models, Biological Processes, Hemoglobinopathies, Study Population, Clinically relevant, inflammation, pathogenesis

Sunday, December 2, 2018: 8:15 AM; Room 33B (San Diego Convention Center)

*Erica Sparkenbaugh, PhD, BS<sup>1\*</sup>, Kathryn Wilson, BS<sup>2\*</sup>, Małgorzata Kasztan, PhD<sup>3\*</sup>, David M. Pollock, PhD<sup>3\*</sup>, Keith R. McCrae, MD<sup>4</sup> and Rafal Pawlinski, PhD<sup>5</sup>*

<sup>1</sup>UNC Chapel Hill McAllister Heart Institute, Chapel Hill, NC

<sup>2</sup>McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC

<sup>3</sup>Department of Medicine Division of Nephrology, The University of Alabama at Birmingham, Birmingham, AL

<sup>4</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC

### **308 Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey**

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: Optimizing Outcomes After Allogeneic Transplantation

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, thalassemia, Pediatric, Hemoglobinopathies, Young Adult, Study Population, Clinically relevant, transplantation

Sunday, December 2, 2018: 7:45 AM; Grand Hall A (Manchester Grand Hyatt San Diego)

*Chunfu Li, MD<sup>1,2</sup>, Vikram Mathews, MD<sup>3</sup>, Biju George, DM<sup>3</sup>, Soyoung Kim<sup>4\*</sup>, Kyle Hebert<sup>5\*</sup>, Hua Jiang, MD<sup>6</sup>, Changgang Li, MD<sup>7\*</sup>, Yiping Zhu<sup>8\*</sup>, Daniel A Keesler, BS<sup>9\*</sup>, Rajni Agarwal, MD<sup>10</sup>, Jaap Jan Boelens, MD, PhD<sup>11</sup>, Christopher C. Dvorak, MD<sup>12</sup>, Jeffery Auletta, MD<sup>13</sup>, Rakesh K. Goyal, MBBS, MD<sup>14,15</sup>, Rabi Hanna, MD<sup>16</sup>, Kimberly A. Kasow, DO<sup>17\*</sup>, David Margolis, MD<sup>9</sup>, Shalini Shenoy, MD<sup>18</sup>, Mark C. Walters, MD<sup>19</sup> and Mary Eapen, MBBS, MS<sup>9</sup>*

<sup>1</sup>Nanfang-Chunfu Children's Institute of Hematology & Oncology, Taixin Hospital, Dongguan, China

<sup>2</sup>Nanfang Hosp. Southern Medical University, Guangzhou, China

<sup>3</sup>Department of Haematology, Christian Medical College, Vellore, India

<sup>4</sup>Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>5</sup>CIBMTR and Medical College of Wisconsin, Milwaukee, WI

<sup>6</sup>Guangzhou Women and Children's Medical Center, Guangzhou, China

<sup>7</sup>Shenzhen Children's Hospital, Shenzhen, China

<sup>8</sup>West China Second University Hospital, Sichuan University, Chengdu, China

<sup>9</sup>Medical College of Wisconsin, Milwaukee, WI

<sup>10</sup>Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University Medical Center, Stanford, CA

<sup>11</sup>Pediatric Blood and Marrow Transplantation Program, Pediatric Blood and Marrow Transplantation Program University Hospital Utrecht, Utrecht, Netherlands

<sup>12</sup>Department of Pediatrics, University of California – San Francisco, San Francisco, CA

<sup>13</sup>Nationwide Children's Hospital, Columbus, OH

<sup>14</sup>Children's Mercy Hospital, Kansas City, MO

<sup>15</sup>School of Medicine, University of Missouri, Kansas City, Kansas City, KS

<sup>16</sup>Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

<sup>17</sup>University of North Carolina, Chapel Hill

<sup>18</sup>Washington University Medical Center, Saint Louis, MO

<sup>19</sup>UCSF Benioff Children's Hospital, Oakland, CA

### **314 Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study**

Program: Oral and Poster Abstracts

Type: Oral

Session: 901. Health Services Research—Non-Malignant Conditions: Sickle Cell Disease

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Adult, Hemoglobinopathies, Study Population, Quality Improvement

Sunday, December 2, 2018: 7:45 AM; Room 28D (San Diego Convention Center)

*Nebras Abu Al Hamayel, MBBS, MPH<sup>1</sup>, Jasmine Brooks, BA<sup>2</sup>, Hang Wang, PhD<sup>2</sup>, Rebecca Seufert, BS<sup>3</sup>, Carlton Haywood Jr., PhD, MA<sup>4</sup>, Ravi Varadhan, PhD<sup>5</sup>, Mustapha Saheed, MD<sup>6</sup>, Jodi Segal, MD<sup>7</sup>, Chiung-Yu Huang, PhD<sup>8</sup>, Joshua J. Field, MD<sup>9</sup>, Steven Frymark<sup>10</sup>, Jane Little, MD<sup>11,12</sup>, Brandi Griffin, BSN, RN<sup>13</sup>, Nicole Arnold<sup>14</sup>, Joseph Ryan Shows, MD<sup>15</sup>, Allie Piehet, BS<sup>16</sup>, Marc Proudford<sup>17</sup>, Derek Robertson, MBA, JD<sup>18</sup>, Marcus Wallace, MD<sup>19</sup>, Adrienne Kincaid<sup>20</sup>, Charles Green<sup>21</sup>, Lorri Burgess, BS<sup>22</sup> and Sophie Lanzkron, MD<sup>23,24</sup>*

<sup>1</sup>Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

<sup>2</sup>Johns Hopkins University, School of Medicine, Baltimore, MD

<sup>3</sup>School of Medicine, Johns Hopkins University, Baltimore, MD

<sup>4</sup>The Johns Hopkins University, Baltimore, MD

<sup>5</sup>Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD

<sup>6</sup>Johns Hopkins University, School of Medicine, Baltimore, MD

<sup>7</sup>School of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD

<sup>8</sup>Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA

<sup>9</sup>Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

<sup>10</sup>Froedtert Adult Sickle Cell Clinic, Blood Center of Wisconsin, Inc, Milwaukee

<sup>11</sup>CWRU School of Medicine, CWRU/University Hospitals, Cleveland, OH

<sup>12</sup>Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>13</sup>Case Western Reserve University Hospital, Cleveland

<sup>14</sup>Case Western Reserve University Hospital, Cl, OH

<sup>15</sup>Our Lady of the Lake Hospital, Baton Rouge

<sup>16</sup>Our Lady of the Lake Regional Medical Center, Baton Rouge, LA

<sup>17</sup>Johns Hopkins Community Based Organization Partner, Baltimore

<sup>18</sup>Community Based Organization Partner, Maryland Sickle Cell Disease Association, Columbia

<sup>19</sup>Louisiana Health Care Connection, Baton Rouge, LA

<sup>20</sup>Community Based Organization Partner, Kincaid's Kindred Spirits, Euclid

<sup>21</sup>Community Based Organization Partner, Blood Center of Wisconsin, Milwaukee

<sup>22</sup>Community Based Organization Partner, Lady of the Lake Regional Medical Center, Baton Rouge, LA

<sup>23</sup>Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

<sup>24</sup>Division of Medicine, Division of Hematology, Johns Hopkins Medicine, Baltimore, MD

**331 Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses**

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Combination Therapy  
Hematology Disease Topics & Pathways: Diseases, AML, Adult, Therapies, Non-Biological, Study  
Population, Myeloid Malignancies

Sunday, December 2, 2018: 9:30 AM; Grand Hall B (Manchester Grand Hyatt San Diego)

*Daniel J. DeAngelo, MD<sup>1</sup>, Brian A. Jonas, MD, PhD<sup>2</sup>, Jane L. Liesveld, MD<sup>3</sup>, Dale L. Bixby, MD, PhD<sup>4</sup>, Anjali S. Advani, MD<sup>5</sup>, Paula Marlton<sup>6</sup>, Michael E O'Dwyer, MD<sup>7</sup>, William E Fogler, PhD<sup>8</sup>, Curt D Wolfgang, PhD<sup>8</sup>, John L Magnani, PhD<sup>8</sup>, Helen M Thackray, MD<sup>8</sup> and Pamela S. Becker, MD<sup>9,10</sup>*

<sup>1</sup>Dana-Farber Cancer Inst., Boston, MA

<sup>2</sup>University of California, Davis, Sacramento, CA

<sup>3</sup>Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

<sup>4</sup>Internal Medicine, University of Michigan, Ann Arbor, MI

<sup>5</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Faculty of Medicine, University of Queensland, Brisbane, Australia

<sup>7</sup>National University of Ireland Galway, Galway City, Ireland

<sup>8</sup>GlycoMimetics, Inc., Rockville, MD

<sup>9</sup>Division of Hematology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>10</sup>Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

**353 A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3K $\gamma$  Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis**

Program: Oral and Poster Abstracts

Type: Oral

Session: 634. Myeloproliferative Syndromes: Clinical: Addressing Areas of Unmet Need in Prognostic Assessments and Therapy for MPNs

Hematology Disease Topics & Pathways: Diseases, MPN, Myeloid Malignancies

Sunday, December 2, 2018: 10:30 AM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)

*Naval G. Daver, MD<sup>1</sup>, Marina Kremyanskaya, MD, PhD<sup>2\*</sup>, Casey O'Connell, MD<sup>3\*</sup>, Kim-Hien Dao, DO, PhD<sup>4</sup>, Stephen T Oh, MD, PhD<sup>5</sup>, Aaron T. Gerds, MD, MS<sup>6</sup>, Srdan Verstovsek, MD, PhD<sup>7</sup>, Sue Erickson-Vitanen, PhD<sup>8\*</sup>, Feng Zhou<sup>8\*</sup>, Albert Assad, MD<sup>8\*</sup> and Abdulraheem Yacoub, MD<sup>9\*</sup>*

<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>2</sup>Mount Sinai Health System, New York, NY

<sup>3</sup>University of Southern California, Los Angeles, CA

<sup>4</sup>Oregon Health & Science University, Portland, OR

<sup>5</sup>Washington University School of Medicine, Saint Louis, MO

<sup>6</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>7</sup>University of Texas MD Anderson Cancer Center, Houston, TX

<sup>8</sup>Incyte Corporation, Wilmington, DE

<sup>9</sup>University of Kansas Medical Center, Kansas City, KS

### **366 Economic Burden of Venous Thromboembolism in Cancer Patients - a Comparative Analysis between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism**

Program: Oral and Poster Abstracts

Type: Oral

Session: 901. Health Services Research—Non-Malignant Conditions: Thrombosis and Anticoagulation  
Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thromboembolism, Clinically relevant, Quality Improvement

Sunday, December 2, 2018: 10:45 AM; Room 8 (San Diego Convention Center)

*Surbhi Shah<sup>1</sup>, Nathan Rubin, MS<sup>2\*</sup> and Alok A. Khorana<sup>3,4,5,6,7,8,9</sup>*

<sup>1</sup>University of Minnesota, Minneapolis, MN

<sup>2</sup>UNIVERSITY OF MINNESOTA, Minneapolis, MN

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>8</sup>Taussig Cancer Institute, Cleveland

<sup>9</sup>Taussig Cancer Institute/Cleveland Clinic, Cleveland, OH

### **371 Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States**

Program: Oral and Poster Abstracts

Type: Oral

Session: 904. Outcomes Research—Malignant Conditions: Outcomes in Myeloid Malignancies and Allogeneic Stem Cell Transplant

Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Study Population, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018: 10:30 AM; Room 25B (San Diego Convention Center)

*Raffi Tchekmedyian, BS<sup>1</sup>, Tomas Radivoyevitch, PhD<sup>2\*</sup>, Aaron T. Gerds, MD, MS<sup>3</sup>, Aziz Nazha, MD<sup>4</sup>, Hetty E. Carraway, MD, MBA<sup>5,6</sup>, Anjali S. Advani, MD<sup>6</sup>, Jaroslaw P. Maciejewski<sup>2</sup>, Matt Kalaycio, MD<sup>7</sup>, Navneet S. Majhail, MD, MS<sup>7</sup>, Mikael A. Sekeres, MD, MS<sup>8</sup> and Sudipto Mukherjee, MD, PhD, MPH<sup>8</sup>*

<sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>4</sup>Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **398 Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma**

Program: Oral and Poster Abstracts

Type: Oral

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents

Hematology Disease Topics & Pathways:

Adult, Diseases, Biological, Therapies, B-Cell Lymphoma, Study Population, Lymphoid Malignancies

Sunday, December 2, 2018: 12:15 PM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

John Radford, MD, FRCP<sup>1</sup>\*, Brad S. Kahl, MD<sup>2</sup>\*, Mehdi Hamadani, MD<sup>3</sup>, Carmelo Carlo-Stella, MD<sup>4</sup>, Paolo Caimi, MD<sup>5</sup>, Kirit M. Ardeshta, MBBChir<sup>6</sup>, Jay Feingold, MD, PhD<sup>7</sup>\*, Shui He, PhD<sup>8</sup>\*, Erin Reid, MD<sup>9</sup>\*, Melhem Solh, MD<sup>10</sup>, Ki-Young Chung, MD<sup>11</sup>\*, Leonard Heffner, MD<sup>12</sup>, David Ungar, MD<sup>13</sup>\* and Owen A. O'Connor, M.D., Ph.D.<sup>14</sup>

<sup>1</sup>Manchester Academic Health Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

<sup>2</sup>Siteman Cancer Center, Washington University, St Louis, MO

<sup>3</sup>Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Hematology, Humanitas Cancer Center, Rozzano, Milano, Italy

<sup>5</sup>University Hospitals of Cleveland, Cleveland, OH

<sup>6</sup>Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom

<sup>7</sup>ADC Therapeutics, Inc, Murray Hill, NJ

<sup>8</sup>ADC Therapeutics, Inc., Murray Hill, NJ

<sup>9</sup>Department of Hematology/Oncology, Moores Cancer Center, University of California, San Diego, CA

<sup>10</sup>Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

<sup>11</sup>Department of Hematology and Oncology, Greenville Health System, Greenville, SC

<sup>12</sup>Winship Cancer Institute / Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

<sup>13</sup>ADC Therapeutics America, Inc, Murray Hill

<sup>14</sup>Center for Lymphoid Malignancies, Department of Medicine, Columbia University, New York, NY

## **416 The Platelet Factor-4 (PF4)-Dependent p-Selectin Expression Assay (PEA) Is Highly Accurate for the Detection of Pathogenic HIT Antibodies: Results of a 440-Sample Prospective Blinded Study**

Program: Oral and Poster Abstracts

Type: Oral

Session: 331. Pathophysiology of Thrombosis: Risk Factors and Thromboembolism

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, HIT

Sunday, December 2, 2018: 4:45 PM; Room 30D (San Diego Convention Center)

Deepti M. Warad, MD<sup>1,2</sup>, Bethany T Samuelson Bannow, MD<sup>3</sup>, Curtis Jones, BS<sup>4</sup>\*, Shannon Pechauer<sup>4</sup>\*, Brian R. Curtis, PhD<sup>5</sup>, Daniel W. Bougie, PhD<sup>4</sup>, Parisa R Khalighi, BS<sup>6</sup>, Diane E. Grill, MS<sup>7</sup>\*, Rachel Leger, BAE<sup>8</sup>\*, Ruchika Sharma, MD<sup>9</sup>, Dong Chen, MD, PhD<sup>10</sup>, Richard H. Aster, MD<sup>11</sup>, David A. Garcia<sup>12</sup> and Anand Padmanabhan, MD, PhD<sup>13</sup>

<sup>1</sup>Division of Hematopathology, Special Coagulation Laboratory, Mayo Clinic, Rochester, MN

<sup>2</sup>Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN

<sup>3</sup>Department of Medicine, Division of Hematology, Oregon Health & Science University, Portland, OR

<sup>4</sup>BloodCenter of Wisconsin, Milwaukee, WI

<sup>5</sup>Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI

<sup>6</sup>Case Western Reserve University School of Medicine, Cleveland, OH

<sup>7</sup>Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

<sup>8</sup>Special Coagulation Laboratory, Mayo Clinic, Rochester, MN

<sup>9</sup>BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI

<sup>10</sup>Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

<sup>11</sup>Blood Research Institute, BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI

<sup>12</sup>Department of Medicine, Division of Hematology, University of Washington, Seattle, WA

<sup>13</sup>Pathology/Transfusion Medicine, Bloodcenter Of Wisconsin, Milwaukee, WI

## **417 Risk of Venous Thrombosis in Patients with Sickle Cell Trait after Orthopedic Surgery**

Program: Oral and Poster Abstracts

Type: Oral

Session: 331. Pathophysiology of Thrombosis: Risk Factors and Thromboembolism

Hematology Disease Topics & Pathways: Diseases, Biological Processes, Hemoglobinopathies, Clinically relevant, immune mechanism, inflammation

Sunday, December 2, 2018: 5:00 PM; Room 30D (San Diego Convention Center)

*Jahnnavi Gollamudi, MD<sup>1</sup>\*, Sadeer Al-Kindi, M.D.<sup>2</sup>\*, Petra Martin<sup>3</sup>\*, Jane Little, MD<sup>4,5</sup> and Lalitha V. Nayak, MD<sup>3</sup>*

<sup>1</sup>Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>2</sup>University Hospitals Case Medical Center, Cleveland

<sup>3</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>4</sup>CWRU School of Medicine, CWRU/University Hospitals, Cleveland, OH

<sup>5</sup>Division of Hematology/Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

## **425 Heparin Vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: The Cleveland Clinic Experience**

Program: Oral and Poster Abstracts

Type: Oral

Session: 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios

Hematology Disease Topics & Pathways: Adult, anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, HIT, Study Population, serologic tests

Sunday, December 2, 2018: 5:30 PM; Room 33B (San Diego Convention Center)

*Daniel S Carlson, DO<sup>1</sup>\*, Keith R. McCrae, MD<sup>2</sup> and Shruti Chaturvedi, MBBS, MS<sup>3</sup>*

<sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

## **437 Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age $\geq 60$ Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial**

Program: Oral and Poster Abstracts

Type: Oral

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Minimal Residual Disease and Genetic Characterization

Hematology Disease Topics & Pathways: AML, Diseases, Therapies, Non-Biological, Elderly, chemotherapy, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, flow cytometry

Sunday, December 2, 2018: 5:30 PM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)

*James M. Foran, MD<sup>1</sup>, Zhuoxin Sun, PhD<sup>2</sup>\*, Elisabeth Paitetta, PhD<sup>3</sup>, Janis Racevskis, PhD<sup>3</sup>\*, David F. Claxton, MD<sup>4</sup>, Hillard M Lazarus, MD<sup>5</sup>, Daniel A. Arber, MD<sup>6</sup>, Jacob M. Rowe, MD<sup>7</sup>, Jessica K. Altman, MD<sup>8</sup>, Aref Al-Kali, MD<sup>9</sup>, Hong Zheng, MD, PhD<sup>10</sup>, Keith W. Pratz, MD<sup>11</sup>, Edward R. Broun, MD<sup>12</sup>, Bayard L. Powell, MD<sup>13</sup>, Kristen Marie O'Dwyer, MD<sup>14</sup>, John Godwin, MD<sup>15</sup>, Yanming Zhang, MD<sup>16</sup>, Martin S. Tallman, MD<sup>17</sup>, Selina Luger, MD<sup>18</sup> and Mark R. Litzow, MD<sup>19</sup>*

<sup>1</sup>Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

<sup>2</sup>ECOG-ACRIN statistical center, Boston

<sup>3</sup>Cancer Center, Montefiore Medical Center, Bronx, NY

<sup>4</sup>Penn State Cancer Institute, Penn State M.S. Hershey Medical Center, Hershey, PA

<sup>5</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>6</sup>University of Chicago, Chicago, IL

<sup>7</sup>The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

<sup>8</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

<sup>9</sup>Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN

<sup>10</sup>Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA

<sup>11</sup>John Hopkins University, Baltimore, MD

<sup>12</sup>OHC, Inc., Cincinnati, OH

<sup>13</sup>Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

<sup>14</sup>University of Rochester Medical Center, Rochester, NY

<sup>15</sup>Providence Portland Medical Center, Portland, OR

<sup>16</sup>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>17</sup>Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

<sup>18</sup>Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

<sup>19</sup>Division of Hematology, Mayo Clinic, Rochester, MN

## **451 Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers**

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma

Hematology Disease Topics & Pathways: Diseases, Adult, Non-Biological, Therapies, Lymphoma (any), DLBCL, chemotherapy, Study Population, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018: 4:30 PM; Ballroom 20D (San Diego Convention Center)

*Shalin K. Kothari, MD<sup>1</sup>, Shaoying Li, MD<sup>2\*</sup>, L. Jeffrey Medeiros, MD<sup>2</sup>, Emily C. Ayers, MD<sup>3</sup>, Daniel J. Landsburg, MD<sup>4</sup>, David A. Bond, MD<sup>5</sup>, Kami J. Maddocks, MD<sup>6</sup>, Anshu Giri, MD<sup>7\*</sup>, Brian T. Hess, MD<sup>8</sup>, Luu Q. Pham<sup>9\*</sup>, Ranjana H. Advani, MD<sup>9</sup>, Yang Liu, MD<sup>10\*</sup>, Stefan Klaus Barta, MD, MRCP, MS<sup>11</sup>, Julie M. Vose, MD, MBA<sup>12</sup>, Michael C. Churnetski, BS<sup>13\*</sup>, Jonathon B. Cohen, MD, MS<sup>14</sup>, Madelyn Burkart, MD<sup>15\*</sup>, Reem Karmali, MD<sup>16</sup>, Joanna Zurko, MD<sup>17\*</sup>, Amitkumar Mehta, MD<sup>17\*</sup>, Adam J Olszewski, MD<sup>18</sup>, Sarah S Lee, MD<sup>19</sup>, Brian T. Hill, MD, PhD<sup>20,21</sup>, Timothy F. Burns, MD<sup>22</sup>, Frederick Lansigan, MD<sup>22</sup>, Emma Rabinovich, MD<sup>23\*</sup>, David Peace, MD<sup>24</sup>, Adrienne Groman, MS<sup>25\*</sup>, Kris Attwood, PhD, MS<sup>25\*</sup>, Francisco J. Hernandez-Ilizaliturri, MD<sup>26</sup> and Pallawi Torka, MD<sup>25</sup>*

<sup>1</sup>Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>2</sup>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>3</sup>University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

<sup>4</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

<sup>5</sup>Divisions of Hematology and Medical Oncology, The Ohio State University Cancer Center, Columbus, OH

<sup>6</sup>Division of Hematology, Ohio State University Hospital, Columbus, OH

<sup>7</sup>Medical University of South Carolina, Charleston, SC

<sup>8</sup>Division of Hematology/Oncology; Hollings Medical Cancer Center, Medical University of South Carolina, Charleston, SC

<sup>9</sup>Stanford University, Stanford, CA

<sup>10</sup>Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA

<sup>11</sup>Fox Chase Cancer Center, Philadelphia, PA

<sup>12</sup>University of Nebraska Medical Center, Omaha, NE

<sup>13</sup>Winship Cancer Institute--Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

<sup>14</sup>Winship Cancer Institute, Emory University, Atlanta, GA

<sup>15</sup>Northwestern University, Chicago, IL

<sup>16</sup>Division of Hematology, Northwestern University, Chicago, IL

<sup>17</sup>University of Alabama at Birmingham, Birmingham, AL

<sup>18</sup>Department of Medicine, Alpert Medical School of Brown University, Providence, RI

<sup>19</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>20</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>21</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>22</sup>Dartmouth-Hitchcock Medical Center, Lebanon, NH

<sup>23</sup>University of Illinois at Chicago, Chicago, IL

<sup>24</sup>Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago

<sup>25</sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>26</sup>Departments of Medicine and Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

## **453 Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunotherapy Following Treatment Failure of Intensive First-Line Immunotherapy**

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018: 5:00 PM; Ballroom 20D (San Diego Convention Center)

*Emily C. Ayers, MD<sup>1</sup>, Shaoying Li, MD<sup>2\*</sup>, Jeffrey Medeiros, MD<sup>2\*</sup>, David A. Bond, MD<sup>3</sup>, Kami J. Maddocks, MD<sup>4</sup>, Pallawi Torka, MD<sup>5</sup>, Angel Mier Hicks, MD<sup>6\*</sup>, Madeira Curry<sup>7\*</sup>, Nina D. Wagner-Johnston, MD<sup>7</sup>, Reem Karmali, MD<sup>8</sup>, Amir Behdad, MD<sup>9\*</sup>, Bita Fakhri, MD, MPH<sup>10</sup>, Brad S Kahl, MD<sup>11</sup>, Michael C Churnetski, BS<sup>12\*</sup>, Jonathon B. Cohen, MD, MS<sup>13</sup>, Nishitha Reddy, MD<sup>14</sup>, Dipen Kumar Modi, MD<sup>15</sup>, Radhakrishnan Ramchandren, MD<sup>16</sup>, Christina Howlett, PharmD, BCOP<sup>17\*</sup>, Lori A. Leslie, MD<sup>18</sup>, Samuel Cytryn<sup>19\*</sup>, Catherine Diefenbach, MD<sup>20</sup>, Rawan Faramand, MD<sup>21</sup>, Julio C. Chavez, MD<sup>22</sup>, Adam J Olszewski, MD<sup>23</sup>, Yang Liu, MD<sup>24\*</sup>, Stefan Klaus Barta, MD, MRCP, MS<sup>25</sup>, Dhruvika Mukhija, MD<sup>26\*</sup>, Brian T. Hill, MD, PhD<sup>27,28</sup>, Helen Ma, MD<sup>29</sup>, Jennifer E Amengual, MD<sup>30</sup>, Sunita Nathan, MD<sup>31</sup>, Sarit Assouline, MD<sup>32</sup>, Victor M. Orellana-Noia, MD<sup>33</sup>, Craig A. Portell, MD<sup>34</sup>, Ashwin Chandar, MD<sup>35</sup>, Kevin A. David, MD<sup>36\*</sup>, Anshu Giri, MD<sup>37\*</sup>, Brian T. Hess, MD<sup>38</sup> and Daniel J. Landsburg, MD<sup>39</sup>*

<sup>1</sup>University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

<sup>2</sup>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>3</sup>Divisions of Hematology and Medical Oncology, The Ohio State University Cancer Center, Columbus, OH

<sup>4</sup>Ohio State University Hospital, Columbus, OH

<sup>5</sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>6</sup>University at Buffalo, Buffalo, NY

<sup>7</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>8</sup>Division of Hematology, Northwestern University, Chicago, IL

<sup>9</sup>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL

<sup>10</sup>Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO

<sup>11</sup>Department of Medicine, Washington University School of Medicine, Saint Louis, MO

<sup>12</sup>Winship Cancer Institute, Emory University, Atlanta, GA

<sup>13</sup>Emory University, Atlanta, GA

<sup>14</sup>Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

<sup>15</sup>Department of Hematology/Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI

<sup>16</sup>Department of Oncology, Karmanos Cancer Institute, Detroit, MI

<sup>17</sup>John Theurer Cancer Center Hackensack Meridian Health, Hackensack, NJ

<sup>18</sup>John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ

<sup>19</sup>NYU Langone Health; NYU Perlmutter Cancer Center, New York, NY

<sup>20</sup>New York University School of Medicine, NYU Cancer Institute, New York, NY

<sup>21</sup>Moffitt Cancer Center/ Malignant Hematology, University of South Florida, Tampa, FL

<sup>22</sup>H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

<sup>23</sup>Division of Hematology-Oncology, Memorial Hospital of Rhode Island, Providence, RI

<sup>24</sup>Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA

<sup>25</sup>Fox Chase Cancer Center, Philadelphia, PA

<sup>26</sup>Cleveland Clinic, Cleveland, OH

<sup>27</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>28</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>29</sup>Columbia University Medical Center, New York, NY

<sup>30</sup>Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY

<sup>31</sup>Rush University Medical Center, Chicago, IL

<sup>32</sup>McGill University Jewish General Hospital, Montreal, QC, Canada

<sup>33</sup>Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA

<sup>34</sup>Division of Hematology/Oncology, University of Virginia, Charlottesville, VA

<sup>35</sup>Cancer Institute of New Jersey, New Brunswick, NJ

<sup>36</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>37</sup>Medical University of South Carolina, Charleston, SC

<sup>38</sup>Division of Hematology/Oncology; Hollings Medical Cancer Center, Medical University of South Carolina, Charleston, SC

<sup>39</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

**455 Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma As Defined By Multicenter Pathology Review Treated with Ibrutinib Monotherapy**

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma

Hematology Disease Topics & Pathways: Diseases, Adult, Biological, Therapies, Biological Processes, Non-Hodgkin Lymphoma, B-Cell Lymphoma, enzyme inhibitors, Study Population, Lymphoid Malignancies, Clinically relevant, signal transduction

Sunday, December 2, 2018: 5:30 PM; Ballroom 20D (San Diego Convention Center)

*Daniel J. Landsburg, MD<sup>1</sup>, Mitchell E. Hughes, PharmD<sup>1\*</sup>, Alexa Koike<sup>1\*</sup>, David A. Bond, MD<sup>2</sup>, Kami J. Maddocks, MD<sup>2</sup>, Ling Guo, MD<sup>3\*</sup>, Allison M. Winter, MD<sup>4</sup>, Brian T. Hill, MD, PhD<sup>4,5</sup>, Sarah L. Ondrejka, DO<sup>4</sup>, Eric D. Hsi, MD<sup>4</sup>, Sunita Dwivedy Nasta, MD<sup>1</sup>, Jakub Svoboda, MD<sup>1</sup>, Stephen J. Schuster, MD<sup>1</sup> and Agata M. Bogusz, MD, PhD<sup>1\*</sup>*

<sup>1</sup>University of Pennsylvania, Philadelphia, PA

<sup>2</sup>Ohio State University, Columbus, OH

<sup>3</sup>Department of Pathology, Ohio State University, Columbus, OH

<sup>4</sup>Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

### 495 Leukocyte Subtypes As Predictors for Venous Thromboembolism in Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Hemophilia, Thrombosis, ITP, and Hereditary Transthyreitin Amyloidosis

Hematology Disease Topics & Pathways: Diseases, Adult, Non-Hodgkin Lymphoma, Biological Processes, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant, inflammation

Sunday, December 2, 2018: 5:00 PM; Room 24B (San Diego Convention Center)

*Jahnnavi Gollamudi, MD<sup>1\*</sup>, Gouri Dharmavaram<sup>2\*</sup>, Petra Martin<sup>3\*</sup>, Kirsten Marie Boughan, DO<sup>4</sup>, Brenda Cooper, MD<sup>4</sup>, Molly M Gallogly, MD, PhD<sup>4</sup>, Ehsan Malek, MD<sup>5</sup>, Leland Metheny, MD<sup>4</sup>, Folashade Otegbeye, MBBChir, MPH<sup>4</sup>, Benjamin K. Tomlinson, MD<sup>6</sup>, Marcos de Lima, MD<sup>4</sup>, Lalitha V. Nayak, MD<sup>3</sup> and Paolo Caimi, MD<sup>4</sup>*

<sup>1</sup>Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>2</sup>School of Medicine, Case Western Reserve University, Cleveland

<sup>3</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>4</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>5</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

<sup>6</sup>University Hospitals Seidman Cancer Center, Cleveland, OH

### 509 Efficacy and Safety of 1500mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Program: Oral and Poster Abstracts

Type: Oral

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Novel or Improved Approaches To Treating Sickle Cell Disease

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies, Young Adult, Study Population

Monday, December 3, 2018: 8:00 AM; Room 28D (San Diego Convention Center)

*Clark Brown<sup>1</sup>, Carolyn Hoppe, MD<sup>2</sup>, Adlette Inati<sup>3</sup>, Miguel R. Abboud<sup>4</sup>, Winfred Wang, MD<sup>5</sup>, Robert Liem, MD<sup>6</sup>, Gerald Woods<sup>7</sup>, Lewis L. Hsu<sup>8</sup>, Victor R. Gordeuk, MD<sup>8</sup>, Connie Piccone<sup>9</sup>, Richard A. Drachtman<sup>10</sup>, Erica Fong<sup>11\*</sup>, Sandra Dixon<sup>11\*</sup>, Margaret Tonda, PharmD<sup>11\*</sup>, Carla Washington<sup>11\*</sup> and Joshua Lehrer-Graiwer<sup>11</sup>*

<sup>1</sup>Children's Healthcare of Atlanta, Atlanta, GA  
<sup>2</sup>UCSF Benioff Children's Hospital, Oakland, CA  
<sup>3</sup>Rafik Hariri University Hospital, Beirut, Lebanon  
<sup>4</sup>American University of Beirut Medical Center, Beirut, Lebanon  
<sup>5</sup>St. Jude Children's Research Hospital, Memphis, TN  
<sup>6</sup>Ann and Robert Lurie Children's Hospital of Chicago, Chicago, IL  
<sup>7</sup>Children's Mercy Hospital, Kansas City, Kansas City, MO  
<sup>8</sup>University of Illinois at Chicago, Chicago, IL  
<sup>9</sup>UH Rainbow Babies and Children's Hospital, Cleveland, OH  
<sup>10</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
<sup>11</sup>Global Blood Therapeutics, South San Francisco, CA

## **516 Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance**

Program: Oral and Poster Abstracts

Type: Oral

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: B and T Cell Biology

Hematology Disease Topics & Pathways: Leukemia, Diseases, LGLL, Lymphoid Malignancies

Monday, December 3, 2018: 8:15 AM; Room 8 (San Diego Convention Center)

***Cassandra M. Hirsch<sup>1\*</sup>, Michael Clemente, MS<sup>2\*</sup>, Peter Chomczynski<sup>2\*</sup>, Bartłomiej P. Przychodzen<sup>3\*</sup>, Yasunobu Nagata<sup>4\*</sup>, Vera Adema, PhD<sup>5\*</sup>, Louis Williams, MD, MBA<sup>1</sup>, Valeria Visconte, PhD<sup>2</sup>, Alan Lichtin, MD<sup>6</sup>, Satu Mustjoki, MD, PhD<sup>7</sup>, Mikael A. Sekeres, MD, MS<sup>8</sup> and Jaroslaw P. Maciejewski<sup>1,9</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

<sup>8</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **537 Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia**

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Acquired Bone Marrow Failure and Somatic Genetics

Hematology Disease Topics & Pathways: Diseases, Anemias, Adult, aplastic anemia, Bone Marrow

Failure, Elderly, Biological Processes, Technology and Procedures, Study Population, immune mechanism, NGS, pathogenesis

Monday, December 3, 2018: 7:30 AM; Grand Ballroom 2 (Marriott Marquis San Diego Marina)

***Sofie Lundgren, BMed<sup>1\*</sup>, Jani Huuhtanen, BMed<sup>1,2\*</sup>, Mikko A Keränen, MD, PhD<sup>1\*</sup>, Cassandra M. Hirsch<sup>3\*</sup>, Emmi Jokinen, MSc<sup>2\*</sup>, Markus Heinonen, PhD<sup>2,4\*</sup>, Paula Savola, MD<sup>1\*</sup>, Tiina Kelkka, PhD<sup>1\*</sup>, Freja Ebeling, MD, PhD<sup>5\*</sup>, Jaroslaw P. Maciejewski<sup>3</sup>, Eva Hellstrom Lindberg, MD, PhD<sup>6</sup>, Harri Lähdesmäki, PhD<sup>2\*</sup> and Satu Mustjoki, MD, PhD<sup>1,7</sup>***

<sup>1</sup>Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

<sup>2</sup>Department of Computer Science, Aalto University School of Science, Espoo, Finland

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Helsinki Institute for Information Technology, Helsinki, Finland

<sup>5</sup>Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

<sup>6</sup>Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

<sup>7</sup>Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland

## 564 Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Targeted Therapy

Hematology Disease Topics & Pathways: Adult, Diseases, AML, Therapies, Non-Biological, Study

Population, Myeloid Malignancies, pharmacology

Monday, December 3, 2018: 8:15 AM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)

*Keith W. Pratz, MD<sup>1</sup>, Mohamad Cherry, MD, MS<sup>2</sup>, Jessica K. Altman, MD<sup>3</sup>, Brenda Cooper, MD<sup>4</sup>, Jose Carlos Cruz, MD<sup>5</sup>, Joseph G. Jurcic, MD<sup>6</sup>, Mark J. Levis, MD<sup>7</sup>, Tara L Lin, MD<sup>8,9</sup>, Alexander E. Perl, MD<sup>10</sup>, Nikolai A. Podoltsev, MD, PhD<sup>11</sup>, Gary J. Schiller, MD<sup>12</sup>, Chaofeng Liu, PhD, MBA<sup>13\*</sup> and Erkut Bahcec, MD<sup>13</sup>*

<sup>1</sup>John Hopkins University, Baltimore, MD

<sup>2</sup>Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK

<sup>3</sup>Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

<sup>4</sup>Adult Hematologic Malignancies and Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>5</sup>Methodist Physician Practices, San Antonio, TX

<sup>6</sup>Columbia University Medical Center, New York, NY

<sup>7</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>8</sup>University of Kansas Medical Center, Kansas City, KS

<sup>9</sup>Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS

<sup>10</sup>Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA

<sup>11</sup>Yale School of Medicine, New Haven, CT

<sup>12</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

<sup>13</sup>Astellas Pharma Global Development, Northbrook, IL

## 575 Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes Of Lymphoma In The Elderly

Hematology Disease Topics & Pathways: Diseases, Adult, Lymphoma (any), Elderly, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Monday, December 3, 2018: 8:00 AM; Pacific Ballroom 18 (Marriott Marquis San Diego Marina)

*Madison Keenan<sup>1\*</sup>, Kirsten Marie Boughan, DO<sup>2</sup>, Brenda Cooper, MD<sup>2</sup>, Molly M Gallogly, MD, PhD<sup>2</sup>, Stanton L. Gerson, MD<sup>3</sup>, Hillard M Lazarus, MD<sup>2</sup>, Ehsan Malek, MD<sup>4</sup>, Leland Metheny, MD<sup>2</sup>, Folashade Otegbeye, MBBChir, MPH<sup>2</sup>, Benjamin K. Tomlinson, MD<sup>2</sup>, Erika Moore, MD<sup>5\*</sup>, Kwadwo Asare Oduro, MD, PhD<sup>5</sup>, Rose Beck, MD, PhD<sup>5\*</sup>, Howard Meyerson, MD<sup>5\*</sup>, Marcos de Lima, MD<sup>2</sup> and Paolo F Caimi, MD<sup>6</sup>*

<sup>1</sup>Case Western Reserve University, Cleveland, OH

<sup>2</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>3</sup>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

<sup>4</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

<sup>5</sup>Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>6</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

## 697 Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Program: Oral and Poster Abstracts

Type: Oral

Session: 703. Adoptive Immunotherapy: In Vitro, Correlative, and Early Phase Studies to Improve Safety and Efficacy of CAR-T Cells

Hematology Disease Topics & Pathways: Biological, Diseases, bioengineering, Therapies, CAR-Ts, Non-

Hodgkin Lymphoma, Technology and Procedures, B-Cell Lymphoma, gene therapy, immunotherapy, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018: 10:30 AM; San Diego Ballroom B (Marriott Marquis San Diego Marina)

*Jennifer Brudno, MD<sup>1</sup>, Steven Hartman<sup>2\*</sup>, Norris Lam, BS<sup>3\*</sup>, David F. Stroncek<sup>4</sup>, John M. Rossi, MS<sup>5\*</sup>, Yueh-wei Shen<sup>5\*</sup>, Allen Xue, PhD<sup>5\*</sup>, Adrian Bot, MD, PhD<sup>5\*</sup>, Jennifer A Kanakry, MD<sup>3\*</sup>, Steven Z. Pavletic, MD<sup>6</sup>, Lekha Mikkilineni, MD<sup>7\*</sup>, Mark Roschewski, MD<sup>8</sup>, Robert M. Dean, MD<sup>9</sup>, Jeremy J. Rose, MS<sup>3\*</sup>, Rashmika Patel<sup>2\*</sup>, Brenna Hansen<sup>2\*</sup>, Steve A. Rosenberg<sup>10\*</sup>, Ronald E. Gress, MD<sup>11</sup> and James N. Kochenderfer, MD<sup>12</sup>*

<sup>1</sup>Experimental Transplantation and Immunology Branch, NIH, NCI, Bethesda, MD

<sup>2</sup>NIH, NCI, Bethesda

<sup>3</sup>Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

<sup>4</sup>National Institutes of Health, Clinical Center, Transfusion Medicine Department, Bethesda, MD

<sup>5</sup>Kite, a Gilead Company, Santa Monica, CA

<sup>6</sup>Experimental Transplantation and Immunology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD

<sup>7</sup>National Institutes of Health Clinical Center, Bethesda, MD

<sup>8</sup>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

<sup>9</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>10</sup>Surgery Branch, National Institutes of Health Clinical Center, Bethesda, MD

<sup>11</sup>Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

<sup>12</sup>Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

## 704 Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Therapy of Post-Transplantation Relapse

Hematology Disease Topics & Pathways: Diseases, Biological, CML, Therapies, Clinically relevant, Myeloid Malignancies, transplantation, TKI

Monday, December 3, 2018: 10:45 AM; Grand Hall B (Manchester Grand Hyatt San Diego)

*Sarah Ann Schmidt, PharmD<sup>1\*</sup>, Jennifer Holter Chakrabarty, MD<sup>2\*</sup>, Ying Liu, PhD<sup>3,4\*</sup>, Zhen-Huan Hu, MPH<sup>3\*</sup>, Kirsten M. Williams, MD<sup>5</sup>, Edwin P. Alyea III, MD<sup>6</sup>, Uday Popat, MD<sup>7</sup>, Ronald Sobecks, MD<sup>8</sup>, Bart L Scott, MD<sup>9</sup> and Wael Saber, MD, MS<sup>3\*</sup>*

<sup>1</sup>University of Oklahoma, Oklahoma City, OK

<sup>2</sup>Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK

<sup>3</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Division of Biostatistics, Institution for Health and Society, Medical College of Wisconsin, Milwaukee

<sup>5</sup>CETI, Children's National Medical Center, Washington, DC

<sup>6</sup>Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA

<sup>7</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>8</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>9</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

## 712 Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Program: Oral and Poster Abstracts

Type: Oral

Session: 902. Health Services Research—Malignant Diseases: Big Data And Outcomes Research

Hematology Disease Topics & Pathways: Quality Improvement

Monday, December 3, 2018: 11:15 AM; Room 24B (San Diego Convention Center)

*Madeline Waldron, PharmD<sup>1\*</sup>, Caitlin Siebenaller, PharmD<sup>2\*</sup>, Marc Earl, PharmD<sup>2\*</sup>, Hetty E. Carraway, MD, MBA<sup>3,4</sup>, Anjali S. Advani, MD<sup>5</sup>, Aziz Nazha, MD<sup>6</sup>, Aaron T. Gerds, MD, MS<sup>3</sup>, Betty K. Hamilton, MD<sup>3</sup>, Ronald Sobecks, MD<sup>7</sup>, Matt Kalaycio, MD<sup>7</sup>, Barb Tripp, CNS<sup>8\*</sup>, Brian P. Hobbs, PhD<sup>9\*</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>10</sup> and Mikael A. Sekeres, MD, MS<sup>11</sup>*

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Pharmacy, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>5</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Cleveland Clinic, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>8</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>10</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>11</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **714 Area-Based Socioeconomic Status and Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Outcomes: A CIBMTR Analysis**

Program: Oral and Poster Abstracts

Type: Oral

Session: 902. Health Services Research—Malignant Diseases: Big Data And Outcomes Research

Hematology Disease Topics & Pathways: Pediatric, Study Population, Quality Improvement

Monday, December 3, 2018: 11:45 AM; Room 24B (San Diego Convention Center)

Kira O Bona, MD, MPH<sup>1</sup>, Ruta Brazauskas, PhD<sup>2,3\*</sup>, Naya He<sup>3\*</sup>, Leslie E. Lehmann, MD<sup>4</sup>, Joanne Wolfe, MD, MPH<sup>5\*</sup>, Jignesh Dalal, MD<sup>6</sup>, Shahrukh K. Hashmi, MD, MPH<sup>7,8</sup>, Theresa E. Hahn, PhD<sup>9</sup>, Nandita Khera, MD<sup>10</sup>, William A. Wood, MD, MPH<sup>11</sup>, Christine Duncan, MD<sup>12</sup> and Wael Saber, MD, MS<sup>3\*</sup>

<sup>1</sup>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

<sup>2</sup>Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

<sup>3</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Dana-Farber/Boston Children's Cancer & Blood Disorders Center, Boston, MA

<sup>5</sup>Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

<sup>6</sup>Rainbow Babies & Children's Hospital, Cleveland, OH

<sup>7</sup>Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

<sup>8</sup>Department of Internal Medicine, Mayo Clinic, Rochester, MN

<sup>9</sup>Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>10</sup>Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

<sup>11</sup>Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC

<sup>12</sup>Dana-Farber Cancer Institute, Boston, MA

## **853 A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial**

Program: Oral and Poster Abstracts

Type: Oral

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Pain and Pain Management in Sickle Cell Disease

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies, Clinically relevant

Monday, December 3, 2018: 4:30 PM; Room 25B (San Diego Convention Center)

Sophie Lanzkron, MD<sup>1</sup>, Jane Little, MD<sup>2,3</sup>, Joshua J. Field, MD<sup>4</sup>, Carlton Haywood Jr., PhD, MA<sup>5\*</sup>, Ravi Varadhan, PhD<sup>6\*</sup>, Mustapha Saheed, MD<sup>7\*</sup>, Marc Proudford<sup>8\*</sup>, Derek Robertson, MBA, JD<sup>9\*</sup>, Adrienne Kincaid<sup>10\*</sup>, Lorri Burgess, BS<sup>11\*</sup>, Charles Green<sup>12\*</sup>, Hang Wang, PhD<sup>13\*</sup>, Rebecca Seufert, BS<sup>14,15\*</sup>, Jasmine Brooks, BA<sup>13\*</sup>, Allie Piehet, BS<sup>16\*</sup>, Brandi Griffin, BSN, RN<sup>17\*</sup>, Nicole Arnold<sup>18\*</sup>, Steven Frymark<sup>19\*</sup>, Chiung-Yu Huang, PhD<sup>20\*</sup>, Marcus Wallace, MD<sup>21\*</sup>, Nebras Abu Al Hamayel, MBBS, MPH<sup>22\*</sup> and Jodi Segal, MD<sup>23\*</sup>

<sup>1</sup>Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

<sup>2</sup>CWRU School of Medicine, CWRU/University Hospitals, Cleveland, OH

<sup>3</sup>Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>4</sup>Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

<sup>5</sup>The Johns Hopkins University, Baltimore, MD

<sup>6</sup>Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD

<sup>7</sup>Johns Hopkins University, School of Medicine, Baltimore, MD

<sup>8</sup>Johns Hopkins Community Based Organization Partner, Baltimore

<sup>9</sup>Community Based Organization Partner, Maryland Sickle Cell Disease Association, Columbia

<sup>10</sup>Community Based Organization Partner, Kincaid's Kindred Spirits, Euclid

<sup>11</sup>Community Based Organization Partner, Lady of the Lake Regional Medical Center, Baton Rouge, LA

<sup>12</sup>Community Based Organization Partner, Blood Center of Wisconsin, Milwaukee

<sup>13</sup>Johns Hopkins University, School of Medicine, Baltimore, MD

<sup>14</sup>Johns Hopkins School of Medicine, Baltimore, MD

<sup>15</sup>School of Medicine, Johns Hopkins University, Baltimore, MD

<sup>16</sup>Our Lady of the Lake Hospital, Baton Rouge

<sup>17</sup>Case Western Reserve University Hospital, Cleveland

<sup>18</sup>Case Western Reserve University Hospital, Cl, OH

<sup>19</sup>Blood Center of Wisconsin, Milwaukee, WI

<sup>20</sup>University of California San Francisco, San Francisco, CA

<sup>21</sup>Louisiana Health Care Connection, Baton Rouge, LA

<sup>22</sup>Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

<sup>23</sup>School of Medicine, Johns Hopkins School of Medicine, Baltimore, MD

## **900 Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?**

Program: Oral and Poster Abstracts

Type: Oral

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy

Hematology Disease Topics & Pathways: Adult, ALL, Leukemia, Diseases, Non-Biological, Therapies,

Elderly, chemotherapy, Pediatric, Young Adult, Study Population, Clinically relevant, Lymphoid

Malignancies

Monday, December 3, 2018: 5:45 PM; Room 6A (San Diego Convention Center)

***Remco J Molenaar, MD PhD<sup>1,2\*</sup>, Tomas Radivoyevitch<sup>3\*</sup>, Aaron T. Gerds, MD, MS<sup>4</sup>, Aziz Nazha, MD<sup>5</sup>, Hetty E. Carraway, MD, MBA<sup>5,6</sup>, Anjali S. Advani, MD<sup>6</sup>, Matt Kalaycio, MD<sup>7</sup>, Navneet S. Majhail, MD, MS<sup>8</sup>, Jaroslaw P. Maciejewski<sup>9</sup>, Mikael A. Sekeres, MD, MS<sup>10</sup> and Sudipto Mukherjee, MD, PhD, MPH<sup>11</sup>***

<sup>1</sup>Academic Medical Center, Amsterdam, Netherlands

<sup>2</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

<sup>4</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>5</sup>Cleveland Clinic, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>11</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **928 Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma**

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma:

Chemotherapy and Response Adapted Approaches

Hematology Disease Topics & Pathways: Diseases, Adult, Biological, Therapies, Study Population,

Lymphoid Malignancies

Monday, December 3, 2018: 5:15 PM; Room 6F (San Diego Convention Center)

***Mehdi Hamadani, MD<sup>1</sup>, Graham P. Collins, MB BS DPhil<sup>2\*</sup>, Felipe Samaniego, MD<sup>3</sup>, Alexander I Spira, MD<sup>4\*</sup>, Andrew Davies, MD<sup>5\*</sup>, John Radford, MD, FRCP<sup>6\*</sup>, Paolo Caimi, MD<sup>7</sup>, Tobias Menne, MD, PhD<sup>8\*</sup>, Joseph Boni, PhD<sup>9\*</sup>, Hans Cruz, PhD<sup>10</sup>, Jay Feingold, MD, PhD<sup>11\*</sup>, Shui He, PhD<sup>9\*</sup>, Jens Wuerthner<sup>10\*</sup> and Steven M. Horwitz, MD<sup>12</sup>***

<sup>1</sup>Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>2</sup>Oxford University Hospitals, NHS Trust, Oxford, United Kingdom

<sup>3</sup>Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>4</sup>Virginia Cancer Specialists Research Institute, Fairfax, VA

<sup>5</sup>Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom

<sup>6</sup>Manchester Academic Health Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

<sup>7</sup>Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>8</sup>The Newcastle upon Tyne Hospitals NHS Trust, Newcastle, United Kingdom

<sup>9</sup>ADC Therapeutics, Inc., Murray Hill, NJ

<sup>10</sup>ADC Therapeutics, Switzerland, Switzerland

<sup>11</sup>ADC Therapeutics, Inc, Murray Hill, NJ

## 929 Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Hodgkin Lymphoma, chemotherapy, Study Population, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018: 5:30 PM; Room 6F (San Diego Convention Center)

*Deborah M. Stephens<sup>1</sup>, Hongli Li, MS<sup>2\*</sup>, Heiko Schoder, MD<sup>3\*</sup>, David J. Straus, MD<sup>4</sup>, Craig H. Moskowitz, MD<sup>3\*</sup>, Michael L. Leblanc, PhD<sup>2\*</sup>, Lisa M. Rimsza, MD<sup>5</sup>, Nancy L. Bartlett, MD<sup>6</sup>, Andrew M. Evens, DO, MSc<sup>7</sup>, Ann S. LaCasce, MD, MSc<sup>8</sup>, Paul Barr, MD<sup>9</sup>, Michael V. Knopp<sup>10\*</sup>, Eric D. Hsi, MD<sup>11</sup>, John P. Leonard, MD<sup>12</sup>, Brad S Kahl, MD<sup>13</sup>, Sonali M. Smith, MD<sup>14</sup> and Jonathan W. Friedberg, MD<sup>15</sup>*

<sup>1</sup>Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

<sup>2</sup>SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY

<sup>4</sup>Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>5</sup>Department of Research, Mayo Clinic - Scottsdale, Scottsdale, AZ

<sup>6</sup>Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

<sup>7</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>8</sup>Dana-Farber Cancer Institute, Partners CancerCare, Boston, MA

<sup>9</sup>University of Rochester, Rochester, NY

<sup>10</sup>The Ohio State University, Columbus, OH

<sup>11</sup>Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>12</sup>Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

<sup>13</sup>Department of Medicine, Washington University School of Medicine, Saint Louis, MO

<sup>14</sup>University of Chicago, Chicago, IL

<sup>15</sup>Wilmot Cancer Institute, University of Rochester, Rochester, NY

## 971 Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results I

Hematology Disease Topics & Pathways: Biological, AML, Diseases, Therapies, MDS, Myeloid Malignancies, transplantation

Monday, December 3, 2018: 5:30 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

*Betul Oran, MD, MS<sup>1</sup>, Marcos de Lima, MD<sup>2</sup>, Guillermo Garcia-Manero, MD<sup>3</sup>, Peter F Thall<sup>4\*</sup>, Ruitao Lin<sup>4\*</sup>, Amin M. Alousi, MD<sup>5</sup>, Chitra Hosing, MD<sup>6</sup>, Partow Kebriaei, MD<sup>1</sup>, Uday Popat, MD<sup>1</sup>, Sergio Giralt, MD<sup>7</sup>, Sairah Ahmed, MD<sup>5</sup>, Elizabeth J. Shpall, MD<sup>5</sup>, Borje S Andersson, MD, PhD<sup>6</sup>, Qaiser Bashir, MBBS<sup>6</sup>, Stefan O. Ciurea<sup>1</sup>, Katy Rezvani, MD, PhD<sup>1</sup>, Glenda Woodworth, BSN, OCN, RN<sup>1\*</sup> and Richard E Champlin, MD<sup>1</sup>*

<sup>1</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>2</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>3</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>4</sup>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>5</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

<sup>6</sup>The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>7</sup>Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

## 988 Monitoring the Effects of Direct Oral Anticoagulants with a Novel Point-of-Care Sensor: Results of a Pilot Clinical Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 332. Antithrombotic Therapy: New Drugs and Technology

Hematology Disease Topics & Pathways: Adult, Diseases, bioengineering, Hemostasis, Bleeding and clotting, Technology and Procedures, Study Population, Clinically relevant

Monday, December 3, 2018: 7:00 PM; Room 29C (San Diego Convention Center)

Aman Opneja, MBBS<sup>1,2</sup>, Debnath Maji, M.Tech<sup>3\*</sup>, Pedram Mohseni, PhD<sup>3\*</sup>, Michael A Suster, PhD<sup>3\*</sup> and Evi X Stavrou, MD<sup>4,5</sup>

<sup>1</sup>Division of Hematology Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, BALTIMORE, MD

<sup>2</sup>Division of Hematology Oncology, Louis Stokes Veterans Administration Hospital, Cleveland, OH

<sup>3</sup>Case Western Reserve University, Cleveland, OH

<sup>4</sup>Division of Hematology-Oncology, Louis Stokes Veterans Administration Hospital, Cleveland, OH

<sup>5</sup>Case Western Reserve University/, Cleveland, OH

**1015 T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes**

Program: Oral and Poster Abstracts

Type: Oral

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted therapy

Hematology Disease Topics & Pathways: Diseases, Leukemia, ALL, AML, Biological, Adult, Therapies, MDS, Study Population, Lymphoid Malignancies, Myeloid Malignancies, transplantation

Monday, December 3, 2018: 6:15 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Scott R Solomon, MD<sup>1</sup>, Andrew St. Martin, MS<sup>2\*</sup>, Nirav N Shah, MD<sup>3</sup>, Giancarlo Fatobene, MD<sup>4\*</sup>, Monzr Al Malki, MD<sup>5</sup>, Karen K. Ballen, MD<sup>6\*</sup>, Asad Bashey, MD, PhD<sup>7</sup>, Nelli Bejanyan, MD<sup>8</sup>, Javier Bolaños-Meade, MD<sup>9</sup>, Claudio G Brunstein, MD, PhD<sup>10</sup>, Zachariah Defilipp, MD<sup>11</sup>, Richard E Champlin, MD<sup>12</sup>, Ephraim J. Fuchs, MD, MBA<sup>9</sup>, Mehdi Hamadani, MD<sup>13</sup>, Peiman Hematti, MD<sup>14</sup>, Christopher G. Kanakry, MD<sup>15\*</sup>, Joseph P. McGuirk, DO<sup>16</sup>, Ian K. McNiece, PhD<sup>17\*</sup>, Stefan O. Ciurea<sup>18</sup>, Marcelo C. Pasquini, MD<sup>19</sup>, Vanderson Rocha, MD, PhD<sup>20\*</sup>, Rizwan Romee, MD<sup>21</sup>, Sagar S. Patel, MD<sup>22</sup>, Sumithra Vasu, MD, MBBS<sup>23</sup>, Edmund K. Waller, MD<sup>24</sup>, John R. Wingard, MD<sup>25</sup>, Mei-Jie Zhang, PhD<sup>26\*</sup> and Mary Eapen, MBBS, MS<sup>2</sup>

<sup>1</sup>Blood and Marrow Transplant Program, BMT Group of Georgia, Atlanta, GA

<sup>2</sup>Medical College of Wisconsin, Milwaukee, WI

<sup>3</sup>Department of Medicine, Medical College of Wisconsin, Brookfield, WI

<sup>4</sup>Médico do Centro de Oncologia do Hospital Sírio-Libanês, São Paulo, Brazil

<sup>5</sup>Department of Hematology/HCT, City of Hope, Duarte, CA

<sup>6</sup>Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA

<sup>7</sup>Blood and Marrow Transplant Group of Georgia, BMT Group of Georgia, Atlanta, GA

<sup>8</sup>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

<sup>9</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>10</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

<sup>11</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute, Massachusetts General Hospital, Boston, MA

<sup>12</sup>The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>13</sup>Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>14</sup>Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI

<sup>15</sup>Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

<sup>16</sup>Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

<sup>17</sup>CellIMED Consulting, Miami, FL

<sup>18</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>19</sup>CBIMTR and Medical College of Wisconsin, Milwaukee, WI

<sup>20</sup>Department of Hematology, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil

<sup>21</sup>Department of Medicine, Division of Oncology, Dana Farber Cancer Institute, Boston, MA

<sup>22</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>23</sup>Hematology, The Ohio State University, Columbus, OH

<sup>24</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

<sup>25</sup>University of Florida Department of Medicine/Division of Hematology Oncology, Gainesville, FL

<sup>26</sup>CBIMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

**1017 Targeted Conditioning of Iomab-B (<sup>131</sup>I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial**

Program: Oral and Poster Abstracts

Type: Oral

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted therapy

Hematology Disease Topics & Pathways: Diseases, AML, Biological, antibodies, Adult, Therapies, bone marrow, Elderly, Biological Processes, Technology and Procedures, immunotherapy, Study Population, Clinically relevant, Myeloid Malignancies, transplantation, stem cells

Monday, December 3, 2018: 6:45 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

*Edward Agura, MD<sup>1</sup>, Boglarka Gyurkocza, MD<sup>2</sup>, Rajneesh Nath, MD<sup>3</sup>, Mark R. Litzow, MD<sup>4</sup>, Benjamin K. Tomlinson, MD<sup>5</sup>, Sunil Abhyankar, MD<sup>6</sup>, Stuart Seropian, MD<sup>7\*</sup>, Patrick J. Stiff, MD<sup>8</sup>, Hannah K. Choe, MD<sup>9</sup>, Partow Kebriaei, MD<sup>10</sup>, James M. Foran, MD<sup>11</sup>, George Chen, MD<sup>12</sup>, Moshe Yair Levy, MD<sup>1</sup>, Hillard M Lazarus, MD<sup>13</sup>, Sergio Giralt, MD<sup>2</sup>, Mark S. Berger, MD<sup>14</sup>, Vijay Reddy, MD, PhD<sup>14</sup> and John M. Pagel, MD, PhD<sup>15</sup>*

<sup>1</sup>Baylor University Medical Center at Dallas, Dallas, TX

<sup>2</sup>Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>3</sup>Banner MD Anderson Cancer Center, Gilbert, AZ

<sup>4</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>5</sup>University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>6</sup>Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

<sup>7</sup>Yale University School of Medicine, New Haven, CT

<sup>8</sup>Loyola Univ. Med. Ctr., Maywood, IL

<sup>9</sup>The Ohio State University Comprehensive Cancer Center, columbus

<sup>10</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>11</sup>Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

<sup>12</sup>Medicine, Roswell Park Cancer Institute, Buffalo, NY

<sup>13</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>14</sup>Actinium Pharmaceuticals, New York, NY

<sup>15</sup>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

**POSTER PRESENTATIONS**

**1038 Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry**

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I

Hematology Disease Topics & Pathways:

Diseases, Anemias, Bleeding and clotting, Thrombosis, PNH

Saturday, December 1, 2018, 6:15 PM-8:15 PM

Hall GH (San Diego Convention Center)

*Regis Peffault De Latour<sup>1,2\*</sup>, Jaroslaw P. Maciejewski<sup>3</sup>, Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPath<sup>4</sup>, Loree Larratt, MD, FRCP(C)<sup>5\*</sup>, Ronald S. Go, MD<sup>6</sup>, David Dingli, MD, PhD<sup>6</sup>, Amanda Wilson, PhD<sup>7\*</sup>, Philippe Gustovic, MD<sup>8\*</sup> and Aleksandr Kulagin<sup>9\*</sup>*

<sup>1</sup>Université Paris Diderot, Paris, France

<sup>2</sup>French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Department of Haematological Medicine, King's College Hospital, NIHR/Wellcome King's Clinical Research Facility, London, United Kingdom

<sup>5</sup>Department of Medicine, University of Alberta, Edmonton, AB, Canada

<sup>6</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>7</sup>Alexion Pharmaceuticals, Inc., Lexington, MA

<sup>8</sup>Alexion Pharma GmbH, Zürich, Switzerland

<sup>9</sup>Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation

**1054 The LSD1 Inhibitor RN-1<sup>3</sup>-Globin<sup>4</sup> Expression<sup>5</sup> in Baboons<sup>6</sup> By Targeting an Early Event<sup>7</sup> Responsible for<sup>8</sup>  $\beta$ -Globin Repression**

Program: Oral and Poster Abstracts

Session: 112. Thalassemia and Globin Gene Regulation: Poster I

Hematology Disease Topics & Pathways:

Anemias, Diseases, Non-Biological, Therapies, Biological Processes, epigenetics, erythropoiesis, pharmacology

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Kestis Vaitkus<sup>1\*</sup>, Vinzon Ibanez, B.S.<sup>1\*</sup>, Maria Armila Ruiz, B.S.<sup>1\*</sup>, Ramasamy Jagadeeswaran, PhD.<sup>2\*</sup>, Yogenthiran Saunthararajah, MD<sup>3</sup>, James Douglas Engel, PhD<sup>4</sup>, Joseph DeSimone, PhD<sup>1\*</sup>, Angela Rivers, MD<sup>2</sup> and Donald Lavelle, PhD<sup>1</sup>*

<sup>1</sup>Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL

<sup>2</sup>Department of Pediatrics, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL

<sup>3</sup>Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH

<sup>4</sup>Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI

**1095 Clinical Testing of Hemechip in Nigeria for Point-of-Care Screening of Sickle Cell Disease**

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster I

Hematology Disease Topics & Pathways:

Adult, Diseases, sickle cell disease, Pediatric, Technology and Procedures, Hemoglobinopathies, Young Adult, Study Population, Clinically relevant, newborn screening

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Muhammad Noman Hasan, MS<sup>1\*</sup>, Arwa Friwan, PhD<sup>1\*</sup>, Priyaleela Thota, MD<sup>2\*</sup>, Tolulope Oginni, BS<sup>3\*</sup>, Grace Mfon Olanipekun<sup>4\*</sup>, Fatimah Hassan-Hanga, MD<sup>5\*</sup>, Jane Little, MD<sup>1,6,7</sup>, Stephen K. Obaro, MD, PhD<sup>4,8\*</sup> and Umut A. Gurkan, PhD<sup>1</sup>*

<sup>1</sup>Case Western Reserve University, Cleveland, OH

<sup>2</sup>Hemex Health Inc., Portland, OR

<sup>3</sup>eHealth Africa, Kano, Nigeria

<sup>4</sup>International Foundation Against Infectious Disease in Nigeria, Abuja, Nigeria

<sup>5</sup>Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria

<sup>6</sup>Division of Hematology/Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>7</sup>Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>8</sup>Division of Pediatric Infectious Diseases, University of Nebraska Medical Center, Omaha, NE

**1116 Human Bone Marrow Derived Mesenchymal Stromal Cells Enhance the Number and Function of Umbilical Cord Blood Peripheral Tregs during IL-2 Driven Ex Vivo Expansion**

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Jeong-Su Do, PhD<sup>1</sup>, Alex Y. Huang, MD, PhD<sup>2\*</sup>, Daniel Zwick, PhD<sup>1\*</sup>, Fei Zhong, MD<sup>1\*</sup>, David Askew, PhD<sup>2\*</sup>, Wouter van't Hof, PhD<sup>3\*</sup>, Marcie Finney, MS<sup>3\*</sup> and Mary Laughlin, MD<sup>3</sup>*

<sup>1</sup>Research & Development, Cleveland Cord Blood Center, Cleveland, OH

<sup>2</sup>Case Western Reserve University, Cleveland, OH

<sup>3</sup>Cleveland Cord Blood Center, Cleveland, OH

**1226 Expression of Recombinant  $\beta$ 2GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome**

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster I

Hematology Disease Topics & Pathways:

cellular interactions, Biological Processes, Technology and Procedures, immune mechanism, inflammation, pathogenesis, signal transduction

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Ravi Kumar Alluri, PhD<sup>1</sup>\*, Suman Kundu, MBA<sup>1</sup>\*, Jack Su, PhD<sup>2</sup>\*, Sekhar Kambakam<sup>2</sup>\*, Edward Yu, PhD<sup>2</sup>\* and Keith R. McCrae, MD<sup>1,3</sup>*

<sup>1</sup>Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Pharmacology, Case Western Reserve University, Cleveland, OH

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

**1237 Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism**

Program: Oral and Poster Abstracts

Session: 332. Antithrombotic Therapy: Poster I

Hematology Disease Topics & Pathways:

anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, Clinically relevant, Thromboembolism

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Deborah Y. Park, BS<sup>1</sup>\*, Shyam K. Poudel, MD<sup>2</sup>\*, Xuefei Jia, MS<sup>3</sup>\*, Mailey Lynn Wilks, CNP, MSN, APRN<sup>2</sup>\*, Vicki Pinkava, MSBS, PA-C<sup>2</sup>\*, Meghan O'Brien, MS, ANP-BC<sup>2</sup>\*, Barbara Tripp, CNS, AOCN<sup>2</sup>\*, Jung-Min Song, RN, CNS<sup>2</sup>\*, Keith R. McCrae, MD<sup>2</sup>, Dana E. Angelini, MD<sup>2</sup> and Alok A. Khorana<sup>2</sup>*

<sup>1</sup>Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH

<sup>2</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

**1242 Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis**

Program: Oral and Poster Abstracts

Session: 332. Antithrombotic Therapy: Poster I

Hematology Disease Topics & Pathways:

Adult, anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, Thrombosis, Study Population, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Shafia Rahman, MD<sup>1</sup>, Fahrettin Covut, MD<sup>1</sup>, Yihong Zhou, MD<sup>1</sup>\*, Shab E Gul Rahim, MD<sup>1</sup>\*, Sudha Amarnath, MD<sup>2</sup>\* and Alok A. Khorana<sup>3</sup>*

<sup>1</sup>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

**1302 Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways:

Diseases, Anemias, aplastic anemia, Therapies, Non-Biological, Bone Marrow Failure, chemical interactions, Biological Processes, hematopoiesis

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Sergei Vatolin, PhD<sup>1</sup>\* and Jaroslaw P. Maciejewski<sup>2</sup>*

<sup>1</sup>Lerner research institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

**1303 Selective Pharmacologic Inhibition of Paroxysmal Nocturnal Hemoglobinuria Clones**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways:

Anemias, Diseases, aplastic anemia, Bone Marrow Failure, Biological Processes, Technology and Procedures, PNH, Clinically relevant, Quality Improvement , flow cytometry, pathogenesis

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Amy C Graham, BS, MS<sup>1</sup>, Alexey Efanov, PhD<sup>2</sup>, Bartlomiej P. Przychodzen<sup>3</sup>, Cassandra M. Hirsch<sup>4</sup>, Vera Adema, PhD<sup>3</sup>, Valeria Visconte, PhD<sup>3</sup> and Jaroslaw P. Maciejewski<sup>1</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

**1388 Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study**

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Adult, Biological, AML, Diseases, bone marrow, Therapies, Elderly, Study Population, Clinically relevant, Myeloid Malignancies, transplantation

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Mohamed L. Sorror, MD, MSc<sup>1,2</sup>, Barry E. Storer, PhD<sup>3,4\*</sup>, Aaron T. Gerds, MD, MS<sup>5</sup>, Bruno C. Medeiros, MD<sup>6</sup>, Paul J Shami, MD<sup>7</sup>, John P. Galvin, MD, MS, MPH<sup>8</sup>, Kehinde U. Adekola, MBBS, MS<sup>9</sup>, Selina Luger, MD<sup>10</sup>, Maria R. Baer, MD<sup>11</sup>, David A. Rizzieri, MD<sup>12</sup>, Tanya M. Wildes, MD, MSC<sup>13</sup>, Eunice S. Wang, MD<sup>14</sup>, Stefan Faderl, MD<sup>15</sup>, Jamie L. Koprivnikar, MD<sup>15</sup>, Mikael A. Sekeres, MD, MS<sup>5</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>5</sup>, Julie Smith, MD<sup>16\*</sup>, Mitchell Garrison, MD<sup>16\*</sup>, Kiarash Kojouri, MD<sup>17\*</sup>, Jennifer E. Nyland, PhD<sup>1\*</sup>, Rachelle R. Moore, BS<sup>1\*</sup>, Sophie L. Fleuret, BS<sup>1\*</sup>, Ylinne Lynch, MD<sup>1,18\*</sup>, Pamela S. Becker, MD<sup>1,19</sup>, Mary-Elizabeth M. Percival, MD<sup>1,19</sup>, Brenda M. Sandmaier, MD<sup>1,2</sup>, Frederick R. Appelbaum, MD<sup>1,2</sup> and Elihu H. Estey, MD<sup>1,19</sup>***

<sup>1</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>2</sup>Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

<sup>3</sup>Department of Biostatistics, University of Washington School of Public Health, Seattle, WA

<sup>4</sup>Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>5</sup>Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Medicine, Division of Hematology, Stanford University, Palo Alto, CA

<sup>7</sup>Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

<sup>8</sup>Feinberg School of Medicine, Northwestern University, Chicago, IL

<sup>9</sup>Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL

<sup>10</sup>Abramson Cancer Center at the University of Pennsylvania School of Medicine, Philadelphia, PA

<sup>11</sup>University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

<sup>12</sup>Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

<sup>13</sup>Division of Oncology, Washington University School of Medicine, St Louis, MO

<sup>14</sup>Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>15</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

<sup>16</sup>Confluence Health/Wenatchee Valley Hospital, Wenatchee, WA

<sup>17</sup>Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA

<sup>18</sup>Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA

<sup>19</sup>Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

**1389 Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy**

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Adult, Diseases, Non-Biological, Therapies, chemotherapy, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Swapna Thota, MD<sup>1</sup>, Bhumika J. Patel, MD<sup>2</sup>, Hetty E. Carraway, MD, MBA<sup>3,4</sup>, Elizabeth A. Griffiths, MD<sup>5</sup>, Amanda Przespollewski, DO<sup>1</sup>, James E. Thompson, MD<sup>1</sup>, Teodora Kuzmanovic<sup>6\*</sup>, Aziz Nazha, MD<sup>2</sup>, Shimoli Vipul Barot, MD<sup>7</sup>, Cassandra M. Hirsch<sup>8\*</sup>, Bartlomiej P. Przychodzen<sup>6\*</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>2</sup>, Meghan Scully, NP<sup>9\*</sup>, Aaron T. Gerds, MD, MS<sup>10</sup>, Anjali S. Advani, MD<sup>4</sup>, Mikkael A. Sekeres, MD, MS<sup>11</sup>, Manja Meggendorfer, PhD<sup>12</sup>, Eunice S. Wang, MD<sup>13</sup> and Jaroslaw P. Maciejewski<sup>8</sup>**

<sup>1</sup>Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>2</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>5</sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>6</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Leukemia, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>9</sup>Cleveland Clinic, Cleveland

<sup>10</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>11</sup>Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

<sup>12</sup>MIL Munich Leukemia Laboratory, Munich, Germany

<sup>13</sup>Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

#### **1404 Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia**

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

AML, Adult, Diseases, Study Population, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Evan Field<sup>1\*</sup>, Paolo F Caimi, MD<sup>2</sup>, Brenda Cooper, MD<sup>3</sup>, Jane Little, MD<sup>4,5</sup>, Ehsan Malek, MD<sup>6</sup>, Leland Metheny, MD<sup>3</sup>, Marcos de Lima, MD<sup>3,7</sup>, Pingfu Fu<sup>8\*</sup> and Ben Tomlinson, MD<sup>3</sup>**

<sup>1</sup>Case Western Reserve University School of Medicine, Cleveland, OH

<sup>2</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

<sup>3</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>4</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH

<sup>5</sup>Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>6</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>7</sup>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

<sup>8</sup>Case Western Reserve University, Cleveland, OH

#### **1428 Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort**

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation:

Poster I

Hematology Disease Topics & Pathways:

AML, Diseases, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Maximilian Stahl, MD<sup>1</sup>, Wei Wei, MD, PhD<sup>2\*</sup>, Pau Fernandez<sup>3\*</sup>, Etienne Lengline, MD<sup>4\*</sup>, Rory M Shallis, MD<sup>1</sup>, Judith Neukirchen, MD<sup>5\*</sup>, Vijaya R. Bhatt, MD<sup>6</sup>, Mikkael A. Sekeres, MD, MS<sup>7</sup>, Amir T. Fathi, MD<sup>8</sup>, Heiko Konig, MD, PhD<sup>9</sup>, Selina Luger, MD<sup>10</sup>, Irum Khan, MBBS<sup>11</sup>, Gail J. Roboz, MD<sup>12</sup>, Thomas Cluzeau, MD, PhD<sup>13\*</sup>, David Martínez-Cuadron, MD<sup>3\*</sup>, Emmanuel Raffoux, MD<sup>4\*</sup>, Ulrich Germing, MD<sup>5\*</sup>, Jayadev Manikkam Umakanthan, MBBS<sup>6</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>7</sup>, Andrew M. Brunner, MD<sup>14</sup>, Adam M. Miller, BS, MD<sup>9\*</sup>, Christine M. McMahon, MD<sup>10</sup>, Ellen K. Ritchie, MD<sup>12</sup>, Rebeca Rodríguez-Veiga, MD<sup>3\*</sup>, Raphael Itzykson, MD, PhD<sup>4</sup>, Blanca Boluda, MD<sup>3\*</sup>, Florence Rabian, MD<sup>4\*</sup>, Mar Tormo, MD<sup>15\*</sup>, Evelyn Gloria Acuna Cruz, MD<sup>3\*</sup>, Emma Rabinovich, MD<sup>11\*</sup>, Brendan Yoo<sup>10\*</sup>, Nikolai A. Podoltsev, MD, PhD<sup>1</sup>, Steven D. Gore, MD<sup>1</sup> and Amer M. Zeidan, MBBS, MHS<sup>1</sup>**

<sup>1</sup>Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT  
<sup>2</sup>Department of Biostatistics, Yale School of Public Health, New Haven, CT  
<sup>3</sup>Hospital Universitari i Politècnic La Fe, Valencia, Spain  
<sup>4</sup>Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France  
<sup>5</sup>Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany  
<sup>6</sup>University of Nebraska Medical Center, Omaha, NE  
<sup>7</sup>Leukemia Program, Cleveland Clinic, Cleveland, OH  
<sup>8</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA  
<sup>9</sup>Indiana University Simon Cancer Center, Indianapolis, IN  
<sup>10</sup>Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA  
<sup>11</sup>University of Illinois, Chicago, IL  
<sup>12</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY  
<sup>13</sup>Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France  
<sup>14</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA  
<sup>15</sup>University Clinical Hospital, INCLIVA, Valencia, Spain, Valencia, Spain

## 1491 Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster I

Hematology Disease Topics & Pathways:

Biological, AML, Adult, Diseases, Elderly, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Olga K Weinberg, MD<sup>1</sup>, Robert P. Hasserjian, MD<sup>2</sup>, Ezra Baraban, MD<sup>3\*</sup>, Chi Young Ok, MD<sup>4</sup>, Julia T Geyer, MD<sup>5\*</sup>, John KSS Philip, MD<sup>6\*</sup>, Jason H. Kurzer, MD, PhD<sup>7</sup>, Heesun J. Rogers, MD, PhD<sup>8</sup>, Valentina Nardi, MD<sup>2</sup>, Richard M. Stone, MD<sup>9,10</sup>, Jacqueline S. Garcia<sup>9</sup>, Eric D. Hsi, MD<sup>11</sup>, Adam Bagg, MD<sup>12</sup>, Sa A. Wang, MD<sup>13\*</sup>, Attilio Orazi, MD<sup>14\*</sup> and Daniel A. Arber, MD<sup>15</sup>

<sup>1</sup>Harvard Medical school, Boston Children's Hospital, Newton, MA

<sup>2</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA

<sup>3</sup>University of Pennsylvania, Philadelphia, PA

<sup>4</sup>Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Pearland, TX

<sup>5</sup>Pathology, Weill Cornell, New York, NY

<sup>6</sup>Pathology, University of Chicago, Chicago, NY

<sup>7</sup>Stanford University Medical School, Stanford, CA

<sup>8</sup>Department of Hematopathology, Cleveland Clinic, Cleveland

<sup>9</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>10</sup>Harvard Medical School, Boston, MA

<sup>11</sup>Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>12</sup>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

<sup>13</sup>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>14</sup>Weill Cornell Medical College, New York, NY

<sup>15</sup>University of Chicago, Chicago, IL

## 1527 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster I

Hematology Disease Topics & Pathways:

Diseases, AML, Biological Processes, Myeloid Malignancies, genomics

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Rachel Hu, MD<sup>1</sup>, Aziz Nazha, MD<sup>2</sup>, Xuefei Jia, MS<sup>3\*</sup>, Brian P. Hobbs, PhD<sup>4\*</sup>, Hetty E. Carraway, MD, MBA<sup>2,5</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>6</sup>, Aaron T. Gerds, MD, MS<sup>7</sup>, Anjali S. Advani, MD<sup>8</sup>, Yasunobu Nagata<sup>9\*</sup>, Cassandra M. Hirsch<sup>9\*</sup>, Bartłomiej P. Przychodzen<sup>9\*</sup>, Babal K. Jha<sup>10\*</sup>, Jarosław P. Maciejewski<sup>9</sup> and Mikkael A. Sekeres, MD, MS<sup>11</sup>

<sup>1</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Cleveland Clinic, Cleveland, OH

<sup>3</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>6</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>8</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>11</sup>Leukemia Program, Cleveland Clinic, Cleveland, OH

## **1591 The Role of High Molecular Weight Kininogen in Lymphoma Microvascular Density and Growth**

Program: Oral and Poster Abstracts

Session: 622. Lymphoma Biology—Non-Genetic Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, Non-Hodgkin Lymphoma, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Huseyin Halil Erdemir, MD<sup>1</sup>, Meenal Shukla, PhD<sup>2\*</sup> and Keith R. McCrae, MD<sup>2,3</sup>***

<sup>1</sup>Department of Pediatric Hematology/Oncology and BMT, Cleveland Clinic Children's Hospital, Cleveland, OH

<sup>2</sup>Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **1648 Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration**

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, Adult, CLL, Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Deborah M. Stephens<sup>1</sup>, Ken Boucher, PhD<sup>2\*</sup>, Elizabeth Kander, MD<sup>3</sup>, Sameer A. Parikh, MD<sup>4</sup>, Erin Parry, MD, PhD<sup>5\*</sup>, Mazyar Shadman, MD, MPH<sup>6</sup>, John M. Pagel, MD, PhD<sup>7</sup>, Jennifer Cooperrider, BA<sup>8\*</sup>, Joanna Rhodes, MD<sup>9</sup>, Anthony R. Mato, MD MSCE<sup>10</sup>, Allison M. Winter, MD<sup>11</sup>, Brian T. Hill, MD, PhD<sup>12,13</sup>, Sameh Gaballa, MD<sup>14\*</sup>, Alexey V Danilov, MD, PhD<sup>15</sup>, Tyce J. Phillips, MD<sup>16</sup>, Danielle M. Brander, MD<sup>17</sup>, Sonali M. Smith, MD<sup>8</sup>, Matthew S Davids<sup>18</sup>, Kerry A. Rogers, MD<sup>19</sup>, Martha Glenn, MD<sup>1</sup> and John C. Byrd, MD<sup>3,20</sup>***

<sup>1</sup>Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT

<sup>2</sup>Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

<sup>3</sup>Division of Hematology, The Ohio State University, Columbus, OH

<sup>4</sup>Mayo Clinic, Rochester, MN

<sup>5</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>6</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>7</sup>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

<sup>8</sup>University of Chicago, Chicago, IL

<sup>9</sup>Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA

<sup>10</sup>CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

<sup>11</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>12</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>13</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>14</sup>Thomas Jefferson University, Philadelphia, PA

<sup>15</sup>Knight Cancer Institute, Oregon Health and Science University, Portland, OR

<sup>16</sup>University of Michigan Cancer Center, Dexter, MI

<sup>17</sup>Duke Cancer Institute, Duke University Health System, Durham, NC

<sup>18</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

<sup>19</sup>Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

<sup>20</sup>Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

## **1675 Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells**

Program: Oral and Poster Abstracts

Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, CAR-Ts

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Ashish Sharma<sup>1\*</sup>, Anne Roe<sup>1\*</sup>, Filipa Blasco Lopes<sup>1\*</sup>, Ruifu Liu<sup>1\*</sup>, Jane Reese<sup>2\*</sup>, Susan Pereira Ribeiro<sup>1\*</sup>, Rafick-Pierre Sekaly, PhD<sup>1\*</sup>, Marcos de Lima, MD<sup>3</sup> and David Wald, MD, PhD<sup>4\*</sup>**

<sup>1</sup>Case Western Reserve University, Cleveland

<sup>2</sup>University Hospitals Seidman Cancer Center, Adult Hematologic Malignancies & Stem Cell Transplant Section, Cleveland, OH

<sup>3</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>4</sup>Department of Clinical Pathology, Case Western Reserve University, Cleveland, OH

**1677 Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study**

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways:

Adult, Diseases, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Marie Maerevoet, MD<sup>1\*</sup>, Joost Vermaat, MD, PhD<sup>2</sup>, Miguel A. Canales<sup>3</sup>, René-Olivier Casasnovas, MD<sup>4\*</sup>, Eric Van Den Neste<sup>5\*</sup>, Andre Goy, MD<sup>6\*</sup>, Brian T. Hill, MD, PhD<sup>7,8</sup>, Catherine Thieblemont, MD, PhD<sup>9\*</sup>, Maria De Fatima De La Cruz<sup>10\*</sup>, Federica Cavallo, MD, PhD<sup>11\*</sup>, George Follows, MD<sup>12\*</sup>, Sylvain Choquet, MD<sup>13\*</sup>, Ronit Gurion, MD<sup>14\*</sup>, Reda Bouabdallah, MD<sup>15\*</sup>, Ulrich Jaeger, MD<sup>16</sup>, Agnes Nagy, MD<sup>17\*</sup>, John Kuruvilla, MD<sup>18</sup>, Krzysztof Warzocha, MD<sup>19\*</sup>, Nagesh Kalakonda, MD<sup>20\*</sup>, Paolo Caimi, MD<sup>21</sup>, Sameer Bakhshi, MD<sup>22\*</sup>, Matthew Ku, MBBS, FRACP, FRCPA<sup>23\*</sup>, Nada Hamad, MD<sup>24\*</sup>, Hendrik Veelken, MD, PhD<sup>2</sup>, Ewa Matczak, MD<sup>25\*</sup>, Xiwen Ma<sup>25\*</sup>, Jean-Richard Saint-Martin<sup>25\*</sup>, Jatin J. Shah, MD<sup>25\*</sup>, Michael G. Kauffman, MD, PhD<sup>25</sup>, Sharon Shacham, PhD, MBA<sup>25\*</sup> and Josée M Zijlstra, MD<sup>26\*</sup>**

<sup>1</sup>Institute Jules Bordet, Brussels, Belgium

<sup>2</sup>Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

<sup>3</sup>Hospital Universitario La Paz, Madrid, Spain

<sup>4</sup>CHU Dijon, Dijon, FRA

<sup>5</sup>Cliniques universitaires Saint-Luc, Brussels, BEL

<sup>6</sup>John Theurer Cancer Center at Hackensack-UMC, Hackensack, NJ

<sup>7</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>8</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Hopital St Louis, Paris, France

<sup>10</sup>Hospital University Virgen del Rocio, Sevilla, Spain

<sup>11</sup>University of Torino, Department of Molecular Biotechnologies and Health Sciences, Turin, Italy

<sup>12</sup>Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom

<sup>13</sup>Hospital Pitie Salpêtrière, Paris, France

<sup>14</sup>Rabin Medical Center, Petah Tikva, ISR

<sup>15</sup>Institut Paoli Calmettes, Department of Hematology, Marseille, France

<sup>16</sup>Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Medical University of Vienna, Vienna, Austria

<sup>17</sup>University of Pécs, ÁOK, Pécs, Hungary

<sup>18</sup>Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

<sup>19</sup>Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

<sup>20</sup>Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom

<sup>21</sup>Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>22</sup>Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

<sup>23</sup>Department of Haematology, St. Vincent's Hospital, Melbourne, Australia

<sup>24</sup>St. Vincent's Hospital, Sydney, Australia

<sup>25</sup>Karyopharm Therapeutics, Newton, MA

<sup>26</sup>Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands

**1692 Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)**

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, chemotherapy, Biological Processes, B-Cell Lymphoma, Lymphoid Malignancies, Clinically relevant, signal transduction

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Brian T. Hill, MD, PhD<sup>1,2</sup>, Robert M. Dean, MD<sup>3</sup>, Deepa Jagadeesh, MD, MPH<sup>3</sup>, Alex V. Mejia Garcia, MD<sup>3</sup>, Brad Pohlman, MD<sup>4</sup>, Allison M. Winter, MD<sup>3</sup>, Ethan Krauspe, BA<sup>5\*</sup>, Patrick Collier, MD, PhD<sup>6\*</sup>, Christopher D'Andrea, PA-C<sup>3\*</sup>, Ashley Morrison, RN<sup>3\*</sup>, Sarah Lehmann, RN<sup>3\*</sup>, Benjamin K. Tomlinson, MD<sup>7</sup>, Brenda Cooper, MD<sup>8</sup>, Marcos de Lima, MD<sup>7</sup>, Sarah L. Ondrejka, DO<sup>9</sup>, Eric D. Hsi, MD<sup>9</sup> and Paolo Caimi, MD<sup>7</sup>***

<sup>1</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>School of Medicine, Case Western Reserve University, Cleveland, OH

<sup>6</sup>Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

<sup>7</sup>University Hospitals of Cleveland, Cleveland, OH

<sup>8</sup>Adult Hematologic Malignancies and Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>9</sup>Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

**1737 Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: A SEER Analysis 1992-2004**

Program: Oral and Poster Abstracts

Session: 632. Chronic Myeloid Leukemia: Therapy: Poster I

Hematology Disease Topics & Pathways:

Biological, Adult, Diseases, Therapies, CML, Study Population, Clinically relevant, Myeloid Malignancies, TKI

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Qian Wang, MD, MPH<sup>1</sup>, Yaning Zhang, MD<sup>2\*</sup>, Bing Yue, MD<sup>1\*</sup>, Yu Zhang, MD<sup>3\*</sup>, Changchuan Jiang, MD MPH<sup>1\*</sup>, Stuthi Perimeti, MD, MPH<sup>1\*</sup> and Michael J. Mauro, MD<sup>4</sup>***

<sup>1</sup>Department of Medicine, Icahn School of Medicine at Mount Sinai St. Luke's and West, New York, NY

<sup>2</sup>Department of General Surgery, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Hematology, 307 Hospital of People's Liberation Army (PLA) of China, Beijing, China

<sup>4</sup>Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

**1797 Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, MDS, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Yazan F. Madanat, MD<sup>1</sup>, Mikael A. Sekeres, MD, MS<sup>2</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>3</sup>, Cassandra M. Hirsch<sup>4\*</sup>, Yihong Guan<sup>5\*</sup>, Yasunobu Nagata<sup>4\*</sup>, Vera Adema, PhD<sup>6\*</sup>, Metis Hasipek, PhD<sup>4\*</sup>, Aaron T. Gerds, MD, MS<sup>7</sup>, Hetty E. Carraway, MD, MBA<sup>1,8</sup>, Anjali S. Advani, MD<sup>1</sup>, Bartlomiej P. Przychodzen<sup>6\*</sup>, Valeria Santini<sup>9</sup>, Jaroslaw P. Maciejewski<sup>6</sup>, Babal K. Jha<sup>6\*</sup> and Aziz Nazha, MD<sup>8</sup>***

<sup>1</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>2</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>8</sup>Cleveland Clinic, Cleveland, OH

<sup>9</sup>MDS Unit, AOU Careggi-University of Florence, Florence, Italy

## **1801 Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, AML, CMML, MDS, Biological Processes, MPN, Technology and Procedures, Myeloid Malignancies, genomics, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Kiyomi Morita, MD<sup>1,2</sup>, Feng Wang, PhD<sup>3\*</sup>, Hideki Makishima, MD, PhD<sup>4</sup>, Yuanqing Yan, PhD<sup>5\*</sup>, Tetsuichi Yoshizato, MD, PhD<sup>6</sup>, Kenichi Yoshida, MD, PhD<sup>6\*</sup>, Bartłomiej P. Przychodzen<sup>7\*</sup>, Keyur Patel, MD, PhD<sup>8\*</sup>, Carlos E. Bueso-Ramos, MD, PhD<sup>8</sup>, Curtis Gumbs<sup>3\*</sup>, Latasha Little<sup>3\*</sup>, Samantha Tippen<sup>3\*</sup>, Jianhua Zhang, PhD<sup>3\*</sup>, Xingzhi Song, PhD<sup>3\*</sup>, Tapan M. Kadia, MD<sup>9</sup>, Naval G. Daver, MD<sup>1</sup>, Naveen Pemmaraju, MD<sup>1</sup>, Courtney D. DiNardo, MD, MSc<sup>1</sup>, Farhad Ravandi, MBBS<sup>1</sup>, Srdan Verstovsek, MD, PhD<sup>9</sup>, Elias J. Jabbour, MD<sup>1</sup>, Jorge E. Cortes, MD<sup>1</sup>, Hagop M. Kantarjian, MD<sup>9</sup>, Guillermo Garcia-Manero, MD<sup>1</sup>, Jaroslaw P. Maciejewski<sup>7</sup>, Seishi Ogawa, MD, PhD<sup>10</sup>, P Andrew Futreal, PhD<sup>3\*</sup> and Koichi Takahashi, MD<sup>3,11</sup>*

<sup>1</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>2</sup>Department of Hematology and Oncology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

<sup>3</sup>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>4</sup>Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

<sup>5</sup>Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX

<sup>6</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>7</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>9</sup>Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX

<sup>10</sup>Department of Pathology and Tumor Biology, Kyoto University, Sakyoku, Japan

<sup>11</sup>Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

## **1802 Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Adult, AML, Diseases, MDS, Biological Processes, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, genomics, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Deepak Singhal, MBBS, MD, FRACP, FRCPA<sup>1,2</sup>, Christopher N. Hahn, PhD<sup>3,4\*</sup>, Cassandra M. Hirsch<sup>5\*</sup>, Amilia Wee, BSc (Hons)<sup>6\*</sup>, Monika M Kutyna, MSc<sup>1\*</sup>, Milena Babic, BMPharBio (Hons)<sup>3\*</sup>, Rakchha Chhetri, MBBS<sup>9</sup>, Smita Hiwase, PhD<sup>7\*</sup>, Wendy Parker, PhD<sup>3,8\*</sup>, Jinghua Feng, PhD<sup>9\*</sup>, Andreas Schreiber, PhD<sup>8,10\*</sup>, Joel Goeghegan, MSc<sup>8\*</sup>, Peer Arts, PhD<sup>3\*</sup>, Nimit Singhal, MBBS MD DM FRACP<sup>1,11\*</sup>, Karin Kassahn, PhD, FFSc (RCPA)<sup>12,13\*</sup>, Susan Branford, PhD<sup>3,14</sup>, Anna L. Brown, PhD, BSc<sup>3,15</sup>, Ian D Lewis, MBBS, PhD<sup>16</sup>, Richard D'Andrea, PhD<sup>4</sup>, Hamish S. Scott, PhD<sup>3,13,17</sup>, Jaroslaw P. Maciejewski<sup>5</sup> and Devendra K Hiwase, MBBS, MD, FRACP, FRCPA, PhD<sup>1,18,19</sup>*

<sup>1</sup>School of Medicine, University of Adelaide, Adelaide, Australia

<sup>2</sup>Royal Adelaide Hospital, Adelaide, SA, Australia

<sup>3</sup>Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia

<sup>4</sup>Centre for Cancer Biology, University of South Australia, Adelaide, Australia

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Department of Haematology, Central Adelaide Local Health Network, Adelaide, Australia

<sup>7</sup>Central Adelaide Local Health Network, Adeladie, AUS

<sup>8</sup>ACRF Cancer Genomics Facility, SA Pathology, Adelaide, Australia

<sup>9</sup>School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

<sup>10</sup>School of Molecular and Biological Sciences, University of Adelaide, Adelaide, Australia

<sup>11</sup>Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia

<sup>12</sup>Technology Advancement Unit, SA Pathology, Adelaide, Australia

<sup>13</sup>School of Biological Sciences, University of Adelaide, Adelaide, Australia

<sup>14</sup>Centre for Cancer Biology, SA Pathology, Adelaide, Australia

<sup>15</sup>Centre For Cancer Biology, SA Genomics Health Alliance, Adelaide, SA, Australia

<sup>16</sup>Adelaide Oncology and Haematology, North Adelaide, Australia

<sup>17</sup>Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia

<sup>18</sup>Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia

<sup>19</sup>Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

## **1805 Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, Biological Processes, genomics, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Hassan Awada, MD<sup>1</sup>, Yasunobu Nagata<sup>1\*</sup>, Abhinav Goyal<sup>1\*</sup>, Mohammad Fahad B. Asad<sup>1</sup>, Bhumika J. Patel, MD<sup>2</sup>, Cassandra M. Hirsch<sup>1\*</sup>, Teodora Kuzmanovic<sup>1\*</sup>, Vera Adema, PhD<sup>1\*</sup>, Mai Aly<sup>1\*</sup>, Bartlomiej P. Przychodzen<sup>1\*</sup>, Yihong Guan<sup>1\*</sup>, Wenyi Shen, MD<sup>3\*</sup>, Louis Williams, MD, MBA<sup>1</sup>, Aziz Nazha, MD<sup>2</sup>, Mohamed Abazeed<sup>1\*</sup>, Mikkael A. Sekeres, MD, MS<sup>2</sup>, Tomas Radivoyevitch<sup>4\*</sup>, Torsten Haferlach, MD<sup>5</sup>, Babal K. Jha<sup>1\*</sup>, Valeria Visconte, PhD<sup>1</sup> and Jaroslaw P. Maciejewski<sup>1,2</sup>*

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

<sup>4</sup>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>5</sup>MLL Munchner Leukemie Labor GmbH, Munchen, Germany

## **1813 Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, CMML, Biological Processes, MDS, Technology and Procedures, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*C. Beau Hilton, BA<sup>1,2</sup>, Mikkael A. Sekeres, MD, MS<sup>2</sup>, Manja Meggendorfer, PhD<sup>3</sup>, Wencke Walter, PhD<sup>3\*</sup>, Stephan Hutter, PhD<sup>3\*</sup>, Eric Padron, MD<sup>4</sup>, Michael R. Savona, MD<sup>5</sup>, Aaron T. Gerds, MD, MS<sup>6</sup>, Yihong Guan<sup>7\*</sup>, David A Sallman, MD<sup>8</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>2</sup>, Mrinal M. Patnaik, MD, MBBS<sup>9</sup>, Brianna Smith, MD<sup>10\*</sup>, Yasunobu Nagata<sup>7\*</sup>, Vera Adema, PhD<sup>11\*</sup>, Metis Hasipek, PhD<sup>7\*</sup>, Cassandra M. Hirsch<sup>7\*</sup>, Bartlomiej P. Przychodzen<sup>11\*</sup>, Rami S. Komrokji, MD<sup>12</sup>, Babal K. Jha<sup>11\*</sup>, Claudia Haferlach, MD<sup>3</sup>, Jaroslaw P. Maciejewski<sup>7</sup>, Torsten Haferlach, MD<sup>3</sup> and Aziz Nazha, MD<sup>2</sup>*

<sup>1</sup>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

<sup>2</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>MLL Munich Leukemia Laboratory, Munich, Germany

<sup>4</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>5</sup>Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

<sup>6</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>7</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>8</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

<sup>9</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>10</sup>Vanderbilt University Medical Center, Nashville, TN

<sup>11</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>12</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

## **1824 Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS)**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, MDS, Biological Processes, Clinically relevant, Myeloid Malignancies, molecular interactions, pathogenesis

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Abhinav Goyal<sup>1\*</sup>, Inom Mirzaev<sup>1\*</sup>, Mohammad Fahad B. Asad<sup>1</sup>, Hassan Awada, MD<sup>1</sup>, Cassandra M. Hirsch<sup>1\*</sup>, Hideki Makishima, MD, PhD<sup>2</sup>, Kenichi Yoshida, MD, PhD<sup>2\*</sup>, Bartlomiej P. Przychodzen<sup>1\*</sup>, Aziz Nazha, MD<sup>3</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>3</sup>, Mikkael A. Sekeres, MD, MS<sup>3</sup>, Seishi Ogawa, MD, PhD<sup>4</sup>, Tomas Radivoyevitch, PhD<sup>5\*</sup>, Jacob Scott, MD<sup>1\*</sup>, Jaroslaw P. Maciejewski<sup>1</sup> and Yasunobu Nagata<sup>5\*</sup>*

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>3</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Pathology and Tumor Biology, Kyoto University, Graduate School of Medicine, Kyoto, Japan

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

### 1825 Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, MDS, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Alexander B Pine, MD, PhD<sup>1</sup>, Nora B Chokr, MD<sup>2\*</sup>, Maximilian Stahl, MD<sup>3</sup>, David P. Steensma, MD<sup>4</sup>, Mikkael A. Sekeres, MD, MS<sup>5</sup>, Mark R. Litzow, MD<sup>6</sup>, Selina Luger, MD<sup>7</sup>, Richard M. Stone, MD<sup>4</sup>, Peter L Greenberg, M.D.<sup>8</sup>, Rafael Bejar, MD, PhD<sup>9</sup>, Steven D. Gore, MD<sup>10</sup> and Amer M. Zeidan, MBBS, MHS<sup>3</sup>*

<sup>1</sup>Department of Medicine, Section of Hematology, Yale School of Medicine, Branford, CT

<sup>2</sup>Department of Medicine, Yale School of Medicine/Waterbury Hospital, Waterbury, CT

<sup>3</sup>Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

<sup>4</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>5</sup>Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>7</sup>Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

<sup>8</sup>Stanford University Cancer Center, Stanford, CA

<sup>9</sup>Moore's Cancer Center, University of California, San Diego, La Jolla, CA

<sup>10</sup>Yale Cancer Center, Yale University School of Medicine, New Haven, CT

### 1875 A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, Leukemia, Adult, CLL, Therapies, Non-Biological, chemical interactions, Elderly, Biological Processes, cellular interactions, Technology and Procedures, Study Population, Lymphoid Malignancies, Clinically relevant, pharmacology, flow cytometry, inflammation

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Basem M. William, MRCP, MD<sup>1</sup>, Kaylee Brillhart<sup>2\*</sup>, Manuel Afable, MD<sup>3</sup>, Kristen Bakalarz, CNP<sup>4\*</sup>, Brenda Cooper, MD<sup>5</sup>, Hillard M Lazarus, MD<sup>6</sup>, Stanton L. Gerson, MD<sup>7</sup>, Richard Creger, PharmD<sup>8\*</sup>, Kalyanam Nagabhushanam, PhD<sup>9\*</sup>, James Grote, MD<sup>10\*</sup>, Pingfu Fu<sup>11\*</sup>, Sandeep Kunati, PhD<sup>12\*</sup>, Shuming Yang, PhD<sup>11\*</sup>, Yan Xu, PhD<sup>11\*</sup>, Philip Woost, PhD<sup>13\*</sup>, James Jacobberger, PhD<sup>13\*</sup>, Marcos de Lima, MD<sup>5</sup> and Paolo Caimi, MD<sup>14\*</sup>*

<sup>1</sup>Division of Hematology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH

<sup>2</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>3</sup>Eli Lilly and Company, Indianapolis, IN

<sup>4</sup>University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>5</sup>Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

<sup>6</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>7</sup>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

<sup>8</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>9</sup>Sabinsa Corporation, East Windsor, NJ

<sup>10</sup>BTR Group, Inc., Pittsfield, IL

<sup>11</sup>Case Western Reserve University, Cleveland, OH

<sup>12</sup>Cleveland State University, Cleveland, OH

<sup>13</sup>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland

<sup>14</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Case Western Reserve University - University Hospitals Case Medical Center, Cleveland, OH

## **1899 Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma**

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Adult, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Rajshekhar Chakraborty, MBBS<sup>1</sup>, Hien D. Liu, MD<sup>2\*</sup>, Lisa Rybicki, MS<sup>3\*</sup>, Robert M. Dean, MD<sup>4</sup>, Beth M. Faiman, PhD, CNP<sup>5</sup>, Matt Kalaycio, MD<sup>6</sup>, Jack Khouri, MD<sup>5</sup>, Christy J. Samaras, DO<sup>5</sup>, Navneet S. Majhail, MD, MS<sup>6</sup> and Jason Valent, MD<sup>7</sup>***

<sup>1</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Motifitt Cancer Center, Tampa, FL

<sup>3</sup>Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>7</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Eastlake, OH

## **1918 Vactosertib, a TGF- $\beta$ Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors**

Program: Oral and Poster Abstracts

Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Biological, Therapies, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

***Byung-Gyu Kim, PhD, DVM<sup>1,2\*</sup>, Sung Hee Choi, PhD<sup>1,2\*</sup>, George Luo<sup>1,2\*</sup>, Olga Sergeeva, PhD<sup>3\*</sup>, Zhenghong Lee, PhD<sup>3\*</sup>, James Driscoll, MD, PhD<sup>4</sup>, Marcos de Lima, MD<sup>5,6</sup>, Rose Beck, MD, PhD<sup>7\*</sup>, Seong-Jin Kim, PhD<sup>8,9\*</sup>, John Letterio, MD<sup>1,2\*</sup> and Ehsan Malek, MD<sup>6,10</sup>***

<sup>1</sup>Department of Pediatrics, Case Western Reserve University, Cleveland, OH

<sup>2</sup>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

<sup>3</sup>Department of Radiology, Case Western Reserve University, Cleveland, OH

<sup>4</sup>Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

<sup>5</sup>Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

<sup>6</sup>Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH

<sup>7</sup>Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>8</sup>Precision Medicine Research Center, Advanced Institute of Convergence Technology, Seoul National University, Suwon, Korea, Republic of (South)

<sup>9</sup>MedPacto Inc., Suwon, Korea, Republic of (South)

<sup>10</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

## **1948 Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Faiza Jamil, MD<sup>1\*</sup>, Madeeha Shafqat<sup>1\*</sup>, Ali Younas Khan, MD<sup>1\*</sup>, Seren Durer, MD<sup>1\*</sup>, Ceren Durer, MD<sup>1\*</sup>, Zunairah Shah, MBBS<sup>1\*</sup>, Anum Qureshi<sup>1\*</sup>, Muhammad Abu Zar, MD<sup>1\*</sup>, Ahmad Kamal, MD<sup>1\*</sup>, Malik Qistas Ahmad, MD, MBBS<sup>1\*</sup>, Chaudhry Saad Sohail, MD<sup>1\*</sup>, Insija Ilyas Selene, MBBS<sup>1\*</sup>, Mustafa Nadeem Malik, MD<sup>1\*</sup>, Abdul Rafee, MD<sup>1\*</sup> and Faiz Anwer, MD<sup>1,2</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

**1949 Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Biological, multiple myeloma, Diseases, antibodies, Therapies, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Zunairah Shah, MBBS<sup>1\*</sup>, Madeeha Shafqat<sup>1\*</sup>, Faiza Jamil, MD<sup>1\*</sup>, Mustafa Nadeem Malik, MD<sup>1\*</sup>, Abdul Rafee, MD<sup>1\*</sup>, Shehroz Aslam, MD<sup>1\*</sup>, Anum Qureshi<sup>1\*</sup>, Maryam Sadiq, MBBS<sup>1\*</sup>, Muhammad Abu Zar, MD<sup>1\*</sup>, Ahmad Kamal, MD<sup>1\*</sup>, Insija Ilyas Selene, MBBS<sup>1\*</sup>, Sharoon Samuel, MBBS<sup>1\*</sup>, Rida Riaz, MBBS<sup>1\*</sup>, Midhat Lakhani, MD<sup>1\*</sup> and Faiz Anwer, MD<sup>2,3</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>University of Arizona, Tucson, AZ

<sup>3</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

**1950 Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, apoptosis, Therapies, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Shehroz Aslam, MD<sup>1\*</sup>, Mustafa Nadeem Malik, MD<sup>1\*</sup>, Abdul Rafee, MD<sup>1\*</sup>, Rida Riaz, MBBS<sup>1\*</sup>, Muhammad Jahanzeb Khalil, MD<sup>1\*</sup>, Faisal Mahfooz, MD<sup>2\*</sup>, Madeeha Shafqat<sup>1\*</sup>, Anum Qureshi<sup>1\*</sup>, Insija Ilyas Selene, MBBS<sup>1\*</sup>, Syed Shabee Hassan, MD<sup>1\*</sup>, Muhammad Junaid Tariq, MD<sup>1\*</sup>, Muhammad Yasir, MD<sup>1\*</sup>, Sharoon Samuel, MBBS<sup>1\*</sup>, Maryam Sadiq, MBBS<sup>1\*</sup> and Faiz Anwer, MD<sup>1,3</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>Nawaz Sharif Medical College, University of Gujrat, Gujrat, Pakistan

<sup>3</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

**1951 Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Biological, multiple myeloma, Diseases, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies, stem cells

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Jemin Aby Jose, MD<sup>1</sup>\*, Insija Ilyas Selene, MBBS<sup>1</sup>\*, Mustafa Nadeem Malik, MD<sup>1</sup>\*, Anum Qureshi<sup>1\*</sup>, Abdul Rafae, MD<sup>1</sup>\*, Hafiz Muhammad Fazeel, MD<sup>1</sup>\*, Muhammad Abu Zar, MD<sup>1</sup>\*, Ahmad Kamal, MD<sup>1</sup>\*, Saad Ullah Malik, MD<sup>1</sup>\*, Ceren Durer, MD<sup>1</sup>\*, Seren Durer, MD<sup>1</sup>\*, Faiza Jamil, MD<sup>1</sup>\*, Madeeha Shafqat<sup>1\*</sup>, Muhammad Usman, MD<sup>2</sup>\*, Giyth Mithim Mahdi<sup>3\*</sup> and Faiz Anwer, MD<sup>4,5</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>uni, Tucson, AZ

<sup>3</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, University of Arizona, Tucson, AZ

<sup>4</sup>Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

<sup>5</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

### **1952 Evidence Based Recommendations for Supportive Care in Multiple Myeloma**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Therapies, Non-Biological, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Anum Qureshi<sup>1</sup>\*, Muhammad Junaid Tariq, MD<sup>1</sup>\*, Zunairah Shah, MBBS<sup>1</sup>\*, Muhammad Abu Zar, MD<sup>1</sup>\*, Shehroz Aslam, MD<sup>1</sup>\*, Abdul Rafae, MD<sup>1</sup>\*, Mustafa Nadeem Malik, MD<sup>1</sup>\*, Ahmad Kamal, MD<sup>1</sup>\*, Jemin Aby Jose, MD<sup>1</sup>\*, Insija Ilyas Selene, MBBS<sup>1</sup>\*, Madeeha Shafqat<sup>1\*</sup>, Faiza Jamil, MD<sup>1</sup>\*, Seren Durer, MD<sup>1</sup>\*, Ceren Durer, MD<sup>1</sup>\* and Faiz Anwer, MD<sup>1,2</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

### **1962 Preclinical Studies and a Phase I Trial of the TGF- $\beta$ Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies,

Clinically relevant, immune mechanism

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Ehsan Malek, MD<sup>1</sup>, Byung-Gyu Kim, PhD, DVM<sup>2\*</sup>, Jason Valent, MD<sup>3</sup>, James Driscoll, MD, PhD<sup>4</sup>, Paolo Caimi, MD<sup>5</sup>, Seong-Jin Kim, PhD<sup>6,7\*</sup>, Marcos de Lima, MD<sup>8</sup> and John Letterio, MD<sup>9\*</sup>*

<sup>1</sup>Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH

<sup>2</sup>Department of Pediatrics, Case Western Reserve University, Solon, OH

<sup>3</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

<sup>5</sup>University Hospitals of Cleveland, Cleveland, OH

<sup>6</sup>MedPacto Inc., Suwon, Korea, Republic of (South)

<sup>7</sup>Precision Medicine Research Center, Advanced Institute of Convergence Technology, Seoul National University, Suwon, Korea, Republic of (South)

<sup>8</sup>Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

<sup>9</sup>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

### **1992 Longer Term Follow up of the $\Delta$ Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Biological, Adult, Therapies, Elderly, enzyme inhibitors, Plasma Cell

Disorders, immunotherapy, Study Population, Lymphoid Malignancies, Clinically relevant, Quality

Improvement

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Brian GM Durie, MD<sup>1</sup>, Antje Hoering, PhD<sup>2\*</sup>, Rachael Sexton, PhD<sup>2\*</sup>, Muneer H. Abidi, MD<sup>3</sup>, Joshua Epstein, DSc<sup>4</sup>, S. Vincent Rajkumar, MD<sup>5</sup>, Angela Dispenzieri, MD<sup>5</sup>, Stephen P. Kahanić, MD<sup>6\*</sup>, Mohan C. Thakuri, MD<sup>7</sup>, Frederic J. Reu, MD<sup>8</sup>, Christopher M. Reynolds, MD<sup>9\*</sup>, Robert Z. Orlowski, MD, PhD<sup>10</sup> and Bart Barlogie, MD, PhD<sup>11</sup>

<sup>1</sup>Cedars Sinai Cancer Center, Los Angeles, CA

<sup>2</sup>SWOG Statistical Center, Seattle, WA

<sup>3</sup>Michigan State University/Spectrum Health Cancer Center, Grand Rapids, MI

<sup>4</sup>Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

<sup>5</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>6</sup>Sanford NCORP of the North Central Plains/ Siouxland Regional Cancer Center, Sioux City, IA

<sup>7</sup>Cancer Care Western NC, Asheville, NC

<sup>8</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Michigan Cancer Research Consortium NCORP, St. Joseph Mercy Hospital, Ann Arbor, MI

<sup>10</sup>Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX

<sup>11</sup>Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

## 2009 Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, Biological, Adult, antibodies, multiple myeloma, Therapies, chemotherapy, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Sarah S Lee, MD, Nathaniel Rosko, PharmD\*, Bhumika J. Patel, MD, Madeline Waldron, PharmD\*, Jackie Tomer, MPH\*, Roman Goldman, CNP\*, Mary Ann Karam, RN\*, Janice Reed, RN\*, Beth M. Faiman, PhD, CNP, Kimberly Hamilton, APRN/PA\*, Saveta Mathur, CNP\*, Christy J. Samaras, DO and Jason Valent, MD  
*Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*

## 2012 Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

multiple myeloma, Adult, Diseases, Technology and Procedures, Study Population, Plasma Cell Disorders, Lymphoid Malignancies, flow cytometry

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

William E. Pierceall<sup>1</sup>, Nizar Bahlis, MD<sup>2</sup>, David S Siegel, MD, PhD<sup>3</sup>, Gary J. Schiller, MD<sup>4</sup>, Christy J. Samaras, DO<sup>5</sup>, Michael Sebag, MD, PhD<sup>6</sup>, Jesus G. Berdeja, MD<sup>7</sup>, Siddhartha Ganguly, MD<sup>8\*</sup>, Jeffrey V. Matous, MD<sup>9</sup>, Kevin Song, MD<sup>10</sup>, Christopher S. Seet, MD<sup>11</sup>, Giampaolo Talamo<sup>12\*</sup>, Shanti Srinivas<sup>13,14\*</sup>, Mirelis Acosta-Rivera<sup>15\*</sup>, Michael Bar<sup>16\*</sup>, Donald P. Quick, MD<sup>17</sup>, Bertrand Anz<sup>18\*</sup>, Gustavo Fonseca<sup>19\*</sup>, Donna Reece<sup>20\*</sup>, Weiyuan Chang<sup>1\*</sup>, Natalya Serbina<sup>1\*</sup>, Faiza Zafar, MPAS<sup>1\*</sup>, Amit Agarwal, MD, PhD<sup>1</sup> and Anjan Thakurta, PhD<sup>1</sup>

<sup>1</sup>Celgene Corporation, Summit, NJ

<sup>2</sup>University of Calgary, Calgary, AB, Canada

<sup>3</sup>John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ

<sup>4</sup>UCLA School of Medicine, Los Angeles, CA

<sup>5</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>McGill University Health Centre, Montreal, QC, Canada

<sup>7</sup>Sarah Cannon Research Institute, Nashville, TN

<sup>8</sup>University of Kansas Medical Center, Westwood, KS

<sup>9</sup>Colorado Blood Cancer Institute, Denver, CO

<sup>10</sup>The Vancouver General Hospital, Vancouver, BC, CAN

<sup>11</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

<sup>12</sup>Penn State Hershey Cancer Institute, Hershey, PA

<sup>13</sup>Veterans Affairs NJ Health Care System, East Orange, NJ

<sup>14</sup>Rutgers-New Jersey Medical School, Newark, NJ

<sup>15</sup>Fundacion de Investigacion, San Juan, Puerto Rico

<sup>16</sup>Stamford Hospital, Stamford, CT

<sup>17</sup>Joe Arrington Cancer Research Treatment Center, Lubbock, TX

<sup>18</sup>Tennessee Oncology, Chattanooga, TN

<sup>19</sup>Florida Cancer Specialists, St. Petersburg, FL

<sup>20</sup>Princess Margaret Cancer Centre, Toronto, Canada

## **2022 Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Adeela Mushtaq, MD<sup>1</sup>\*, Ahmad Iftikhar, MD<sup>2</sup>\*, Midhat Lakhani, MD<sup>3</sup>\*, Fnu Sagar, MD<sup>3</sup>\*, Ahmad Kamal, MD<sup>3</sup>\*, Umar Zahid, MD, MPH<sup>4,5</sup>\*, Hamza Hassan, MD<sup>6</sup>\*, Zeeshan Ali, MD<sup>3</sup>\*, Faryal Razzaq, MBBS<sup>3</sup>\*, Saad Ullah Malik, MD<sup>3</sup>\*, Syeda Fatima Hassan, MBBS<sup>3</sup>\*, Muhammad Abu Zar, MD<sup>3</sup>\*, Mohammad Bilal Chaudhary, MD<sup>7</sup>\*, Ahmad Safdar<sup>3</sup>\*, Mohamed Mokhtar Bakr, MD<sup>8</sup> and Faiz Anwer, MD<sup>3,9</sup>*

<sup>1</sup>Department of Medicine, University of Pittsburgh Medical Center, McKeesport, PA

<sup>2</sup>Department of Medicine, University of Arizona, Tucson, AZ

<sup>3</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>4</sup>Johns Hopkins University, Baltimore, MD

<sup>5</sup>Jersey Shore Medical University, Tucson, AZ

<sup>6</sup>Department of Medicine, Rochester General Hospital, Rochester, NY

<sup>7</sup>Elmhurst Hospital Center, Queens, NY

<sup>8</sup>Jersey Shore University Medical Center, New Jersey

<sup>9</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

## **2025 Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

antibodies, Biological, Leukemia, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Muhammad Aadil Rahman, MD<sup>1</sup>\*, Ali Younas Khan, MD<sup>1</sup>\*, Awais Ijaz, MD<sup>2</sup>\*, Muhammad Junaid Tariq, MD<sup>1</sup>\*, Muhammad Usman, MD<sup>1</sup>\*, Muhammad Jahanzeb Khalil, MD<sup>1</sup>\*, Muhammad Asad Fraz, MD<sup>3</sup>\*, Faiza Jamil, MD<sup>1</sup>\*, Abdul Rafee, MD<sup>1</sup>\*, Mustafa Nadeem Malik, MD<sup>1</sup>\*, Insija Ilyas Selene, MBBS<sup>1</sup>\*, Jemin Aby Jose, MD<sup>1</sup>\*, Ahmad Safdar, BS<sup>4</sup>\*, Ali McBride, PharmD, MS<sup>5</sup> and Faiz Anwer, MD<sup>1,6</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>3</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Buford, GA

<sup>4</sup>Department of Medicine, University of Arizona, Tucson

<sup>5</sup>Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ

<sup>6</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

## **2075 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia**

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I

Hematology Disease Topics & Pathways:

AML, Adult, Diseases, Therapies, Non-Biological, Biological Processes, chemotherapy, Technology and

Procedures, Study Population, cytogenetics, Clinically relevant, Myeloid Malignancies, immune mechanism, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Sagar S. Patel, MD<sup>1</sup>, Betty K. Hamilton, MD<sup>1</sup>, Lisa Rybicki, MS<sup>2\*</sup>, Dawn Thomas<sup>3\*</sup>, Arden Emrick<sup>1\*</sup>, Aziz Nazha, MD<sup>4</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>4</sup>, Anjali S. Advani, MD<sup>4</sup>, Hetty E. Carraway, MD, MBA<sup>4,5</sup>, Brad Pohlman, MD<sup>6</sup>, Brian J. Bolwell, MD<sup>1</sup>, Robert M. Dean, MD<sup>1</sup>, Aaron T. Gerds, MD, MS<sup>1</sup>, Rabi Hanna, MD<sup>7</sup>, Matt Kalaycio, MD<sup>1</sup>, Aiwen Zhang, PhD<sup>8\*</sup>, Mikael A. Sekeres, MD, MS<sup>4</sup>, Jaroslaw P. Maciejewski<sup>9</sup>, Navneet S. Majhail, MD, MS<sup>1</sup>, Medhat Askar, MD, PhD<sup>10\*</sup> and Ronald Sobecks, MD<sup>1</sup>

<sup>1</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Allogen Laboratories, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>6</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Pediatric Blood and Marrow Transplant Program, Pediatrics Institute and Children's Hospital, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Department of Pathology and Laboratory Medicine, Baylor University Medical Center, Dallas, TX

### 2123 Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Program: Oral and Poster Abstracts

Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I

Hematology Disease Topics & Pathways:

AML, ALL, Leukemia, Biological, Diseases, CML, Therapies, Clinically relevant, Lymphoid Malignancies, Myeloid Malignancies, transplantation, stem cells

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Jaap Jan Boelens, MD, PhD<sup>1,2</sup>, Coco de Koning<sup>3\*</sup>, Mitchell E. Horwitz, MD<sup>4</sup>, Guillermo Sanz, MD, PhD<sup>5</sup>, Madan Jagasia, MD, MS<sup>6</sup>, John E. Wagner, MD<sup>7</sup>, Patrick J. Stiff, MD<sup>8</sup>, Rabi Hanna, MD<sup>9</sup>, Daniela Cilloni, MD, PhD<sup>10\*</sup> and Stefan Nierkens, PhD<sup>1\*</sup>

<sup>1</sup>Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, Netherlands

<sup>2</sup>Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands

<sup>3</sup>University Medical Center Utrecht, Utrecht, Netherlands

<sup>4</sup>Duke University School of Medicine, Durham, NC

<sup>5</sup>Hematology Department, Hospital Universitario La Fe, Valencia, Spain

<sup>6</sup>Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

<sup>7</sup>Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN

<sup>8</sup>Loyola Univ. Med. Ctr., Maywood, IL

<sup>9</sup>Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

<sup>10</sup>University of Turin, Orbassano, Italy

### 2081 The Direction of KIR Ligand Incompatibility Is Associated with Graft Failure and May Predict the Dominant Donor Following Double Umbilical Cord Blood Transplantation

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, Biological Processes, Clinically relevant, NK cells, transplantation

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Lucy Li<sup>1\*</sup>, Merle Kolk<sup>2\*</sup>, Kirsten Marie Boughan, DO<sup>2</sup>, Paolo F Caimi, MD<sup>2</sup>, Molly M Gallogly, MD, PhD<sup>2</sup>, Jane Little, MD<sup>3</sup>, Ehsan Malek, MD<sup>4</sup>, Leland Metheny, MD<sup>2</sup>, Ben Tomlinson, MD<sup>2</sup>, Brenda Cooper, MD<sup>2</sup>, Marcos de Lima, MD<sup>2</sup> and Folashade Otegbeye, MBBChir, MPH<sup>5</sup>

<sup>1</sup>Case Western Reserve University School of Medicine, Cleveland, OH

<sup>2</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>3</sup>Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>4</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

<sup>5</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

## **2130 Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant**

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Petra Martin<sup>1</sup>, Rebecca Ye, BA<sup>2</sup>, Merle Kolk<sup>3</sup>, Nicole Ferrari<sup>4\*</sup>, Paolo Caimi, MD<sup>5</sup>, Leland Metheny, MD<sup>3</sup>, James Driscoll, MD, PhD<sup>6</sup>, Marcos de Lima, MD<sup>3</sup> and Ehsan Malek, MD<sup>7</sup>**

<sup>1</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>2</sup>New York University, Cleveland, OH

<sup>3</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>4</sup>University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>5</sup>University Hospitals of Cleveland, Cleveland, OH

<sup>6</sup>Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

<sup>7</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

## **2170 Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study**

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster I

Hematology Disease Topics & Pathways:

Therapies, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Celalettin Ustun, MD<sup>1</sup>, Jennifer Le-Rademacher, PhD<sup>2\*</sup>, Hai-Lin Wang, MPH<sup>3\*</sup>, Megan Othus<sup>4\*</sup>, Zhuoxin Sun, PhD<sup>5\*</sup>, Brittny Major<sup>6\*</sup>, Mei-Jie Zhang, PhD<sup>3\*</sup>, Elizabeth Storrick<sup>7\*</sup>, Jacqueline M Lafky<sup>8\*</sup>, Selina Chow<sup>9\*</sup>, Krzysztof Mrózek, MD, PhD<sup>10</sup>, Eyal C. Attar, MD<sup>11,12\*</sup>, Clara D. Bloomfield, MD<sup>13</sup>, Larry D Cripe, MD<sup>14\*</sup>, Richard A. Larson, MD<sup>15</sup>, Guido Marcucci, MD<sup>16</sup>, Gail J. Roboz, MD<sup>17</sup>, Geoffrey L. Uy, MD<sup>18</sup>, Richard M. Stone, MD<sup>19\*</sup>, Aminah Jatoi<sup>18\*</sup>, Thomas C. Shea, MD<sup>20</sup>, Marcos de Lima, MD<sup>21</sup>, James M. Foran, MD<sup>22</sup>, Brenda M. Sandmaier, MD<sup>23,24,25</sup>, Mark R. Litzow, MD<sup>26</sup>, Harry P. Erba, MD, PhD<sup>27</sup>, Arti Hurria, MD<sup>28\*</sup>, Daniel J. Weisdorf, MD<sup>29</sup> and Andrew S. Artz, MD<sup>30,31</sup>**

<sup>1</sup>Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN

<sup>2</sup>Dept of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

<sup>3</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle

<sup>5</sup>Harvard T.H. Chan School of Public Health, Boston

<sup>6</sup>Department of Health Sciences Research, Mayo Clinic, Rochester

<sup>7</sup>Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

<sup>8</sup>Mayo Clinic, Rochester

<sup>9</sup>University of Chicago Comprehensive Cancer Center, Chicago

<sup>10</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH

<sup>11</sup>Massachusetts General Hospital, Boston

<sup>12</sup>Agios Pharmaceuticals, Inc., Cambridge, MA

<sup>13</sup>Comprehensive Cancer Center, The Ohio State University, Columbus, OH

<sup>14</sup>Indiana University Simon Cancer Center, Indianapolis

<sup>15</sup>Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL

<sup>16</sup>Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA

<sup>17</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>18</sup>Washington University School of Medicine, Saint Louis, MO

<sup>19</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>20</sup>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

<sup>21</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>22</sup>Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

<sup>23</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>24</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>25</sup>Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

<sup>26</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>27</sup>Duke University, Durham

<sup>28</sup>City of Hope, Duarte, CA

<sup>29</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

<sup>30</sup>Department of Medicine, Section of Hematology/Oncology, University of Chicago Hospital, Chicago, IL

<sup>31</sup>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

## **2194 Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases**

Program: Oral and Poster Abstracts

Session: 801. Gene Therapy and Transfer: Poster I

Hematology Disease Topics & Pathways:

Biological, sickle cell disease, Diseases, Therapies, thalassemia, Hemoglobinopathies, gene therapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Hafiz Muhammad Fazeel, MD<sup>1</sup>\*, Muhammad Abu Zar, MD<sup>1</sup>\*, Saad Ullah Malik, MD<sup>1</sup>\*, Ahmad Kamal, MD<sup>1</sup>\*, Mustafa Nadeem Malik, MD<sup>1</sup>\*, Syed Shabee Hassan, MD<sup>1</sup>\*, Syeda Sabeeka Batool, MD<sup>2</sup>\*, Ceren Durer, MD<sup>1</sup>\*, Seren Durer, MD<sup>1</sup>\*, Shehroz Aslam, MD<sup>1</sup>\*, Madeeha Shafqat<sup>1</sup>\*, Faiqa Ijaz, MBBS<sup>1</sup>\*, Faiz Anwer, MD<sup>1,3</sup> and Shahrukh K. Hashmi, MD, MPH<sup>4</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>Department of Internal Medicine, University of Alabama, Huntsville, AL

<sup>3</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Division of Hematology, Mayo Clinic, Rochester, MN

## **2245 Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster I

Hematology Disease Topics & Pathways:

Adult, Elderly, Study Population, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Kah Poh Loh, MBBCHBAO<sup>1</sup>, Jian Liang Tan<sup>2\*</sup>, Colin M. McHugh, MD<sup>1\*</sup>, Jane L. Liesveld, MD<sup>1</sup>, Kristen M. O'Dwyer, MD<sup>1\*</sup>, Michael W. Becker, MD<sup>1</sup>, Jason H. Mendler, MD, PhD<sup>1</sup>, Omar S. Aljutawi, MD<sup>1</sup>, Heidi D. Klepin, MD<sup>3</sup>, Wendy Stock, MD<sup>4</sup>, Tanya Wildes, MD<sup>5</sup>, Andrew S. Artz, MD<sup>4,6</sup>, Areej El-Jawahri, MD<sup>7</sup> and Navneet S. Majhail, MD, MS<sup>8</sup>*

<sup>1</sup>Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

<sup>2</sup>Department of Medicine, Crozer-Chester Medical Center, Chester, PA

<sup>3</sup>Wake Forest University School of Medicine, Winston Salem, NC

<sup>4</sup>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

<sup>5</sup>Washington University, Saint Louis, MO

<sup>6</sup>Department of Medicine, Section of Hematology/Oncology, University of Chicago Hospital, Chicago, IL

<sup>7</sup>Massachusetts General Hospital, Allston, MA

<sup>8</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

## **2246 Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster I

Hematology Disease Topics & Pathways:

Elderly, Study Population, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Kah Poh Loh, MBBCHBAO<sup>1</sup>, Sindhuja Kadambi, MD<sup>2\*</sup>, Supriya G. Mohile, MD, MS<sup>1\*</sup>, Jason H. Mendler, MD, PhD<sup>1</sup>, Jane L. Liesveld, MD<sup>1</sup>, Kristen M. O'Dwyer, MD<sup>1\*</sup>, Michael W. Becker, MD<sup>1</sup>, Colin M. McHugh,*

**MD<sup>1</sup>\*, Marsha Wittink, MD, MBE<sup>3</sup>\*, Wendy Stock, MD<sup>4</sup>, Navneet S. Majhail, MD, MS<sup>5</sup>, Tanya Wildes, MD<sup>6</sup>, Paul Duberstein, PhD<sup>3</sup>\* and Heidi D. Klepin, MD<sup>7</sup>**

<sup>1</sup>Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

<sup>2</sup>Division of Geriatrics and Aging, University of Rochester Medical Center, Rochester, NY

<sup>3</sup>Department of Psychiatry, University of Rochester Medical Center, Rochester, NY

<sup>4</sup>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

<sup>5</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Washington University, Saint Louis, MO

<sup>7</sup>Wake Forest University School of Medicine, Winston Salem, NC

## **2259 Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster I

Hematology Disease Topics & Pathways:

Diseases, Adult, MPN, Polycythemia vera, Study Population, Myeloid Malignancies, Quality Improvement

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Ivy Altomare, MD<sup>1</sup>\*, Aaron T. Gerds, MD, MS<sup>2</sup>, David Lessen, MD<sup>3</sup>, Philomena Colucci, DO, MS<sup>4</sup>\*, Shreekant Parasuraman, BPharm, PhD<sup>4</sup>\*, Dilan Chamikara Paranagama, PhD<sup>4</sup>\* and Ruben A. Mesa, MD, FACP<sup>5</sup>**

<sup>1</sup>Duke University Medical Center, Durham, NC

<sup>2</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>3</sup>Southeast Florida Hem-Onc Group, Fort Lauderdale, FL

<sup>4</sup>Incyte Corporation, Wilmington, DE

<sup>5</sup>University of Texas Health Science Center, San Antonio, TX

## **2273 Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISH)**

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster I

Hematology Disease Topics & Pathways:

Diseases, autoimmune disorders, Bleeding and clotting, ITP, Immune Disorders

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Caroline Kruse<sup>1</sup>\*, Alexandra Kruse<sup>1</sup>\*, Shirley Watson<sup>2</sup>\*, Mervyn Morgan<sup>2</sup>\*, Nichola Cooper, MRCP<sup>3</sup>, Waleed Ghanima<sup>4</sup>, Andrew Provan<sup>5</sup>\*, Donald M. Arnold, MD, MSc, FRCPC<sup>6</sup>, Cristina Santoro<sup>7</sup>\*, Ming Hou, MD<sup>8</sup>\*, Yoshiaki Tomiyama, MD<sup>9</sup>, Serge Laborde<sup>10</sup>\*, Barbara Lovrencic<sup>11</sup>\*, John Waller, PhD, BSc<sup>12</sup>\*, Gavin Taylor-Stokes<sup>12</sup>\*, Tom Bailey<sup>12</sup>\*, Miona Stankovic<sup>13</sup>\* and James B. Bussel, MD<sup>14</sup>**

<sup>1</sup>Platelet Disorder Support Association, Cleveland

<sup>2</sup>ITP Support Association, Bognor Regis, United Kingdom

<sup>3</sup>Hammersmith Hospital, Imperial College London, London, United Kingdom

<sup>4</sup>Department of Medicine, Oslo University Hospital, Oslo, Norway

<sup>5</sup>Barts and The London School of Medicine and Dentistry, London, United Kingdom

<sup>6</sup>Department of Medicine, McMaster University, Hamilton, ON, Canada

<sup>7</sup>Department of Cellular Biotechnologies & Haematology, 'Sapienza' University of Rome, Rome, Italy

<sup>8</sup>Department of Hematology, Shandong University, Jinan, China

<sup>9</sup>Osaka University Hospital, Osaka, Japan

<sup>10</sup>O'Cryo, Saint Lô, France

<sup>11</sup>Italian Association Immune Thrombocytopenic Purpura, Caprino Veronese, Italy

<sup>12</sup>Bespoke Team, Adelphi Real World, Macclesfield, United Kingdom

<sup>13</sup>Novartis Pharma AG, Basel, Switzerland

<sup>14</sup>Division of Hematology/Oncology, Weill Cornell Medical College, New York

## **2298 Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States**

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster I

### Hematology Disease Topics & Pathways:

Adult, AML, Diseases, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Raffi Tchekmedyan, BS<sup>1</sup>, Tomas Radivoyevitch, PhD<sup>2,3\*</sup>, Aaron T. Gerds, MD, MS<sup>4</sup>, Aziz Nazha, MD<sup>5</sup>, Hetty E. Carraway, MD, MBA<sup>6,7</sup>, Anjali S. Advani, MD<sup>7</sup>, Jaroslaw P. Maciejewski<sup>3</sup>, Matt Kalaycio, MD<sup>8</sup>, Navneet S. Majhail, MD, MS<sup>8</sup>, Mikael A. Sekeres, MD, MS<sup>9</sup> and Sudipto Mukherjee, MD, PhD, MPH<sup>9</sup>**

<sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>5</sup>Cleveland Clinic, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>8</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

### **2330 A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria**

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II

### Hematology Disease Topics & Pathways:

Diseases, Anemias, PNH

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Robert A. Brodsky, MD<sup>1</sup>, Regis Peffault De Latour<sup>2,3\*</sup>, Scott T. Rottinghaus, MD<sup>4\*</sup>, Alexander Röth, MD<sup>5</sup>, Antonio M. Risitano, MD, PhD<sup>6</sup>, Ilene C. Weitz, MD<sup>7\*</sup>, Peter Hillmen, MB ChB, PhD, FRCP, FRCPath<sup>8</sup>, Jaroslaw P. Maciejewski<sup>9</sup>, Jeffrey Szer, MBBS<sup>10</sup>, Jong-Wook Lee, MD, PhD<sup>11</sup>, Austin G. Kulasekaran, MBBS, MD, MRCP, FRCPath<sup>12\*</sup>, Lori Volles, MD<sup>4\*</sup>, Andrew I. Damokosh, PhD<sup>4\*</sup>, Stephan Ortiz, RPh, PhD<sup>4\*</sup>, Lori Shafner, PhD<sup>4\*</sup>, Anita Hill, MD, PhD<sup>13\*</sup> and Hubert Schrezenmeier, MD<sup>14,15</sup>**

<sup>1</sup>Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

<sup>2</sup>Université Paris Diderot, Paris, France

<sup>3</sup>French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

<sup>4</sup>Alexion Pharmaceuticals, Inc., New Haven, CT

<sup>5</sup>Department of Hematology, University Hospital Essen, Essen, Germany

<sup>6</sup>Hematology, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy

<sup>7</sup>Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA

<sup>8</sup>Department of Haematology, St James's University Hospital, Leeds, United Kingdom

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia

<sup>11</sup>Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

<sup>12</sup>Department of Haematological Medicine, King's College Hospital, NIHR/Wellcome King's Clinical Research Facility, London, United Kingdom

<sup>13</sup>Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom

<sup>14</sup>Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany

<sup>15</sup>Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

### **2383 Mean Platelet Volume Predicts Mortality in Sickle Cell Disease**

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

### Hematology Disease Topics & Pathways:

Diseases, sickle cell disease, Hemoglobinopathies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Aravind Thavamani, MBBS, MD<sup>1\*</sup>, Regi Ramanathan, MBBS<sup>2\*</sup> and Mammen Puliyl, MD, MBBS<sup>3,4</sup>**

<sup>1</sup>Department of Pediatrics, Metrohealth Medical Center, Cleveland, OH

<sup>2</sup>Metrohealth Medical Center, Cleveland, OH

<sup>3</sup>Department of Pediatrics, Case Western Reserve University, Cleveland, OH

<sup>4</sup>Metro Health Medical Center, Cleveland, OH

**2386 Red Blood Cell Adhesion in Adult Patients with Sickle Cell Disease, at Baseline and with Pain, Measured on SCD Biochip Microfluidic Assay**

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways:

Adult, Diseases, sickle cell disease, bioengineering, Technology and Procedures, Hemoglobinopathies, Study Population, Clinically relevant, flow cytometry, serologic tests

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Alexandra Boye-Doe<sup>1</sup> and Jane Little, MD<sup>2</sup>*

<sup>1</sup>Case Western Reserve University School of Medicine, Cleveland

<sup>2</sup>Division of Hematology/Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

**2387 Red Blood Cell Adhesion Is Increased in the Young Adult Population with Sickle Cell Disease**

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways:

sickle cell disease, Diseases, Hemoglobinopathies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Erina Quinn<sup>1\*</sup>, Charlotte Yuan, BA<sup>2\*</sup>, Sargam Kapoor, MD<sup>3</sup>, Karen Ireland, RN<sup>4\*</sup>, Janine Keenan, RN<sup>4\*</sup>, Deepa Manwani, MD<sup>5</sup>, Umut A. Gurkan, PhD<sup>2</sup> and Jane Little, MD<sup>3</sup>*

<sup>1</sup>Case Western Reserve University, Bradenton, FL

<sup>2</sup>Case Western Reserve University, Cleveland, OH

<sup>3</sup>Division of Hematology/Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>4</sup>Division of Hematology/Oncology, The Children's Hospital at Montefiore, Bronx, NY

<sup>5</sup>Children's Hospital at Montefiore, Bronx, NY

**2475 A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia**

Program: Oral and Poster Abstracts

Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II

Hematology Disease Topics & Pathways:

Diseases, Hemophilia, Bleeding and clotting, Technology and Procedures, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Michael A Suster, PhD<sup>1\*</sup>, Debnath Maji, M.Tech<sup>1\*</sup>, Lalitha V. Nayak, MD<sup>2</sup>, Christina Jenkins, MSN-PNP, RN<sup>3\*</sup>, Susan Hunter, BSN, RN-BC<sup>3\*</sup>, Alvin H. Schmaier, MD<sup>1</sup>, Pedram Mohseni, PhD<sup>1\*</sup> and Sanjay Ahuja<sup>4</sup>*

<sup>1</sup>Case Western Reserve University, Cleveland, OH

<sup>2</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>3</sup>University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

<sup>4</sup>University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

**2500 Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure**

Program: Oral and Poster Abstracts

Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II

Hematology Disease Topics & Pathways:

Adult, Biological, Diseases, Bleeding and clotting, Therapies, Pediatric, Study Population, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Manuel Carcao<sup>1</sup>, Amy Shapiro<sup>2</sup>, Nina Hwang<sup>3\*</sup>, Steven Pipe<sup>4</sup>, Sanjay Ahuja<sup>5</sup>, Kenneth Lieuw, MD, PhD<sup>6</sup>, Janice Staber<sup>7</sup>, Haowei Linda Sun<sup>8\*</sup>, Hilda Ding<sup>9\*</sup>, Michael Wang, MD<sup>10</sup>, Macgregor Steele<sup>11\*</sup>, Elisa Tsao<sup>12\*</sup>, Jing Feng<sup>12\*</sup>, Zahra Al-Khateeb<sup>13\*</sup>, Jennifer Dumont<sup>12</sup> and Nisha Jain<sup>12\*</sup>*

<sup>1</sup>Hospital for Sick Children, Toronto, ON, CAN

<sup>2</sup>Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, IN

<sup>3</sup>Center for Inherited Blood Disorders, Orange, CA

<sup>4</sup>Pediatrics and Pathology, University of Michigan, Ann Arbor, MI

<sup>5</sup>University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

<sup>6</sup>Walter Reed National Military Medical Center, Bethesda, MD

<sup>7</sup>University of Iowa Stead Family Children's Hospital, Iowa City, IA

<sup>8</sup>University of Alberta Hospital, Edmonton, AB, Canada

<sup>9</sup>Rady Children's Hospital San Diego, San Diego, CA

<sup>10</sup>Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO

<sup>11</sup>Alberta Children's Hospital, Edmonton, AB, Canada

<sup>12</sup>Bioverativ, a Sanofi company, Waltham, MA

<sup>13</sup>Trinity Partners LLC, Waltham, MA

## **2510 Venous Thromboembolism in Cancer Patients Receiving Immunotherapy**

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster II

Hematology Disease Topics & Pathways:

Diseases, Biological, Bleeding and clotting, Therapies, immunotherapy, Thromboembolism, Clinically relevant, Quality Improvement

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Joanna Roopkumar, MBBS, MPH<sup>1</sup>, Ann S. Kim, BA<sup>2</sup>, Thapa Bicky, MD<sup>3</sup>, Brian P. Hobbs, PhD<sup>4</sup> and Alok A. Khorana<sup>1</sup>***

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH

<sup>4</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **2523 Safety of Apixaban in Patients with CKD Stage V and ESRD with Venous Thromboembolism**

Program: Oral and Poster Abstracts

Session: 332. Antithrombotic Therapy: Poster II

Hematology Disease Topics & Pathways:

Therapies, Non-Biological

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Jahnnavi Gollamudi, MD<sup>1</sup>, Sadeer Al-Kindi, M.D.<sup>2</sup>, Petra Martin<sup>3</sup>\* and Lalitha V. Nayak, MD<sup>3</sup>***

<sup>1</sup>Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>2</sup>Division of Cardiology, Case Western Reserve University, Cleveland

<sup>3</sup>University Hospitals Cleveland Medical Center, Cleveland, OH

## **2572 Distinct Features of Chip-Derived and De Novo MDS**

Program: Oral and Poster Abstracts

Session: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster II

Hematology Disease Topics & Pathways:

Diseases, MDS, Biological Processes, Myeloid Malignancies, genomics

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Yasunobu Nagata<sup>1</sup>\*, Hideki Makishima, MD, PhD<sup>2</sup>, Cassandra M. Hirsch<sup>1</sup>\*, Hassan Awada, MD<sup>1</sup>, Abhinav Goyal<sup>1</sup>\*, Teodora Kuzmanovic, BA<sup>1</sup>\*, Bartłomiej P. Przychodzen<sup>1</sup>\*, Tetsuichi Yoshizato, MD, PhD<sup>2</sup>, Kenichi Yoshida, MD, PhD<sup>2</sup>\*, Kenichi Chiba, PhD<sup>3</sup>\*, Hiroko Tanaka, BA<sup>3</sup>\*, Yuichi Shiraishi, PhD<sup>3</sup>\*, Satoru Miyano, PhD<sup>3</sup>\*, Sudipto Mukherjee, MD, PhD, MPH<sup>4</sup>, Tomas Radivoyevitch, PhD<sup>1</sup>\*, Thomas Laframboise, PhD<sup>5</sup>\*, Aziz Nazha, MD<sup>6</sup>, Mikael A. Sekeres, MD, MS<sup>4</sup>, Torsten Haferlach, MD<sup>7</sup>, Seishi Ogawa, MD, PhD<sup>8</sup> and Jaroslaw P. Maciejewski<sup>1</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>3</sup>Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

<sup>4</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

<sup>6</sup>Cleveland Clinic, Cleveland, OH

<sup>7</sup>MLL Munich Leukemia Laboratory, Munich, Germany

<sup>8</sup>Department of Pathology and Tumor Biology, Kyoto University, Sakyoku, Japan

## **2583 Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Wenyi Shen, MD<sup>1,2\*</sup>, Cassandra M. Hirsch<sup>3\*</sup>, Bartłomiej P. Przychodzen<sup>4\*</sup>, Hideki Makishima, MD, PhD<sup>5</sup>, Louis Williams, MD, MBA<sup>6</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>7</sup>, Hetty E. Carraway, MD, MBA<sup>8,9</sup>, Mikael A. Sekeres, MD, MS<sup>10</sup> and Jaroslaw P. Maciejewski<sup>7,11</sup>

<sup>1</sup>The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

<sup>2</sup>Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>6</sup>NYU, New York, NY

<sup>7</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Cleveland Clinic, Cleveland, OH

<sup>9</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>10</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>11</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

## **2590 Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Bhumika J. Patel, MD<sup>1</sup>, Shimoli Vipul Barot, MD<sup>2</sup>, Teodora Kuzmanovic, BA<sup>3\*</sup>, Bartłomiej P. Przychodzen<sup>3\*</sup>,

Cassandra M. Hirsch<sup>4\*</sup>, Hassan Awada, MD<sup>5</sup>, Metis Hasipek, PhD<sup>4\*</sup>, Swapna Thota, MD<sup>6</sup>, Tomas Radivoyevitch, PhD<sup>4\*</sup>, Anjali S. Advani, MD<sup>7</sup>, Matt Kalaycio, MD<sup>8</sup>, Mikael A. Sekeres, MD, MS<sup>9</sup>, Hetty E. Carraway, MD, MBA<sup>7,10</sup> and Jaroslaw P. Maciejewski<sup>4</sup>

<sup>1</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Internal Medicine, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Fairview Park, OH

<sup>6</sup>Department of Medicine, Roswell Park, Buffalo, NY

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>8</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>10</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

## **2647 Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123**

### **Antibody-Drug Conjugate in Acute Myeloid Leukemia Models**

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II

Hematology Disease Topics & Pathways:

apoptosis, antibodies, AML, Diseases, Non-Biological, Therapies, Biological Processes, DNA repair, Myeloid Malignancies, pharmacology

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Claire Fritz<sup>1,2\*</sup>, Scott M. Portwood, MS, MBA<sup>3\*</sup>, Julie Adams, BS<sup>3\*</sup>, Tara Cronin, BA<sup>3\*</sup>, Linda Lutgen-Dunckley<sup>3\*</sup>, Brandon L Martens, BS<sup>3\*</sup>, Callum M. Sloss, PhD<sup>4</sup>, Krystal Watkins<sup>4\*</sup>, Yelena Kovtun, PhD<sup>4</sup>, Sharlene Adams, PhD<sup>4\*</sup> and Eunice S. Wang, MD<sup>5</sup>*

<sup>1</sup>Department of Medicine, Case Western Reserve University, Buffalo, NY

<sup>2</sup>Case Western Reserve University, Cleveland, OH

<sup>3</sup>Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>4</sup>ImmunoGen, Inc., Waltham, MA

<sup>5</sup>Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

## **2699 Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials**

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Hagop M. Kantarjian, MD<sup>1</sup>, Wendy Stock, MD<sup>2</sup>, Ryan D. Cassaday, MD<sup>3</sup>, Daniel J. DeAngelo, MD<sup>4</sup>, Elias J.*

*Jabbar, MD<sup>5</sup>, Susan M. O'Brien, MD<sup>6</sup>, Matthias Stelljes, MD<sup>7</sup>, Tao Wang<sup>8\*</sup>, Katherine F Liou<sup>9\*</sup>, Kevin*

*Nguyen<sup>10\*</sup>, Barbara Sleight<sup>8\*</sup>, Erik Vandendries, MD, PhD<sup>11\*</sup>, Alexander Neuhof, MD<sup>12\*</sup>, A. Douglas*

*Laird<sup>9\*</sup> and Anjali S. Advani, MD<sup>13</sup>*

<sup>1</sup>Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX

<sup>2</sup>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

<sup>3</sup>UW/FHCRC, Seattle, WA

<sup>4</sup>Dana-Farber Cancer Inst., Boston, MA

<sup>5</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>6</sup>UCI Cancer Center, Orange, CA

<sup>7</sup>Universitätsklinikum Münster, Münster, Germany

<sup>8</sup>Pfizer Inc, Groton, CT

<sup>9</sup>Pfizer Inc, San Diego, CA

<sup>10</sup>Navigate BioPharma Services (formerly Genoptix BioPharma Services), a Novartis subsidiary, Carlsbad, CA

<sup>11</sup>Pfizer Inc, Cambridge, MA

<sup>12</sup>Pfizer Pharma GmbH, Berlin, Germany

<sup>13</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

## **2732 Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events**

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Biological, Therapies, enzyme inhibitors, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Jorge E. Cortes, MD<sup>1</sup>, Cristina Papayannidis<sup>2</sup>, Catriona Jamieson, MD, PhD<sup>3,4</sup>, Gary J. Schiller, MD<sup>5</sup>, Anna*

*Candoni, MD<sup>6\*</sup>, Brian Leber, MD<sup>7</sup>, Claudia D. Baldus, MD<sup>8</sup>, José A. Pérez-Simón, MD, PhD<sup>9</sup>, Weidong*

*Wendy Ma<sup>10\*</sup>, Corrado Gallo Stampino<sup>10\*</sup>, Ashleigh O'Connell<sup>10\*</sup>, Mirjana Zeremski, MD<sup>11\*</sup>, Geoffrey Chan,*

*MD<sup>12</sup> and Mikael A. Sekeres, MD, MS<sup>13</sup>*

<sup>1</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>2</sup>Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seragnoli", University of Bologna, Bologna, Italy

<sup>3</sup>Sanford Stem Cell Clinical Center, University California, San Diego, La Jolla, CA

<sup>4</sup>Moores Cancer Center, University of California, San Diego, La Jolla, CA

<sup>5</sup>Ronald Regan University of California Los Angeles Medical Center, Santa Monica, CA

<sup>6</sup>Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

<sup>7</sup>Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

<sup>8</sup>Hämatologie und Onkologie, Charité-Universitätsmedizin Berlin, Berlin, Germany

<sup>9</sup>Instituto de Biomedicina de Sevilla (IBIS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain

<sup>10</sup>Pfizer Inc, New York, NY

<sup>11</sup>Pfizer Canada Inc., Kirkland, QC, CAN

<sup>12</sup>Pfizer Oncology, Collegeville, PA

<sup>13</sup>Leukemia Program, Cleveland Clinic, Cleveland, OH

## **2735 Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)**

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

AML, Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Rachel J. Cook, MD<sup>1</sup>, Tamara Moyo, MD, PhD<sup>2\*</sup>, Jane L. Liesveld, MD<sup>3</sup>, David A. Rizzieri, MD<sup>4</sup>, Eytan M. Stein, MD<sup>5</sup>, Stephane De Botton, MD, PhD<sup>6\*</sup>, Gail J. Roboz, MD<sup>7</sup>, Mikkael A. Sekeres, MD, MS<sup>8</sup>, Joseph G. Jurcic, MD<sup>9</sup>, Azra Raza, MD<sup>10</sup>, Robert L. Redner, MD<sup>11</sup>, Dale L. Bixby, MD, PhD<sup>12\*</sup>, Jorge E. Cortes, MD<sup>13</sup>, Kristin Stephens<sup>14\*</sup>, Angela Volkert<sup>14\*</sup>, Qing Kang, PhD<sup>14\*</sup>, Emmanuelle Di Tomaso, PhD<sup>14\*</sup>, David A. Roth, MD<sup>14</sup> and Carlos E Vigil, MD<sup>15</sup>*

<sup>1</sup>Knight Cancer Institute, Oregon Health and Science University, Portland, OR

<sup>2</sup>Vanderbilt University, Nashville, TN

<sup>3</sup>Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

<sup>4</sup>Dept. of Medicine, Div. of Hematological Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC

<sup>5</sup>Division of Hematologic Oncology, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>6</sup>Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France

<sup>7</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>8</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

<sup>9</sup>Columbia University Medical Center, New York, NY

<sup>10</sup>Myelodysplastic Syndrome Center, Columbia University Medical Center, New York, NY

<sup>11</sup>UPMC Hillman Cancer Center, Pittsburgh, PA

<sup>12</sup>Internal Medicine, University of Michigan, Ann Arbor, MI

<sup>13</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>14</sup>Syros Pharmaceuticals, Cambridge, MA

<sup>15</sup>Division of Hematology, Oncology, and Blood & Marrow Transplantation, The University of Iowa, Iowa City, IA

## **2809 Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype**

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Aziz Nazha, MD<sup>1</sup>, Manja Meggendorfer, PhD<sup>2</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>1</sup>, Wencke Walter, PhD<sup>2\*</sup>, Stephan Hutter, PhD<sup>2\*</sup>, Ahed Makhoul, MD<sup>3\*</sup>, Cassandra M. Hirsch<sup>4\*</sup>, Bartlomiej P. Przychodzen<sup>5\*</sup>, Hetty E. Carraway, MD, MBA<sup>6,7</sup>, Yasunobu Nagata<sup>4\*</sup>, Yihong Guan<sup>8\*</sup>, Teodora Kuzmanovic, BA<sup>5\*</sup>, Metis Hasipek, PhD<sup>4\*</sup>, Babal K. Jha<sup>5\*</sup>, Jaroslaw P. Maciejewski<sup>5</sup>, Claudia Haferlach, MD<sup>2</sup>, Mikkael A. Sekeres, MD, MS<sup>9</sup> and Torsten Haferlach, MD<sup>2</sup>*

<sup>1</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>MLL Munich Leukemia Laboratory, Munich, Germany

<sup>3</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>8</sup>Taussig Cancer Institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **2874 Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study**

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Follicular Lymphoma, Diseases, Biological, Adult, Therapies, Mantle Cell Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Paolo Caimi, MD<sup>1</sup>, Brad S. Kahl, MD<sup>2\*</sup>, Mehdi Hamadani, MD<sup>3</sup>, Carmelo Carlo-Stella, MD<sup>4</sup>, Shui He, PhD<sup>5\*</sup>, David Ungar, MD<sup>6\*</sup>, Jay Feingold, MD, PhD<sup>7\*</sup>, Kirit M. Ardeshta, MA MD FRCR FRCPath<sup>8</sup>, John Radford, MD, FRCR<sup>9\*</sup>, Melhem Solh, MD<sup>10</sup>, Leonard Heffner, MD<sup>11\*</sup> and Owen A. O'Connor, M.D., Ph.D.<sup>12</sup>***

<sup>1</sup>Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>2</sup>Siteman Cancer Center, Washington University, St Louis, MO

<sup>3</sup>Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Hematology, Humanitas Cancer Center, Rozzano, Milano, Italy

<sup>5</sup>ADC Therapeutics, Inc., Murray Hill, NJ

<sup>6</sup>ADC Therapeutics America, Inc, Murray Hill

<sup>7</sup>ADC Therapeutics, Inc, Murray Hill, NJ

<sup>8</sup>Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

<sup>9</sup>The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

<sup>10</sup>Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

<sup>11</sup>Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory

<sup>12</sup>Center for Lymphoid Malignancies, Department of Medicine, Columbia University, New York, NY

**2878 Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration**

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Adult, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Matthew J Maurer, MS<sup>1,2</sup>, Amy S. Ruppert, MAS, PhD<sup>3\*</sup>, Brian K. Link, MD<sup>4</sup>, Lawrence D Kaplan, MD<sup>5</sup>, David J Inwards, MD<sup>6\*</sup>, Andrew L. Feldman, MD<sup>7</sup>, Eric D. Hsi, MD<sup>8</sup>, Adam Pettinger<sup>9\*</sup>, Jonathon B. Cohen, MD, MS<sup>10</sup>, Peter Martin, FRCPC, MD, MS<sup>11</sup>, Brad S Kahl, MD<sup>12</sup>, Nancy L. Bartlett, MD<sup>13</sup>, James R. Cerhan, MD, PhD<sup>14</sup>, John P. Leonard, MD<sup>15</sup> and Thomas M. Habermann, MD<sup>14</sup>***

<sup>1</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, MN

<sup>2</sup>Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

<sup>3</sup>Division of Hematology, The Ohio State University, Columbus, OH

<sup>4</sup>Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

<sup>5</sup>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA

<sup>6</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>7</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

<sup>8</sup>Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>9</sup>Alliance Statistical and Data Center, Mayo Clinic, Rochester, MN

<sup>10</sup>Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

<sup>11</sup>Division of Hematology and Oncology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY

<sup>12</sup>Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO

<sup>13</sup>Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

<sup>14</sup>Mayo Clinic, Rochester, MN

<sup>15</sup>Weill Medical College of Cornell University, New York, NY

**2893 Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies**

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Follicular Lymphoma, Leukemia, Diseases, Adult, Non-Biological, Therapies, CLL, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Andrew D. Zelenetz, MD, PhD<sup>1</sup>, Jacob D. Soumerai, MD<sup>2</sup>, Deepa Jagadeesh, MD, MPH<sup>3</sup>, Nishitha Reddy, MD<sup>4</sup>, Anastasios Stathis, MD<sup>5\*</sup>, Adam S. Asch, MD<sup>6</sup>, Huda S. Salman, MD<sup>7</sup>, Vaishalee P. Kenkre, MD<sup>8</sup>, Haresh Jhangiani, MD, MBA<sup>9\*</sup>, Alexia Iasonos, PhD<sup>10\*</sup>, Patel Krish, MD<sup>11\*</sup>, Richard G Ghalie, MD, MBA<sup>12</sup> and John M. Pagel, MD, PhD<sup>13</sup>

<sup>1</sup>Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY

<sup>2</sup>Center for Lymphoma, Massachusetts General Hospital, Boston, MA

<sup>3</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

<sup>5</sup>Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

<sup>6</sup>Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK

<sup>7</sup>Stony Brook University, Stony Brook, NY

<sup>8</sup>Division of Hematology/Oncology, University of Wisconsin, Madison, WI

<sup>9</sup>Compassionate Care Research Group, Fountain Valley, CA

<sup>10</sup>Memorial Sloan-Kettering Cancer Center, New York, NY

<sup>11</sup>Swedish Cancer Institute, Seattle, WA

<sup>12</sup>MEI Pharma, San Diego, CA

<sup>13</sup>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

### **2914 The Predictive Value of PET/CT for Post-Transplant Outcomes in T Cell Lymphoma**

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Adult, Non-Biological, Therapies, Biological Processes, chemotherapy, Technology and Procedures, T-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement , imaging

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Nancy Kaddis, MD, MPH<sup>1</sup>, Eric D Jacobsen, MD<sup>2</sup>, Ailbhe O'Neill, MD<sup>3\*</sup>, Nikhil Ramaiya, MD<sup>4\*</sup> and Robert A. Redd, MS<sup>5\*</sup>

<sup>1</sup>Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

<sup>2</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

<sup>3</sup>Department of Radiology, St Vincent's University Hospital, Dublin 4, Ireland

<sup>4</sup>Department of Radiology, Case Western Reserve Hospitals, Cleveland, OH

<sup>5</sup>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

### **2925 Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3K $\gamma$ / $\beta$ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies**

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Biological, Therapies, Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies, TKI

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Swami P. Iyer, MD<sup>1</sup>, Auris Huen, MD<sup>2\*</sup>, Andres J M Ferreri, MD<sup>3</sup>, Brad M. Haverkos, MD, MPH, MS<sup>4</sup>, Jasmine M. Zain, MD<sup>5</sup>, Radhakrishnan Ramchandren, MD<sup>6</sup>, Mary Jo Lechowicz, MD<sup>7</sup>, Sumana Devata, MD<sup>8</sup>, Neil Korman, MD<sup>9\*</sup>, Lauren C. Pinter-Brown, MD<sup>10</sup>, Richard Delarue, MD<sup>11</sup>, Kasi Viswanath V Routhu, PhD<sup>12\*</sup>, Prajak Barde, MD<sup>13\*</sup>, Ajit M Nair, PhD<sup>13\*</sup> and Carmelo Carlo-Stella, MD<sup>14</sup>

<sup>1</sup>The Methodist Cancer Center, Houston, TX

<sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>3</sup>Unit of Lymphoid Malignancies, IRCCS San Raffaele Scientific Institute, Milano, Italy

<sup>4</sup>University of Colorado, Denver, CO

<sup>5</sup>Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

<sup>6</sup>Department of Oncology, Karmanos Cancer Institute, Detroit, MI

<sup>7</sup>Emory University, Atlanta, GA

<sup>8</sup>Internal Medicine/Hematology/Oncology, University of Michigan, Ann Arbor, MI

<sup>9</sup>Department of Dermatology at Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>10</sup>University of California, Irvine, Beverly Hills, CA

<sup>11</sup>Hematology Department / Hemophilia Center, Necker University Hospital, AP-HP, Paris, France

<sup>12</sup>Rhizen Pharmaceuticals S.A., Hyderabad, Telangana, India

<sup>13</sup>Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland

<sup>14</sup>Hematology, Humanitas Cancer Center, Rozzano, Milano, Italy

## **2927 Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis**

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Chul S. Ha, MD<sup>1</sup>, Hongli Li, MS<sup>2\*</sup>, Heiko Schoder, MD<sup>3\*</sup>, Chelsea C Pinnix, MD<sup>4\*</sup>, Elizabeth Brem, MD<sup>5</sup>, Nancy L. Bartlett, MD<sup>6</sup>, Andrew M. Evens, DO, MSc<sup>7</sup>, Eric D. Hsi, MD<sup>8</sup>, Lisa M. Rimsza, MD<sup>9</sup>, John P. Leonard, MD<sup>10</sup>, Brad S Kahl, MD<sup>11</sup>, Michael L. Leblanc, PhD<sup>2\*</sup>, Sonali M. Smith, MD<sup>12</sup>, Louis S. Constine, MD<sup>13</sup> and Jonathan W. Friedberg, MD<sup>13</sup>

<sup>1</sup>University of Texas Health Science Center At San Antonio, San Antonio, TX

<sup>2</sup>SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY

<sup>4</sup>Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston

<sup>5</sup>Division of Hematology/Oncology, Dept. of Medicine, University of California at Irvine School of Medicine, Huntington Beach, CA

<sup>6</sup>Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

<sup>7</sup>Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>8</sup>Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>9</sup>Department of Research, Mayo Clinic - Scottsdale, Scottsdale, AZ

<sup>10</sup>Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

<sup>11</sup>Department of Medicine, Washington University School of Medicine, Saint Louis, MO

<sup>12</sup>University of Chicago, Chicago, IL

<sup>13</sup>Wilmot Cancer Institute, University of Rochester, Rochester, NY

## **2967 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma**

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II

Hematology Disease Topics & Pathways:

Diseases, Biological, Lymphoma (any), Therapies, CAR-Ts, Non-Hodgkin Lymphoma, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sattva S. Neelapu, MD<sup>1</sup>, Armin Ghobadi, MD<sup>2\*</sup>, Caron A. Jacobson, MD, MMSc<sup>3\*</sup>, David B. Miklos, MD, PhD<sup>4</sup>, Lazaros J. Lekakis, MD<sup>5\*</sup>, Olalekan O. Oluwole, MBBS, MPH<sup>6</sup>, Yi Lin, MD, PhD<sup>7</sup>, Ira Braunschweig, MD<sup>8\*</sup>, Brian T. Hill, MD, PhD<sup>9,10</sup>, John M. Timmerman, MD<sup>11</sup>, Abhinav Deol, MD<sup>12</sup>, Patrick M. Reagan, MD<sup>13</sup>, Patrick J. Stiff, MD<sup>14</sup>, Ian W. Flinn, MD, PhD<sup>15</sup>, Umar Farooq, MD<sup>16</sup>, Andre Goy, MD<sup>17</sup>, Peter A. McSweeney, MD<sup>18\*</sup>, Javier Munoz, MD<sup>19</sup>, Tanya Siddiqi, MD<sup>20</sup>, Julio C. Chavez, MD<sup>21</sup>, Alex F. Herrera, MD<sup>22</sup>, Allen Xue, PhD<sup>23\*</sup>, Yizhou Jiang, PhD<sup>23\*</sup>, Adrian Bot, MD, PhD<sup>23\*</sup>, John M. Rossi, MS<sup>23\*</sup>, Jenny J. Kim, MD, MS<sup>23\*</sup>, William Y. Go, MD, PhD<sup>23</sup> and Frederick L. Locke, MD<sup>24</sup>

<sup>1</sup>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>2</sup>Washington University School of Medicine, St. Louis, MO

<sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

<sup>4</sup>Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA

<sup>5</sup>University of Miami Health System, Sylvester Comprehensive Care Center, Miami, FL

<sup>6</sup>Vanderbilt-Ingram Cancer Center, Nashville, TN

<sup>7</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>8</sup>Department of Hematology and Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

<sup>9</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>11</sup>UCLA David Geffen School of Medicine, Los Angeles, CA

<sup>12</sup>Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

<sup>13</sup>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

<sup>14</sup>Loyola University Medical Center, Maywood, IL

<sup>15</sup>Sarah Cannon Research Institute, Nashville, TN

<sup>16</sup>Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

<sup>17</sup>John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ

<sup>18</sup>Colorado Blood Cancer Institute, Denver, CO

<sup>19</sup>Banner MD Anderson Cancer Center, Gilbert, AZ

<sup>20</sup>City of Hope National Medical Center, Duarte, CA

<sup>21</sup>H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

<sup>22</sup>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

<sup>23</sup>Kite, a Gilead Company, Santa Monica, CA

<sup>24</sup>Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

### **3027 Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)**

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Biological, Adult, Therapies, Non-Biological, Biological Processes, MPN, epigenetics, Study Population, Clinically relevant, Myeloid Malignancies, TKI, signal transduction

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Rajjit K. Rampal, MD, PhD<sup>1</sup>, John Mascarenhas, MD<sup>2</sup>, Heidi E. Kosiorek, MS<sup>3\*</sup>, Rupali Bhave, M.D.<sup>4\*</sup>, Elizabeth O. Hexner, MD, MS<sup>5</sup>, Eunice S. Wang, MD<sup>6</sup>, Aaron T. Gerds, MD, MS<sup>7</sup>, Mark L Heaney, MD, PhD<sup>8</sup>, Camille N Abboud, MD<sup>9</sup>, Marina Kremyanskaya, MD, PhD<sup>10\*</sup>, Dmitriy Berenzon, MD<sup>11\*</sup>, Olatoyosu Odenike, MD<sup>12</sup>, Elizabeth Virtgasm<sup>13\*</sup>, Lonette Sandy<sup>10\*</sup>, Rona Singer Weinberg, PhD<sup>14</sup>, Vesna Najfeld, PhD<sup>15</sup>, Mohamed E. Salama, MD<sup>16</sup>, Ross L. Levine, MD<sup>17</sup>, Ruben A. Mesa, MD, FACP<sup>18</sup>, Amylou C. Dueck, PhD<sup>19</sup> and Ronald Hoffman, MD<sup>10</sup>*

<sup>1</sup>Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY

<sup>2</sup>Icahn School of Medicine at Mount Sinai, New York, NY

<sup>3</sup>Department of Biostatistics, Mayo Clinic, Scottsdale, AZ

<sup>4</sup>Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC

<sup>5</sup>Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA

<sup>6</sup>Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

<sup>7</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>8</sup>Columbia University Medical Center, New York, NY

<sup>9</sup>Division of Oncology, Washington University School of Medicine, Saint Louis, MO

<sup>10</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

<sup>11</sup>Comprehensive Cancer Center, Wake Forest Baptist Health, Comprehensive Cancer Center, Wake Forest Baptist Health, Winston-Salem, NC

<sup>12</sup>Section of Hematology/Oncology, University of Chicago, Chicago, IL

<sup>13</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

<sup>14</sup>New York Blood Center, New York, NY

<sup>15</sup>Division of Hematology/Medical Oncology/Pathology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY

<sup>16</sup>Mayo Medical Laboratories, Rochester, MN

<sup>17</sup>Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>18</sup>UT Health San Antonio Cancer Center, San Antonio, TX

<sup>19</sup>Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ

### **3073 LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS, RNA sequencing

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Courtney Hershberger, BS<sup>1\*</sup>, James Hiznay<sup>1\*</sup>, Rosemary Dietrich<sup>1\*</sup>, Xiaorong Gu, PhD<sup>2\*</sup>, Cassandra M. Hirsch<sup>3\*</sup>, Amy Graham, BS, MS<sup>3\*</sup>, Bartlomiej P. Przychodzen<sup>3\*</sup>, Valeria Visconte, PhD<sup>3</sup>, Vera Adema, PhD<sup>4\*</sup>,*

**Yvonne Parker<sup>5\*</sup>, Hetty E. Carraway, MD, MBA<sup>6,7</sup>, Tomas Radivoyevitch, PhD<sup>3\*</sup>, Mikkael A. Sekeres, MD, MS<sup>8</sup>, Yogenthiran Saunthararajah, MD<sup>9</sup>, Jaroslaw P. Maciejewski<sup>3</sup> and Richard A Padgett<sup>1\*</sup>**

<sup>1</sup>Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland

<sup>5</sup>Cleveland Clinic, Cleveland

<sup>6</sup>Cleveland Clinic, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>8</sup>Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH

### **3074 Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Cassandra M. Hirsch<sup>1\*</sup>, Wenyi Shen, MD<sup>2\*</sup>, Bartłomiej P. Przychodzen<sup>1\*</sup>, Yasunobu Nagata<sup>3\*</sup>, Vera Adema, PhD<sup>4\*</sup>, Teodora Kuzmanovic, BA<sup>1\*</sup>, Louis Williams, MD, MBA<sup>1</sup>, Aziz Nazha, MD<sup>5</sup>, Valeria Visconte, PhD<sup>6</sup>, Hetty E. Carraway, MD, MBA<sup>7</sup>, Mikkael A. Sekeres, MD, MS<sup>8</sup> and Jaroslaw P. Maciejewski<sup>1,9</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland, OH

<sup>5</sup>Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>8</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

### **3084 Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, CMML, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Teodora Kuzmanovic<sup>1\*</sup>, Bhumika J. Patel, MD<sup>2</sup>, Srinivasa Reddy Sanikommu, MD<sup>3</sup>, Yasunobu Nagata<sup>4\*</sup>, Hassan Awada, MD<sup>5</sup>, Cassandra M. Hirsch<sup>4\*</sup>, Bartłomiej P. Przychodzen<sup>1\*</sup>, Remco J Molenaar, MD PhD<sup>6,7\*</sup>, Babal K. Jha<sup>1\*</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>2</sup>, Anjali S. Advani, MD<sup>8</sup>, Aziz Nazha, MD<sup>2</sup>, Aaron T. Gerds, MD, MS<sup>9</sup>, Hetty E. Carraway, MD, MBA<sup>8,10</sup>, Mikkael A. Sekeres, MD, MS<sup>11</sup>, Jaroslaw P. Maciejewski<sup>4,12</sup> and Tomas Radivoyevitch, PhD<sup>4,13\*</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium health, Charlotte, NC

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Fairview Park, OH

<sup>6</sup>Academic Medical Center, Amsterdam, Netherlands

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>9</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>10</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>11</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>12</sup>Leukemia Program, Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>13</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

## **3091 Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, apoptosis, Non-Biological, Therapies, MDS, Biological Processes, chemotherapy, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***David A Sallman, MD<sup>1</sup>, Amy E. DeZern, MD<sup>2</sup>, David P. Steensma, MD<sup>3</sup>, Kendra L. Sweet, MD<sup>1</sup>, Thomas Cluzeau, MD, PhD<sup>4\*</sup>, Mikkael A. Sekeres, MD, MS<sup>5</sup>, Guillermo Garcia-Manero, MD<sup>6</sup>, Gail J. Roboz, MD<sup>7</sup>, Amy F McLemore, M.S.<sup>1\*</sup>, Kathy L McGraw, PhD<sup>1</sup>, John Puskas, PhD<sup>1\*</sup>, Ling Zhang, MD<sup>1</sup>, Chirag K Bhagat, PharmD<sup>8\*</sup>, Jiqiang Yao, PhD<sup>9\*</sup>, Najla Al Ali, M.Sc<sup>10\*</sup>, Eric Padron, MD<sup>1</sup>, Roger Tell, MD, PhD<sup>11\*</sup>, Jeffrey E. Lancet, MD<sup>1</sup>, Pierre Fenaux, MD, PhD<sup>12\*</sup>, Alan F. List, MD<sup>1</sup> and Rami S. Komrokji, MD<sup>1</sup>***

<sup>1</sup>Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>2</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

<sup>4</sup>Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

<sup>5</sup>Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>7</sup>Weill Cornell Medical College, New York, NY

<sup>8</sup>Genoptix, Inc, Carlsbad, CA

<sup>9</sup>Cancer Informatics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa

<sup>10</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>11</sup>Aprea Therapeutics, Solna, Sweden

<sup>12</sup>Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France

## **3095 Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, MDS, chemotherapy, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Sudipto Mukherjee, MD, PhD, MPH<sup>1,2</sup>, Tomas Radivoyevitch, PhD<sup>3,4\*</sup>, Brian P. Hobbs, PhD<sup>5\*</sup>, Xuefei Jia, MS<sup>3\*</sup>, Rami S. Komrokji, MD<sup>6</sup>, David P. Steensma, MD<sup>7</sup>, Amy E. DeZern, MD<sup>8</sup>, Gail J. Roboz, MD<sup>9</sup>, Guillermo Garcia-Manero, MD<sup>10</sup>, Jaroslaw P. Maciejewski<sup>4</sup>, Aziz Nazha, MD<sup>1</sup> and Mikkael A. Sekeres, MD, MS<sup>11,12</sup>***

<sup>1</sup>Cleveland Clinic, Cleveland, OH

<sup>2</sup>Leukemia Program, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

<sup>7</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>8</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>9</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>10</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>11</sup>Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

<sup>12</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **3096 Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, MDS, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Sudipto Mukherjee, MD, PhD, MPH<sup>1</sup>, David P. Steensma, MD<sup>2</sup>, Rami S. Komrokji, MD<sup>3</sup>, Amy E. DeZern, MD<sup>4</sup>, Gail J. Roboz, MD<sup>5</sup>, Guillermo Garcia-Manero, MD<sup>6</sup>, Aziz Nazha, MD<sup>7</sup>, Jaroslaw P. Maciejewski<sup>8</sup>, Mikkael A. Sekeres, MD, MS<sup>9</sup>, Brian P. Hobbs, PhD<sup>10\*</sup> and Xuefei Jia, MS<sup>11\*</sup>**

<sup>1</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>3</sup>Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

<sup>4</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>5</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>6</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>7</sup>Cleveland Clinic, Cleveland, OH

<sup>8</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>9</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>10</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>11</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

### **3098 What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, MDS, chemotherapy, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Rami S. Komrokji, MD<sup>1</sup>, Najla Al Ali, MSc<sup>2\*</sup>, David A Sallman, MD<sup>3</sup>, Eric Padron, MD<sup>1</sup>, Aziz Nazha, MD<sup>4</sup>, David P. Steensma<sup>5</sup>, Amy E. DeZern, MD<sup>6</sup>, Gail J. Roboz, MD<sup>7</sup>, Guillermo Garcia-Manero, MD<sup>8</sup>, Mikkael A. Sekeres, MD, MS<sup>9</sup>, Jeffrey E. Lancet, MD<sup>1</sup> and Alan F. List, MD<sup>9</sup>**

<sup>1</sup>Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>2</sup>Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

<sup>3</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

<sup>4</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>6</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>7</sup>Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York

<sup>8</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>9</sup>H. Lee Moffitt Cancer Center, Tampa, FL

### **3103 Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Adult, MDS, Study Population, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Andrea Kuendgen, MD<sup>1\*</sup>, Meritxell Nomdedeu<sup>2\*</sup>, Heinz Tuechler<sup>3\*</sup>, Guillermo Garcia-Manero, MD<sup>4</sup>, Rami S. Komrokji, MD<sup>5</sup>, Mikkael A. Sekeres, MD, MS<sup>6</sup>, Matteo Giovanni Della Porta<sup>7\*</sup>, Alan F. List, MD<sup>8</sup>, Mario Cazzola<sup>9</sup>, Amy E. DeZern, MD<sup>10</sup>, Gail J. Roboz, MD<sup>11</sup>, David P. Steensma, MD<sup>12</sup>, Arjan A. Van de Loosdrecht, MD, PhD<sup>13</sup>, Hartmut Döhner, MD<sup>14</sup>, Xavier Calvo, MD<sup>15\*</sup>, Sabine Blum<sup>16\*</sup>, Arturo Pereira, MD, PhD<sup>17\*</sup>, Peter Valent<sup>18</sup>, Dolors Costa<sup>19\*</sup>, Aristoteles Giagounidis<sup>20</sup>, Luis Benlloch<sup>21\*</sup>, Uwe Platzbecker, MD<sup>22</sup>, Carme Pedro, MD<sup>23\*</sup>, Michael Lübbert<sup>24</sup>, Itziar Oiartzabal<sup>25\*</sup>, Javier Grau<sup>26\*</sup>, María Díez-Campelo<sup>27\*</sup>, María Teresa Cedena<sup>28\*</sup>, Sigrid Machherndl-Spandl, MD<sup>29\*</sup>, María López-Pavía<sup>30\*</sup>, Claudia D. Baldus, MD<sup>31</sup>, Montserrat Martínez-de-Sola<sup>32\*</sup>, Reinhard Stauder, MD, MSc<sup>33</sup>, Brayan Merchan<sup>34\*</sup>, Christina Ganster<sup>35</sup>, Thomas Schroeder<sup>36\*</sup>, Barbara Hildebrandt<sup>37\*</sup>, Jordi Esteve, MD, PhD<sup>38</sup>, Benet Nomdedeu<sup>39\*</sup>, Francesc Cobo<sup>40\*</sup>, Francesc Sole, PhD<sup>41</sup>, Rainer Haas, MD<sup>42\*</sup>, Ulrich Germing, MD<sup>43\*</sup>, Peter L Greenberg, M.D.<sup>44</sup>, Detlef Haase, MD, PhD<sup>35\*</sup> and Guillermo Sanz, MD, PhD<sup>45</sup>**

<sup>1</sup>Department of Hematology, Oncology, and Clinical Immunology, Duesseldorf, DEU  
<sup>2</sup>Hospital Clinic, Spanish MDS Cooperative Group, Barcelona, ESP  
<sup>3</sup>Boltzmann Institute for Leukemia Research, Hanusch Hospital, Vienna, Austria  
<sup>4</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX  
<sup>5</sup>Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL  
<sup>6</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH  
<sup>7</sup>Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University, Rozzano - Milan, Italy  
<sup>8</sup>H. Lee Moffitt Cancer Center, Tampa, FL  
<sup>9</sup>Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy  
<sup>10</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD  
<sup>11</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY  
<sup>12</sup>Dana-Farber Cancer Institute, Boston, MA  
<sup>13</sup>Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands  
<sup>14</sup>Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany  
<sup>15</sup>Laboratori de Citolgia Hematològica i Citogenètica, servei de Patologia, Hospital del Mar. GRETNHE- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain  
<sup>16</sup>Service of Hematology, University Hospital Lausanne, Lausanne, Switzerland  
<sup>17</sup>Hemotherapy and Hemostasis Department, Hospital Clínic, Barcelona, Spain  
<sup>18</sup>Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria  
<sup>19</sup>Hospital Clínic-IDIBAPS, Barcelona, Spain  
<sup>20</sup>Department of Oncology, Hematology and Palliative Care, Marienhospital Düsseldorf, Düsseldorf, Germany  
<sup>21</sup>Spanish Cooperative Group, Valencia, Spain  
<sup>22</sup>University Hospital Dresden, Dresden, Germany  
<sup>23</sup>Hospital del Mar, Barcelona, Spain  
<sup>24</sup>Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany  
<sup>25</sup>Hospital Universitario Araba, Vitoria-Gasteiz, Spain  
<sup>26</sup>Department of Laboratory Hematology, University Hospital Germans Trias i Pujol. ICO Josep Carreras Leukemia Research Institute, Badalona, Spain  
<sup>27</sup>Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain  
<sup>28</sup>Hospital Universitario 12 de Octubre, Madrid, Spain  
<sup>29</sup>1st. Internal Department – Hematology with stem cell transplants, hemostaseology and medical oncology, Elisabethinen Hospital, Linz, Austria  
<sup>30</sup>Hospital General Universitari de València, Hematology Service, Valencia, Spain  
<sup>31</sup>Hämatologie und Onkologie, Charité-Universitätsmedizin Berlin, Berlin, Germany  
<sup>32</sup>Hospital Parc Taulí, Sabadell, Spain  
<sup>33</sup>Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria  
<sup>34</sup>Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain  
<sup>35</sup>Clinics of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany  
<sup>36</sup>Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany  
<sup>37</sup>Institute of Human Genetics, University Duesseldorf, düsseldorf, Germany  
<sup>38</sup>Hematology Department, Hospital Clínic, Barcelona, Spain  
<sup>39</sup>Hospital Clínic i Provincial, Barcelona, Spain  
<sup>40</sup>Hospital Quirón Teknon, Barcelona, Spain  
<sup>41</sup>MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain  
<sup>42</sup>Department for Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Duesseldorf, Germany  
<sup>43</sup>Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany  
<sup>44</sup>Stanford University Cancer Center, Stanford, CA  
<sup>45</sup>Hematology Department, Hospital Universitario La Fe, Valencia, Spain

## 3142 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Adult, antibodies, Biological, Leukemia, Diseases, Therapies, CLL, Study Population, Clinically relevant, Lymphoid Malignancies, TKI

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Anthony R. Mato, MD MSCE<sup>1</sup>, Lindsey E. Roeker, MD<sup>1</sup>, Toby A. Eyre<sup>2\*</sup>, Chadi Nabhan, MD<sup>3</sup>, Nicole Lamanna, MD<sup>4</sup>, Brian T. Hill, MD, PhD<sup>5,6</sup>, Danielle M. Brander, MD<sup>7</sup>, Paul Barr, MD<sup>8,9</sup>, Frederick Lansigan, MD<sup>10</sup>, Bruce Cheson, MD<sup>11</sup>, Arun K Singavi, MD<sup>12</sup>, Maryam Yazdy, MD<sup>13</sup>, Nirav N Shah, MD<sup>14</sup>, John N. Allan, MD<sup>15</sup>, Erica B Bhavsar, BS<sup>16\*</sup>, Joanna Rhodes, MD<sup>17</sup>, Kaitlin Kennard, RN, BSN<sup>18\*</sup>, Stephen J. Schuster, MD<sup>19</sup>, Annalynn M Williams, MS<sup>20</sup>, Alan P Skarbnik, MD<sup>21</sup>, Andre Goy, MD<sup>22</sup>, Catherine C. Coombs, MD<sup>23</sup>, Hande H. Tuncer, MD<sup>24</sup>, Chaitra S. Ujjani, MD<sup>25</sup>, Ryan Jacobs, MD<sup>26</sup>, Allison M. Winter,

*MD<sup>27</sup>, John M. Pagel, MD, PhD<sup>28</sup>, Neil Bailey, MSc<sup>28\*</sup>, Anna Schuh, MD<sup>29</sup>, Mazyar Shadman, MD, MPH<sup>25</sup>, Andrea Sitlinger, MD<sup>30</sup>, Hanna Weissbrot, BS<sup>31\*</sup>, Sivraj Muralikrishnan, MD<sup>10</sup>, Amy A Kirkwood, MSc<sup>32\*</sup> and Christopher P. Fox, MD, PhD<sup>33\*</sup>*

<sup>1</sup>CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

<sup>2</sup>Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom

<sup>3</sup>Cardinal Health Specialty Solutions, Deerfield, IL

<sup>4</sup>Herbert Irving Comprehensive Cancer Center (New York-Presbyterian Columbia University Medical Center), New York, NY

<sup>5</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Duke Cancer Institute, Duke University Health System, Durham, NC

<sup>8</sup>Wilmot Cancer Institute, University of Rochester, Rochester, NY

<sup>9</sup>University of Rochester, Rochester, NY

<sup>10</sup>Dartmouth-Hitchcock Medical Center, Lebanon, NH

<sup>11</sup>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

<sup>12</sup>Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>13</sup>Department of hematology and oncology, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

<sup>14</sup>Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>15</sup>Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

<sup>16</sup>CLL Research Center, Weill Cornell Medicine, New York, NY

<sup>17</sup>Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA

<sup>18</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

<sup>19</sup>Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA

<sup>20</sup>University of Rochester Medical Center, Rochester, NY

<sup>21</sup>John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ

<sup>22</sup>John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

<sup>23</sup>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

<sup>24</sup>Tufts Medical Center, Boston, MA

<sup>25</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>26</sup>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

<sup>27</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>28</sup>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

<sup>29</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

<sup>30</sup>Department of Medicine, Duke University Medical Center, Durham, NC

<sup>31</sup>Columbia University Medical Center, New York, NY

<sup>32</sup>Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom

<sup>33</sup>Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

## **3233 Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

antibodies, Biological, multiple myeloma, Diseases, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Ujjawal H Gandhi, PhD, MBBS<sup>1</sup>, Arjun Lakshman, MD, MRCP<sup>2\*</sup>, Zhubin Gahvari, MD<sup>3</sup>, Elizabeth McGehee, MD<sup>4\*</sup>, Megan Helena Jagosky, MD<sup>5\*</sup>, Ridhi Gupta, MBBS<sup>6\*</sup>, William Varnado, MD<sup>7\*</sup>, Saurabh Chhabra, MD<sup>8</sup>, Mark A. Fiala, BS<sup>9\*</sup>, Ehsan Malek, MD<sup>10</sup>, Joshua Mansour, MD<sup>11</sup>, Barry Paul, MD<sup>12\*</sup>, Alyssa Barnstead<sup>13\*</sup>, Saranya Kodali, MD<sup>14</sup>, Amarendra K. Neppalli, MD<sup>15</sup>, Michaela Liedtke, MD<sup>6</sup>, Kelly N. Godby, MD<sup>7\*</sup>, Yubin Kang, MD<sup>16</sup>, Ankit Kansagra, MD<sup>4</sup>, Emma C. Scott, MD<sup>17</sup>, Elvira Umyarova, MD<sup>14</sup>, Parameswaran Hari, MBBS, MD<sup>18</sup>, Ravi Vij, MBBS<sup>19</sup>, Saad Z. Usmani, MD<sup>20</sup>, Natalie Scott Callander, MD<sup>21</sup>, Robert Frank Cornell, MD<sup>22</sup>, Shaji K. Kumar, MD<sup>23</sup> and Luciano J Costa, MD, PhD<sup>24</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN

<sup>2</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>3</sup>University of Wisconsin, Madison, WI

<sup>4</sup>University of Texas Southwestern Medical Center, Dallas, TX

<sup>5</sup>Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, Levine Cancer Institute, Charlotte, NC

<sup>6</sup>Stanford Cancer Institute, Stanford, CA

<sup>7</sup>University of Alabama at Birmingham, Birmingham, AL

<sup>8</sup>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>9</sup>Washington University School of Medicine, Saint Louis, MO

<sup>10</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH  
<sup>11</sup>Medical University of South Carolina, Charleston, SC  
<sup>12</sup>Department of Medicine, Duke University School of Medicine, Durham, NC  
<sup>13</sup>Oregon Health & Science University, Portland, OR  
<sup>14</sup>University of Vermont, College of Medicine, Burlington, VT  
<sup>15</sup>Hollings Cancer Center, Medical University of South Carolina, Charleston, SC  
<sup>16</sup>Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC  
<sup>17</sup>Knight Cancer Institute, Oregon Health & Science University, Portland, OR  
<sup>18</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI  
<sup>19</sup>Section of Stem Cell Transplant and Leukemia, Division of Oncology, Washington University School of Medicine, Saint Louis, MO  
<sup>20</sup>Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC  
<sup>21</sup>Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI  
<sup>22</sup>Department of Medicine, Division of Hematology & Oncology, Vanderbilt Univ. Medical Center, Nashville, TN  
<sup>23</sup>Department of Hematology, Mayo Clinic, Rochester, MN  
<sup>24</sup>Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL

### **3239 Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Muhammad Usman, MD<sup>1\*</sup>, Warda Faridi, MD<sup>1\*</sup>, Muhammad Asad Fraz, MD<sup>1\*</sup>, Muhammad Junaid Tariq, MD<sup>1\*</sup>, Saad Ullah Malik, MD<sup>1\*</sup>, Fnu Sagar, MD<sup>1\*</sup>, Awais Ijaz, MD<sup>1\*</sup>, Abid Hussain, MD<sup>1\*</sup>, Malik Qistas Ahmad, MD, MBBS<sup>1\*</sup>, Muhammad Jahanzeb Khalil, MD<sup>1\*</sup>, Amna Khalid, MD<sup>1\*</sup>, Midhat Lakhani, MD<sup>1\*</sup>, Ceren Durer, MD<sup>1\*</sup>, Seren Durer, MD<sup>1\*</sup>and Faiz Anwer, MD<sup>1,2</sup>*

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

### **3271 Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Adult, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*David S Siegel, MD, PhD<sup>1</sup>, Gary J. Schiller, MD<sup>2</sup>, Christy J. Samaras, DO<sup>3</sup>, Michael Sebag, MD, PhD<sup>4</sup>, Jesus G. Berdeja, MD<sup>5</sup>, Siddhartha Ganguly, MD<sup>6\*</sup>, Jeffrey V Matous, MD<sup>7</sup>, Kevin Song, MD<sup>8</sup>, Christopher S. Seet, MD<sup>9</sup>, Giampaolo Talamo<sup>10\*</sup>, Mirelis Acosta-Rivera<sup>11\*</sup>, Michael Bar<sup>12\*</sup>, Donald P. Quick, MD<sup>13</sup>, Bertrand Anz, MD<sup>14\*</sup>, Gustavo Fonseca<sup>15\*</sup>, Donna Reece<sup>16\*</sup>, Amit Agarwal, MD, PhD<sup>17</sup>, Weiyuan Chung<sup>17\*</sup>, Faiza Zafar, MPAS<sup>17\*</sup> and Nizar Bahlis, MD<sup>18</sup>*

<sup>1</sup>John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ

<sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>McGill University Health Centre, Montreal, QC, Canada

<sup>5</sup>Sarah Cannon Research Institute, Nashville, TN

<sup>6</sup>The University of Kansas Cancer Center, Fairway, KS

<sup>7</sup>Colorado Blood Cancer Institute, Denver, CO

<sup>8</sup>The Vancouver General Hospital, Vancouver, BC, CAN

<sup>9</sup>UCLA Medical Center, Los Angeles, CA

<sup>10</sup>Penn State Hershey Cancer Institute, Hershey, PA

<sup>11</sup>Fundacion de Investigacion, San Juan, Puerto Rico

<sup>12</sup>Stamford Hospital, Stamford, CT

<sup>13</sup>Joe Arrington Cancer Research Treatment Center, Lubbock, TX

<sup>14</sup>Tennessee Oncology, Chattanooga, TN

<sup>15</sup>Florida Cancer Specialists, St. Petersburg, FL

<sup>16</sup>Princess Margaret Cancer Centre, Toronto, Canada

<sup>17</sup>Celgene Corporation, Summit, NJ

<sup>18</sup>University of Calgary, Calgary, AB, Canada

## **3292 Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Muhammad Abu Zar, MD<sup>1\*</sup>, Ahmad Kamal, MD<sup>1\*</sup>, Ali Younas Khan, MD<sup>1\*</sup>, Saad Ullah Malik, MD<sup>1\*</sup>, Mustafa Nadeem Malik, MD<sup>1\*</sup>, Abdul Rafee, MD<sup>1\*</sup>, Ceren Durer, MD<sup>1\*</sup>, Seren Durer, MD<sup>1\*</sup>, Insija Illyas Selene, MBBS<sup>1\*</sup>, Anum Qureshi<sup>1\*</sup>, Jemin Aby Jose, MD<sup>1\*</sup>, Hafiz Muhammad Fazeel, MD<sup>1\*</sup>, Zunairah Shah, MBBS<sup>1\*</sup>, Muhammad Adil Rehman, MBBS<sup>1\*</sup> and Faiz Anwer, MD<sup>1,2</sup>**

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

## **3303 Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Adult, antibodies, Biological, multiple myeloma, Diseases, Therapies, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**William Varnado, MD<sup>1,2</sup>, Megan Helena Jagosky, MD<sup>3\*</sup>, Zhubin Gahvari, MD<sup>4</sup>, Saurabh Chhabra, MD<sup>5</sup>, Ujjawal H Gandhi, PhD, MBBS<sup>6</sup>, Arjun Lakshman, MD, MRCP<sup>7\*</sup>, Elizabeth McGehee, MD<sup>8\*</sup>, Ridhi Gupta, MBBS<sup>9\*</sup>, Ehsan Malek, MD<sup>10</sup>, Mark A. Fiala, BS<sup>11\*</sup>, Joshua Mansour, MD<sup>12</sup>, Barry Paul, MD<sup>13\*</sup>, Alyssa Barnstead<sup>14\*</sup>, Saranya Kodali, MD<sup>15</sup>, Neppalli Amarendra, MD<sup>16\*</sup>, Michaela Liedtke, MD<sup>17</sup>, Kelly N. Godby, MD<sup>1</sup>, Yubin Kang, MD<sup>18</sup>, Ankit Kansgra, MD<sup>19\*</sup>, Emma C. Scott, MD<sup>20</sup>, Elvira Umyarova, MD<sup>15</sup>, Parameswaran Hari, MBBS, MD<sup>21</sup>, Ravi Vij<sup>22</sup>, Saad Z. Usmani, MD<sup>23</sup>, Robert Frank Cornell, MD<sup>24</sup>, Shaji K. Kumar, MD<sup>25</sup>, Natalie Scott Callander, MD<sup>26</sup> and Luciano J Costa, MD, PhD<sup>27</sup>**

<sup>1</sup>University of Alabama at Birmingham, Birmingham, AL

<sup>2</sup>University of Alabama in Birmingham, Birmingham

<sup>3</sup>Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, Levine Cancer Institute, Charlotte, NC

<sup>4</sup>University of Wisconsin, Madison, WI

<sup>5</sup>Medical College of Wisconsin, Milwaukee, WI

<sup>6</sup>Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN

<sup>7</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>8</sup>University of Texas Southwestern Medical Center, Dallas, TX

<sup>9</sup>Stanford Cancer Institute, Stanford, CA

<sup>10</sup>University of Cincinnati, Cleveland, OH

<sup>11</sup>Washington University School of Medicine, Saint Louis, MO

<sup>12</sup>Medical University of South Carolina, Charleston, SC

<sup>13</sup>Department of Medicine, Duke University School of Medicine, Durham, NC

<sup>14</sup>Oregon Health & Science University, Portland, OR

<sup>15</sup>University of Vermont, College of Medicine, Burlington, VT

<sup>16</sup>Medical University of South Carolina, Charleston

<sup>17</sup>Stanford University Cancer Center, Stanford, CA

<sup>18</sup>Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

<sup>19</sup>UT Southwestern Medical Center, Dallas, TX

<sup>20</sup>Knight Cancer Institute, Oregon Health & Science University, Portland, OR

<sup>21</sup>Department of Medicine, Medical College of Wisconsin, Menomonee Falls, WI

<sup>22</sup>Washington University School of Medicine at St. Louis, St Louis, MO

<sup>23</sup>Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC

<sup>24</sup>Department of Medicine, Division of Hematology & Oncology, Vanderbilt Univ. Medical Center, Nashville, TN

<sup>25</sup>Department of Hematology, Mayo Clinic, Rochester, MN

<sup>26</sup>Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI

<sup>27</sup>Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL

### **3309 Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review**

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Non-Biological, Therapies, chemotherapy

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Insija Ilyas Selene, MBBS<sup>1</sup>, Jemin Aby Jose, MD<sup>1\*</sup>, Muhammad Jahanzeb Khalil, MD<sup>1\*</sup>, Muhammad Junaid Tariq, MD<sup>1\*</sup>, Seren Durer, MD<sup>1\*</sup>, Ceren Durer, MD<sup>1\*</sup>, Madeeha Shafqat<sup>1\*</sup>, Shehroz Aslam, MD<sup>1\*</sup>, Zunairah Shah, MBBS<sup>1\*</sup>, Anum Qureshi<sup>1\*</sup>, Faiza Jamil, MD<sup>1\*</sup>, Mustafa Nadeem Malik, MD<sup>1\*</sup>, Abdul Rafea, MD<sup>1\*</sup>, Muhammad Masab, MD<sup>2\*</sup> and Faiz Anwer, MD<sup>3,4</sup>

<sup>1</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

<sup>2</sup>West Virginia University, West Virginia

<sup>3</sup>Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

<sup>4</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

### **3365 Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia**

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways:

AML, Adult, Diseases, Non-Biological, Therapies, chemotherapy, Technology and Procedures, Study Population, cytogenetics, Clinically relevant, Quality Improvement, Myeloid Malignancies, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sagar S. Patel, MD<sup>1</sup>, Lisa Rybicki, MS<sup>2\*</sup>, Arden Emrick<sup>1\*</sup>, Victoria Winslow, RN<sup>1\*</sup>, Jamie Starn, RN<sup>1\*</sup>, Jamie Elberson, RN<sup>1\*</sup>, Brittany Hodgerman, RN<sup>1\*</sup>, Brad Pohlman, MD<sup>3</sup>, Brian J. Bolwell, MD<sup>1</sup>, Aaron T. Gerds, MD, MS<sup>4</sup>, Betty K. Hamilton, MD<sup>1</sup>, Rabi Hanna, MD<sup>4</sup>, Matt Kalaycio, MD<sup>1</sup>, Navneet S. Majhail, MD, MS<sup>1</sup> and Ronald Sobecks, MD<sup>1</sup>

<sup>1</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Pediatric Blood and Marrow Transplant Program, Pediatrics Institute and Children's Hospital, Cleveland Clinic, Cleveland, OH

### **3379 Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation**

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways:

Biological, Adult, Therapies, Bone Marrow Failure, Biological Processes, Technology and Procedures, cell expansion, Study Population, Clinically relevant, hematopoiesis, transplantation

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Hillard M Lazarus, MD<sup>1</sup>, Leland Metheny, MD<sup>2,3</sup>, Tsila Zuckerman, MD<sup>4,5</sup>, Carolina Escobar, MD<sup>6\*</sup>, Joseph P. McGuirk, DO<sup>7</sup>, Yael Rosen, MD<sup>8\*</sup> and Jacob M. Rowe, MD<sup>9</sup>

<sup>1</sup>Case Western Reserve University School of Medicine, Cleveland, OH

<sup>2</sup>Case Western Reserve University, Cleveland, OH

<sup>3</sup>Stem Cell Transplant Program, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>4</sup>Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

<sup>5</sup>The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

<sup>6</sup>Texas Oncology-Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, Dallas, TX

<sup>7</sup>Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

<sup>8</sup>Pluristem Ltd., Haifa, Israel

<sup>9</sup>Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

### **3456 Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR**

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Biological, Therapies, Myeloid Malignancies, transplantation

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Rajneesh Nath, MD<sup>1</sup>, Zheng Zhou, MD, PhD<sup>2</sup>, Jan Cerny, MD, PhD<sup>3</sup>, Hai-Lin Wang, MPH<sup>4\*</sup>, Khalid Bo-*

*Subait<sup>4\*</sup>, Zartash Guth<sup>5\*</sup>, Gulrayz Ahmed<sup>6\*</sup>, Muhammad Wagas Khan<sup>7\*</sup>, Gerhard Carl Hildebrandt, MD<sup>8</sup>,*

*Hassan B. Alkhateeb, MD<sup>9\*</sup>, Moussab Damlaj, MD<sup>10\*</sup>, Mrinal M. Patnaik, MD, MBBS<sup>9</sup>, Brenda M.*

*Sandmaier, MD<sup>11,12,13</sup>, Daniel J. Weisdorf, MD<sup>14</sup>, Marcos de Lima, MD<sup>15</sup>, Mark R. Litzow, MD<sup>9</sup> and Wael*

*Saber, MD, MS<sup>4\*</sup>*

<sup>1</sup>Banner MD Anderson Cancer Center, Gilbert, AZ

<sup>2</sup>Lahey Hospital and Medical Center, Burlington, MA

<sup>3</sup>Division of Stem Cell Transplantation, UMass Memorial Medical Center, Worcester, MA

<sup>4</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>5</sup>University of Cincinnati, Cincinnati, OH

<sup>6</sup>Mount Auburn Hospital-Harvard Medical School, Boston, MA

<sup>7</sup>University of Kentucky, Lexington, KY

<sup>8</sup>Department of Internal Medicine, Division of Hematology/BMT, University of Kentucky, Lexington, KY

<sup>9</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>10</sup>McGill, Montreal, QC, Canada

<sup>11</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>12</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>13</sup>Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

<sup>14</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

<sup>15</sup>Case Western Reserve University, Cleveland, OH

### **3562 The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: A Five Years U.S Nationwide Study**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster II

Hematology Disease Topics & Pathways:

Diseases, Clinically relevant, Quality Improvement

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Mohamed Mokhtar Bakr, MD<sup>1\*</sup>, Umar Zahid, MD, MPH<sup>1,2\*</sup>, Pavan Tenneti, MD<sup>3\*</sup>, Rehan Farooqi,*

*MD<sup>4\*</sup> and Faiz Anwer, MD<sup>5,6</sup>*

<sup>1</sup>Jersey Shore University Medical Center, Neptune, NJ

<sup>2</sup>Johns Hopkins University, Baltimore, MD

<sup>3</sup>University of Arizona, Tucson, AZ

<sup>4</sup>Internal Medicine, MedStar Health, Baltimore, MD

<sup>5</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

### **3570 Deaths Due to Thrombotic Versus Bleeding Events within 90 Days of Cancer Associated Thrombosis**

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster II

Hematology Disease Topics & Pathways:

Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Mailey L Wilks, MSN, APRN, NP-C<sup>1</sup>\*, Shyam K. Poudel, MD<sup>2</sup>\*, Deborah Y. Park, BS<sup>3</sup>\*, Xuefei Jia, MS<sup>4</sup>\*, Vicki Pinkava, MSBS, PA-C<sup>2</sup>\*, Meghan O'Brien, MS, ANP-BC<sup>2</sup>\*, Barb Tripp, CNS<sup>1</sup>\*, Jung-Min Song, RN, CNS<sup>2</sup>\*, Keith R. McCrae, MD<sup>5</sup>, Alok A. Khorana<sup>6</sup> and Dana E. Angelini, MD<sup>2</sup>*

<sup>1</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH

<sup>4</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

**3600 Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) As a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes**

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster II

Hematology Disease Topics & Pathways:

Adult, Study Population, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Sanghee Hong<sup>1</sup>, Lisa Rybicki, MS<sup>2</sup>\*, Jane Dabney, LISW-S<sup>3</sup>\*, Christine Lawrence, LISW-S<sup>4</sup>\*, Betty K. Hamilton, MD<sup>5</sup>, Matt Kalaycio, MD<sup>6</sup>, Linda McLellan, LISW<sup>6</sup>\*, Ronald Sobecks, MD<sup>6</sup>, Stephanie J. Lee, MD, MPH<sup>7</sup> and Navneet S. Majhail, MD, MS<sup>6</sup>*

<sup>1</sup>University of Washington, Seattle, WA

<sup>2</sup>Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

<sup>3</sup>Blood & Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>7</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

**3671 Heterogeneous Hypoxia-Mediated Neutrophil and Red Blood Cell Adhesion to E-Selectin in Microscale Flow**

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster III

Hematology Disease Topics & Pathways:

sickle cell disease, Diseases, cellular interactions, Biological Processes, Hemoglobinopathies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Yuncheng Man<sup>1</sup>\*, Erdem Kucukal, MS<sup>1</sup>\*, Shichen Liu<sup>1</sup>\*, Deepa Manwani, MD<sup>2,3</sup>, Jane Little, MD<sup>1,4</sup> and Umut A. Gurkan, PhD<sup>1</sup>*

<sup>1</sup>Case Western Reserve University, Cleveland, OH

<sup>2</sup>Children's Hospital at Montefiore, Bronx, NY

<sup>3</sup>Albert Einstein College of Medicine, Bronx

<sup>4</sup>Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

**3672 Hypoxia Enhanced Red Cell Adhesion in Vitro May Identify Patients at Risk for Vasculopathy**

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster III

Hematology Disease Topics & Pathways:

sickle cell disease, Diseases, Hemoglobinopathies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Charlotte Yuan, BA<sup>1</sup>\*, Erina Quinn<sup>1</sup>\*, Sargam Kapoor, MD<sup>2</sup>, Myeongseop Kim, MS<sup>1</sup>\*, Erdem Kucukal, MS<sup>1</sup>\*, Umut A. Gurkan, PhD<sup>1</sup> and Jane Little, MD<sup>2</sup>*

<sup>1</sup>Case Western Reserve University, Cleveland, OH

<sup>2</sup>Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

### **3798 The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category**

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bleeding and clotting, Thrombosis, Thromboembolism

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Alok A. Khorana**<sup>1</sup>, **Nicole M. Kuderer**<sup>2</sup>, **Keith R. McCrae, MD**<sup>3</sup>, **Dejan Milentijevic, PhD**<sup>4\*</sup>, **Guillaume Germain, MA**<sup>5\*</sup>, **François Laliberté, MA**<sup>5\*</sup>, **Nguyen Le, BSc**<sup>6\*</sup>, **Patrick Lefebvre, MA**<sup>7\*</sup>, **Gary H. Lyman**<sup>8</sup> and **Michael B. Streiff**<sup>9</sup>

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>University of Washington, Seattle, WA

<sup>3</sup>Cleveland Clinic, Cleveland, OH

<sup>4</sup>Janssen Scientific Affairs, LLC, Titusville, NJ

<sup>5</sup>Groupe d'analyse, Ltée, Montréal, QC, Canada

<sup>6</sup>Analysis Group, Inc., Boston

<sup>7</sup>Analysis Group, Inc, Montreal, QC, Canada

<sup>8</sup>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>9</sup>Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

### **3799 Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism**

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bleeding and clotting, Thrombosis, Thromboembolism

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Michael B. Streiff**<sup>1</sup>, **Keith R. McCrae, MD**<sup>2</sup>, **Nicole M. Kuderer**<sup>3</sup>, **Dejan Milentijevic, PhD**<sup>4\*</sup>, **Guillaume Germain, MA**<sup>5\*</sup>, **François Laliberté, MA**<sup>5\*</sup>, **Nguyen Le, BSc**<sup>6\*</sup>, **Patrick Lefebvre, MA**<sup>7\*</sup>, **Gary H. Lyman**<sup>8</sup> and **Alok A. Khorana**<sup>9</sup>

<sup>1</sup>Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

<sup>2</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>University of Washington, Seattle, WA

<sup>4</sup>Janssen Scientific Affairs, LLC, Titusville, NJ

<sup>5</sup>Groupe d'analyse, Ltée, Montréal, QC, Canada

<sup>6</sup>Analysis Group, Inc., Boston

<sup>7</sup>Analysis Group, Inc, Montreal, QC, Canada

<sup>8</sup>Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>9</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

### **3800 Exosome Polyphosphate Mediates the Activation of FXII By Cancer Cell-Derived Exosomes**

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways:

Biological Processes, cellular interactions, inflammation, molecular interactions, pathogenesis

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Dewen You, PhD**<sup>1,2\*</sup>, **Suman Kundu, MBA**<sup>3\*</sup>, **Alvin H. Schmaier, MD**<sup>4</sup>, **Alok A. Khorana**<sup>5,6</sup> and **Keith R. McCrae, MD**<sup>3,7</sup>

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Department of Cellular and Molecular Medicine, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>3</sup>Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Case Western Reserve University, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute/Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

<sup>7</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

### **3840 Targeting NAD<sup>+</sup> Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure**

Program: Oral and Poster Abstracts

Session: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Biological, Animal models, Therapies, bone marrow, Bone Marrow Failure, chemical interactions, Biological Processes, Technology and Procedures, cell expansion, Xenograft models, Study Population, Clinically relevant, Quality Improvement , Myeloid Malignancies, pharmacology, hematopoiesis, transfusion, inflammation, stem cells, metabolomics

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Phillip J Maciejewski<sup>1</sup>, Yihong Guan<sup>2\*</sup>, Metis Hasipek, PhD<sup>2</sup>, Anand D. Tiwari, PhD.<sup>1\*</sup>, Dale Grabowski, BS<sup>2</sup>, James G Phillips, PhD<sup>2</sup>, Yogenthiran Saunthararajah, MD<sup>1</sup>, Jaroslaw P. Maciejewski<sup>2,3</sup> and Babal K. Jha<sup>1,4\*</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Leukemia Program, Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Cleveland Clinic Lerner College of Medicine, Cleveland

### **3866 Heterozygous CTC1 Variants in Acquired Bone Marrow Failure**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Wenyi Shen, MD<sup>1,2\*</sup>, Cassandra M. Hirsch<sup>3\*</sup>, Bartlomiej P. Przychodzen<sup>4\*</sup>, Reda Z. Mahfouz, MD, PhD<sup>5\*</sup>, Tomas Radivoyevitch<sup>6\*</sup>, Louis Williams, MD, MBA<sup>7</sup>, Mohammad Fahad B. Asaad<sup>3</sup> and Jaroslaw P. Maciejewski<sup>8</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

<sup>2</sup>Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>7</sup>NYU, New York, NY

<sup>8</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

### **3869 Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Bhumika J. Patel, MD<sup>1</sup>, Shimoli Vipul Barot, MD<sup>2</sup>, Bartlomiej P. Przychodzen<sup>3\*</sup>, Teodora Kuzmanovic, BA<sup>3\*</sup>, Michael Clemente, MS<sup>4\*</sup>, Cassandra M. Hirsch<sup>5\*</sup>, Valeria Visconte, PhD<sup>6</sup>, Roy Souaid, MD<sup>7\*</sup>, Marissa Versalle<sup>8\*</sup>, Sarah S Lee, MD<sup>9</sup>, Tomas Radivoyevitch<sup>10\*</sup>, Metis Haspiek<sup>8\*</sup>, Swapna Thota, MD<sup>11</sup>, Aziz Nazha, MD<sup>12</sup>, Matt Kalaycio, MD<sup>13</sup>, Anjali S. Advani, MD<sup>14</sup>, Hetty E. Carraway, MD, MBA<sup>14,15</sup>, Mikkael A. Sekeres, MD, MS<sup>5</sup> and Jaroslaw P. Maciejewski<sup>5</sup>***

<sup>1</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Internal Medicine, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

<sup>7</sup>Thor, Cleveland

<sup>8</sup>Cleveland Clinic, Cleveland

<sup>9</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>10</sup>Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

<sup>11</sup>Department of Medicine, Roswell Park, Buffalo, NY

<sup>12</sup>Cleveland Clinic, Cleveland, OH

<sup>13</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>14</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>15</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

### **3871 The Shwachman-Diamond Syndrome Registry: Hematologic Complications**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure, Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Kasiani C. Myers, MD<sup>1</sup>, Elissa M. Furutani, MD<sup>2</sup>, Sara Loveless, BSN<sup>3\*</sup>, Maggie Malsch, MSN, RN<sup>4\*</sup>, Ashley Galvin<sup>5\*</sup>, Ellie Fratt<sup>5\*</sup>, Jordan Larson<sup>5\*</sup>, Jacob Cotton<sup>5\*</sup>, Leah Cheng<sup>5\*</sup>, Kelly McIntosh<sup>6\*</sup>, Joan Moore, RN<sup>6\*</sup>, Leann Mount, RN<sup>6\*</sup>, Rabi Hanna, MD<sup>7</sup>, Winfred Wang, MD<sup>8</sup>, Alison A. Bertuch, MD, PhD<sup>9</sup>, Stella M. Davies, PhD, MBBS, MRCP<sup>10</sup> and Akiko Shimamura, MD, PhD<sup>11</sup>*

<sup>1</sup>Bone Marrow Transplantation & Immune Deficiency, Cincinnati Children's Hospital, Cincinnati, OH

<sup>2</sup>Cancer and Blood Disorders Center, Boston Children's Hospital, Boston, MA

<sup>3</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH

<sup>4</sup>Boston Childrens Hospital, Boston

<sup>5</sup>Cancer and Blood Disorders Center, Dana-Farber/Boston Children's, Boston

<sup>6</sup>Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati

<sup>7</sup>Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

<sup>8</sup>St. Jude Children's Research Hospital, Memphis, TN

<sup>9</sup>Texas Children's Hospital, Houston, TX

<sup>10</sup>Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

<sup>11</sup>Dana-Farber/Boston Children's Cancer & Blood Disorders Center, Boston, MA

### **3995 FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years**

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

AML, Diseases, Elderly, Technology and Procedures, Study Population, Clinically relevant, genetic profiling, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*James M. Foran, MD<sup>1</sup>, Zhuoxin Sun, PhD<sup>2\*</sup>, Elisabeth Paietta, PhD<sup>3</sup>, Janis Racevskis, PhD<sup>3\*</sup>, David F.*

*Claxton, MD<sup>4</sup>, Hillard M Lazarus, MD<sup>5</sup>, Daniel A. Arber, MD<sup>6</sup>, Jacob M. Rowe, MD<sup>7</sup>, John Godwin, MD<sup>8</sup>,*

*Yanming Zhang, MD<sup>9</sup>, Martin S. Tallman, MD<sup>10</sup>, Mark R. Litzow, MD<sup>11</sup>, Keith W. Pratz, MD<sup>12</sup> and Selina*

*Luger, MD<sup>13</sup>*

<sup>1</sup>Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

<sup>2</sup>ECOG-ACRIN statistical center, Boston

<sup>3</sup>Cancer Center, Montefiore Medical Center, Bronx, NY

<sup>4</sup>Penn State Cancer Institute, Penn State M.S. Hershey Medical Center, Hershey, PA

<sup>5</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>6</sup>University of Chicago, Chicago, IL

<sup>7</sup>The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

<sup>8</sup>Providence Portland Medical Center, Portland, OR

<sup>9</sup>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>10</sup>Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

<sup>11</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>12</sup>John Hopkins University, Baltimore, MD

<sup>13</sup>Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

### **3999 Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database**

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, AML, Adult, Study Population, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Rory M Shallis, MD<sup>1</sup>, Maximilian Stahl, MD<sup>2</sup>, Wei Wei, MD, PhD<sup>3\*</sup>, Pau Fernandez<sup>4\*</sup>, Etienne Lengline, MD<sup>5\*</sup>, Judith Neukirchen, MD<sup>6\*</sup>, Vijaya R. Bhatt, MD<sup>7</sup>, Mikkael A. Sekeres, MD, MS<sup>8</sup>, Amir T. Fathi, MD<sup>9</sup>, Heiko Konig, MD, PhD<sup>10</sup>, Selina Luger, MD<sup>11</sup>, Irum Khan, MBBS<sup>12</sup>, Gail J. Roboz, MD<sup>13</sup>, Thomas Cluzeau, MD, PhD<sup>14\*</sup>, David Martínez-Cuadron, MD<sup>15\*</sup>, Emmanuel Raffoux, MD<sup>16\*</sup>, Ulrich Germing, MD<sup>17\*</sup>, Jayadev Manikkam Umakanthan, MBBS<sup>18</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>19</sup>, Andrew M. Brunner, MD<sup>20</sup>, Adam M. Miller, BS, MD<sup>10\*</sup>, Christine M. McMahon, MD<sup>11</sup>, Ellen K. Ritchie, MD<sup>13</sup>, Rebeca Rodríguez-Veiga, MD<sup>15\*</sup>, Raphael Itzykson, MD, PhD<sup>21</sup>, Blanca Boluda, MD<sup>15\*</sup>, Florence Rabian, MD<sup>16\*</sup>, Mar Tormo, MD, PhD<sup>22</sup>, Evelyn Gloria Acuna Cruz, MD<sup>15\*</sup>, Nikolai Podoltsev, MD, PhD<sup>23,24</sup>, Steven D. Gore, MD<sup>2,24</sup> and Amer M. Zeidan, MBBS, MHS<sup>23,24\*</sup>**

<sup>1</sup>Department of Internal Medicine, Section of Hematology, Yale School of Medicine, West Haven, CT

<sup>2</sup>Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

<sup>3</sup>Department of Biostatistics, Yale School of Public Health, New Haven, CT

<sup>4</sup>Hospital Universitari i Politècnic La Fe, Valencia; CIBERONC, Instituto Carlos III, Madrid, Spain

<sup>5</sup>Hôpital St. Louis, Paris, France

<sup>6</sup>Dept. of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Duesseldorf, Germany

<sup>7</sup>Department of Internal Medicine, Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE

<sup>8</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA

<sup>10</sup>Indiana University Simon Cancer Center, Indianapolis, IN

<sup>11</sup>Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

<sup>12</sup>University of Illinois, Chicago, IL

<sup>13</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>14</sup>Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

<sup>15</sup>Hospital Universitari i Politècnic La Fe, Valencia, Spain

<sup>16</sup>Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France

<sup>17</sup>Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany

<sup>18</sup>University of Nebraska Medical Center, Omaha, NE

<sup>19</sup>Cleveland Clinic, Cleveland, OH

<sup>20</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>21</sup>Hématologie clinique, Hôpital Saint-Louis, Paris, France

<sup>22</sup>Hematology Department, Hospital Clínico Universitario, Instituto de Investigación INCLIVA, Valencia, Valencia, Spain

<sup>23</sup>Yale Cancer Center, Yale University School of Medicine, New Haven, CT

<sup>24</sup>Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, CT

**4031 Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study**

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:

Leukemia, Diseases, Biological, ALL, antibodies, Therapies, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Partow Kebriaei, MD<sup>1</sup>, Daniel J. DeAngelo, MD<sup>2</sup>, Anjali S. Advani, MD<sup>3</sup>, Susan M. O'Brien, MD<sup>4</sup>, David Marks<sup>5</sup>, Hagop M. Kantarjian, MD<sup>6</sup>, Elias J. Jabbour, MD<sup>6</sup>, Tao Wang<sup>7\*</sup>, Erik Vandendries, MD, PhD<sup>8\*</sup>, A. Douglas Laird, PhD<sup>9\*</sup>, Sonja Nick, MSc<sup>10\*</sup> and Matthias Stelljes, MD<sup>11</sup>**

<sup>1</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>2</sup>Dana-Farber Cancer Inst., Boston, MA

<sup>3</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>University of California Irvine Medical Center, Orange, CA

<sup>5</sup>University Hospitals Bristol, Bristol, United Kingdom

<sup>6</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX

<sup>7</sup>Pfizer Inc, Groton, CT

<sup>8</sup>Pfizer Inc, Cambridge, MA

<sup>9</sup>Pfizer Inc, San Diego, CA

<sup>10</sup>Pfizer AG, Zurich, Switzerland

<sup>11</sup>Universitätsklinikum Münster, Münster, Germany

## **4040 Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort**

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:

Diseases, AML, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Maximilian Stahl, MD<sup>1</sup>, Wei Wei, MD, PhD<sup>2\*</sup>, Pau Fernandez<sup>3\*</sup>, Etienne Lengline, MD<sup>4\*</sup>, Rory M Shallis, MD<sup>1</sup>, Judith Neukirchen, MD<sup>5\*</sup>, Vijaya R. Bhatt, MD<sup>6</sup>, Mikkael A. Sekeres, MD, MS<sup>7</sup>, Amir T. Fathi, MD<sup>8</sup>, Heiko Konig, MD, PhD<sup>9</sup>, Selina Luger, MD<sup>10</sup>, Irum Khan, MBBS<sup>11</sup>, Gail J. Roboz, MD<sup>12</sup>, Thomas Cluzeau, MD, PhD<sup>13\*</sup>, David Martínez-Cuadron, MD<sup>3\*</sup>, Emmanuel Raffoux, MD<sup>4\*</sup>, Ulrich Germing, MD<sup>5\*</sup>, Jayadev Manikkam Umakanthan, MBBS<sup>6</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>7</sup>, Andrew M. Brunner, MD<sup>14</sup>, Adam M. Miller, BS, MD<sup>9\*</sup>, Christine M. McMahon, MD<sup>10</sup>, Ellen K. Ritchie, MD<sup>12</sup>, Rebeca Rodríguez-Veiga, MD<sup>3\*</sup>, Raphael Itzykson, MD, PhD<sup>4</sup>, Blanca Boluda, MD<sup>3\*</sup>, Florence Rabian, MD<sup>4\*</sup>, Mar Tormo, MD<sup>15\*</sup>, Evelyn Gloria Acuna Cruz, MD<sup>3\*</sup>, Emma Rabinovich, MD<sup>11\*</sup>, Brendan Yoo<sup>10\*</sup>, Nikolai A. Podoltsev, MD, PhD<sup>1</sup>, Steven D. Gore, MD<sup>1</sup> and Amer M. Zeidan, MBBS, MHS<sup>1\*</sup>***

<sup>1</sup>Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

<sup>2</sup>Department of Biostatistics, Yale School of Public Health, New Haven, CT

<sup>3</sup>Hospital Universitari i Politècnic La Fe, Valencia, Spain

<sup>4</sup>Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France

<sup>5</sup>Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

<sup>6</sup>University of Nebraska Medical Center, Omaha, NE

<sup>7</sup>Leukemia Program, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA

<sup>9</sup>Indiana University Simon Cancer Center, Indianapolis, IN

<sup>10</sup>Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

<sup>11</sup>University of Illinois, Chicago, IL

<sup>12</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>13</sup>Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

<sup>14</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

<sup>15</sup>University Clinical Hospital, INCLIVA, Valencia, Spain, Valencia, Spain

## **4067 Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia**

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:

apoptosis, Diseases, AML, Therapies, Non-Biological, chemical interactions, cellular interactions, Biological Processes, Technology and Procedures, epigenetics, Clinically relevant, Quality Improvement, Myeloid Malignancies, hematopoiesis, flow cytometry, metabolomics, RNA sequencing, molecular interactions, signal transduction

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Metis Hasipek, PhD<sup>1\*</sup>, Dale Grabowski, BS<sup>1\*</sup>, Yihong Guan<sup>1\*</sup>, James G Phillips, PhD<sup>1\*</sup>, Jaroslaw P. Maciejewski<sup>1</sup>, Hetty E. Carraway, MD, MBA<sup>2,3</sup> and Babal K. Jha<sup>4\*</sup>***

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>3</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## **4146 Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival**

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Adult, Follicular Lymphoma, Diseases, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Allison M. Winter, MD<sup>1</sup>, Loretta J. Nastoupil, MD<sup>2</sup>, Melody R. Becnel, MD<sup>2</sup>, James R. Cerhan, MD, PhD<sup>3</sup>, Thomas M. Habermann, MD<sup>3</sup>, Brian K. Link, MD<sup>4</sup>, Matthew J. Maurer, MS<sup>3</sup>, Bita Fakhri, MD, MPH<sup>5</sup>, Prathima Reddy, MD<sup>6\*</sup>, Stephen D. Smith, MD<sup>6</sup>, Dhruvika Mukhija, MD<sup>1\*</sup>, Deepa Jagadeesh, MD, MPH<sup>1</sup>, Amrita Desai, MD<sup>7\*</sup>, Juan Pablo Alderuccio, MD<sup>7</sup>, Izidore S. Lossos, MD<sup>8</sup>, Pooja Mehra, MD<sup>9\*</sup>, Craig A. Portell, MD<sup>9</sup>, Christopher R. D'Angelo, MD<sup>10\*</sup>, Vaishalee P. Kenkre, MD<sup>10</sup>, Max L. Goldman, MD<sup>11</sup>, Oscar Calzada, BS<sup>11\*</sup>, Jonathon B. Cohen, MD, MS<sup>11</sup>, Mohammad Junaid Hussain, MD<sup>12</sup>, Nilanjan Ghosh, MD, PhD<sup>12</sup>, Yang Liu, MD<sup>13\*</sup>, Stefan Klaus Barta, MD, MRCP, MS<sup>14</sup>, Paolo F Caimi, MD<sup>15</sup>, Adam Kittai, MD<sup>16</sup>, Alexey V Danilov, MD, PhD<sup>16</sup>, Timothy Tiutan, MD<sup>17\*</sup>, Peter Martin, FRCPC, MD, MS<sup>17</sup>, Nathalie Danielson, MSN, RN, ACNP-BC<sup>18\*</sup>, Manali Kamdar, MD<sup>19</sup>, Abhigna Kodali, MD<sup>20\*</sup>, Andrew M. Evens, DO, MSc<sup>21</sup>, Brad S Kahl, MD<sup>5</sup> and Brian T. Hill, MD, PhD<sup>22,23</sup>*

<sup>1</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>3</sup>Mayo Clinic, Rochester, MN

<sup>4</sup>Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

<sup>5</sup>Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO

<sup>6</sup>Seattle Cancer Care Alliance, University of Washington, Seattle, WA

<sup>7</sup>Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

<sup>8</sup>Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL

<sup>9</sup>Division of Hematology and Oncology, University of Virginia, Charlottesville, VA

<sup>10</sup>Division of Hematology/Oncology, University of Wisconsin, Madison, WI

<sup>11</sup>Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

<sup>12</sup>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

<sup>13</sup>Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA

<sup>14</sup>Fox Chase Cancer Center, Philadelphia, PA

<sup>15</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>16</sup>Knight Cancer Institute, Oregon Health and Science University, Portland, OR

<sup>17</sup>Division of Hematology and Oncology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY

<sup>18</sup>Vanderbilt-Ingram Cancer Center, Nashville, TN

<sup>19</sup>Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Denver, CO

<sup>20</sup>Tufts University School of Medicine and Cancer Center, Boston, MA

<sup>21</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>22</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>23</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

**4153 Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL)**

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Adult, Diseases, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Kirthika Shanmugasundaram, MD<sup>1</sup>, Subir Goyal, MPH, MBBS<sup>2\*</sup>, Jeffrey M. Switchenko, PhD, MS<sup>3\*</sup>, Oscar Calzada, BS<sup>4\*</sup>, Michael C Churnetski, BS<sup>5\*</sup>, Bhaskar Kolla, MBBS<sup>6</sup>, Veronika Bachanova, MD, PhD<sup>7</sup>, James Nathan Gerson, MD<sup>8</sup>, Stefan Klaus Barta, MD, MRCP, MS<sup>8</sup>, Max J. Gordon, MD<sup>9</sup>, Alexey V Danilov, MD, PhD<sup>10</sup>, Natalie S Grover, MD<sup>11</sup>, Stephanie Mathews, MD<sup>12\*</sup>, Madelyn Burkart, MD<sup>13\*</sup>, Reem Karmali, MD<sup>14</sup>, Yazeed Sawalha, MD<sup>15</sup>, Brian T. Hill, MD, PhD<sup>16,17</sup>, Nilanjan Ghosh, MD, PhD<sup>18</sup>, Steven I Park, MD<sup>19</sup>, Narendranath Epperla, MD, MS<sup>20,21</sup>, David A. Bond, MD<sup>22</sup>, Talha Badar, MD<sup>23</sup>, Kristie A. Blum, MD<sup>24,25</sup>,*

*Mehdi Hamadani, MD<sup>26</sup>, Timothy S. Fenske, MD<sup>27</sup>, Mary Malacek, MD<sup>28\*</sup>, Brad S. Kahl, MD<sup>29\*</sup>, Christopher R Flowers, MD, MS<sup>30</sup> and Jonathon B. Cohen, MD, MS<sup>24</sup>*

<sup>1</sup>*Department of Hematology and Medical Oncology, Emory University Hospital, Atlanta, GA*

<sup>2</sup>*Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA*

<sup>3</sup>*Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA*

<sup>4</sup>*Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA*

<sup>5</sup>*Winship Cancer Institute, Emory University, Atlanta, GA*

<sup>6</sup>*University of Minnesota, Minneapolis, MN*

<sup>7</sup>*Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN*

<sup>8</sup>*Fox Chase Cancer Center, Philadelphia, PA*

<sup>9</sup>*Oregon Health and Science University, Portland, OR*

<sup>10</sup>*Knight Cancer Institute, Oregon Health and Science University, Portland, OR*

<sup>11</sup>*Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC*

<sup>12</sup>*UNC, Chapel Hill, NC*

<sup>13</sup>*Northwestern University, Chicago, IL*

<sup>14</sup>*Division of Hematology, Northwestern University, Chicago, IL*

<sup>15</sup>*Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH*

<sup>16</sup>*Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH*

<sup>17</sup>*Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*

<sup>18</sup>*Levine Cancer Institute, Charlotte, NC*

<sup>19</sup>*Levine Cancer Institute, Concord, NC*

<sup>20</sup>*Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH*

<sup>21</sup>*Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI*

<sup>22</sup>*Divisions of Hematology and Medical Oncology, The Ohio State University Cancer Center, Columbus, OH*

<sup>23</sup>*Division of Hematology and Oncology, Medical College of Wisconsin, Brookfield, WI*

<sup>24</sup>*Emory University, Atlanta, GA*

<sup>25</sup>*Division of Hematology, The Ohio State University, Columbus, OH*

<sup>26</sup>*Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI*

<sup>27</sup>*Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI*

<sup>28</sup>*Siteman Cancer Center, Washington University, St. Louis, MO*

<sup>29</sup>*Siteman Cancer Center, Washington University, St Louis, MO*

<sup>30</sup>*Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA*

## **4202 Risk of Post-Transplant Lymphoproliferative Disorders (PTLD) in Solid Organ Transplantation Patients with EBV Viremia**

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Yazeed Sawalha, MD<sup>1</sup>, John McMichael, PhD<sup>2\*</sup>, Lisa Rybicki, MS<sup>3\*</sup>, Tamara A. Sussman, MD<sup>1\*</sup>, Alex V.***

***Mejia Garcia, MD<sup>1</sup>, Robert M. Dean, MD<sup>1</sup>, Brad Pohlman, MD<sup>1</sup>, Brian T. Hill, MD, PhD<sup>4,5</sup> and Deepa***

***Jagadeesh, MD, MPH<sup>1</sup>***

<sup>1</sup>*Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH*

<sup>2</sup>*Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland*

<sup>3</sup>*Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH*

<sup>4</sup>*Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH*

<sup>5</sup>*Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*

## **4274 Poisson Regression Modeling of Chronic Myeloid Leukemia Mortality Trends**

Program: Oral and Poster Abstracts

Session: 632. Chronic Myeloid Leukemia: Therapy: Poster III

Hematology Disease Topics & Pathways:

Diseases, Biological, Adult, CML, Therapies, immunotherapy, Study Population, Myeloid Malignancies, TKI

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Tomas Radivoyevitch<sup>1\*</sup>, Brian P. Hobbs, PhD<sup>2\*</sup> and Jaroslaw P. Maciejewski<sup>3</sup>***

<sup>1</sup>Departments of Quantitative Health Sciences and Translational Hematology & Oncology Research, Quantitative Health Sciences, Cleveland, OH

<sup>2</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

## 4282 Hepcidin Suppression By Mometrolinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Therapies, Non-Biological, Biological Processes, Study Population, Clinically relevant, erythropoiesis, Myeloid Malignancies, inflammation, iron metabolism, signal transduction

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Stephen T Oh, MD, PhD<sup>1</sup>, Moshe Talpaz, MD<sup>2</sup>, Aaron T. Gerds, MD, MS<sup>3</sup>, Vikas Gupta, MD, FRCP, FRCPath<sup>4</sup>, Srdan Verstovsek, MD, PhD<sup>5</sup>, Ruben A. Mesa, MD, FACP<sup>6</sup>, Carole Brennan Miller, MD<sup>7\*</sup>, Candido E. Rivera, MD<sup>8</sup>, Angela Fleischman, MD, PhD<sup>9</sup>, Swati Goel<sup>10\*</sup>, Mark L Heaney, MD, PhD<sup>11</sup>, Casey O'Connell, MD<sup>12\*</sup>, Murat Arcasoy, MD<sup>13\*</sup>, Yafeng Zhang, PhD, MD<sup>14\*</sup>, Jun Kawashima, MD<sup>15\*</sup>, Tomas Ganz, MD, PhD<sup>16</sup> and Carrie Baker Brachmann<sup>17\*</sup>**

<sup>1</sup>Washington University School of Medicine, Saint Louis, MO

<sup>2</sup>Rogel Cancer Center, The University of Michigan - Michigan Medicine, Ann Arbor, MI

<sup>3</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>4</sup>Princess Margaret Cancer Centre, Toronto, ON, Canada

<sup>5</sup>Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX

<sup>6</sup>Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX

<sup>7</sup>Cancer Center, Ascension/St Agnes, Baltimore, MD

<sup>8</sup>Hematology, Mayo Clinic - Jacksonville, Jacksonville, FL

<sup>9</sup>University of California, Irvine, Irvine, CA

<sup>10</sup>Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY

<sup>11</sup>Columbia University Medical Center, New York, NY

<sup>12</sup>Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles, CA

<sup>13</sup>Duke Cancer Institute, Duke University School of Medicine, Durham, NC

<sup>14</sup>Biostatistics, Gilead Sciences, Inc., Foster City, CA

<sup>15</sup>Gilead Sciences, Inc., Foster City, CA

<sup>16</sup>Medicine, University of California, Los Angeles, Los Angeles, CA

<sup>17</sup>Gilead Science, Inc., Foster City, CA

## 4288 Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

Hematology Disease Topics & Pathways:

Diseases, Biological, Therapies, Bone Marrow Failure, transplantation, TKI

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Krisstina L. Gowin, DO<sup>1</sup>, Karen K. Ballen, MD<sup>2\*</sup>, Kwang Woo Ahn, PhD<sup>3,4\*</sup>, Zhen-Huan Hu, MPH<sup>3\*</sup>, Ying Liu, PhD<sup>3,5\*</sup>, Lucia Masarova, MD<sup>6\*</sup>, Srdan Verstovsek, MD, PhD<sup>7</sup>, Maria Coakley<sup>8\*</sup>, Tania Jain, MBBS<sup>9\*</sup>, Andrew Kuykendall, MD<sup>10\*</sup>, Rami Komrokji, MD<sup>11\*</sup>, Martha Wadleigh, MD<sup>12\*</sup>, Sarah Patches<sup>12\*</sup>, Murat Arcasoy, MD<sup>13\*</sup>, Michael Green<sup>13\*</sup>, Malathi Kandarpa, PhD<sup>14\*</sup>, Moshe Talpaz, MD<sup>15</sup>, Haris Ali, MD<sup>16</sup>, Vikas Gupta, MD, FRCP, FRCPath<sup>17</sup>, Rebecca Devlin<sup>18\*</sup>, Laura C. Michaelis, MD<sup>19</sup>, Gabriela S. Hobbs, MD<sup>20</sup>, Brady Lee Stein, MD<sup>21</sup>, Ashley Pariser, MD<sup>22\*</sup>, Aaron T. Gerds, MD, MS<sup>23</sup>, Kierstin Kuber<sup>24\*</sup>, Raajit Rampal<sup>25\*</sup>, Edwin P. Alyea III, MD<sup>26</sup>, Uday Popat, MD<sup>27</sup>, Ronald Sobecks, MD<sup>28</sup>, Bart L Scott, MD<sup>29</sup>, Ruben Mesa, MD<sup>9\*</sup> and Wael Saber, MD, MS<sup>3\*</sup>**

<sup>1</sup>Department of Hematology, University of Arizona, Tacoma, WA

<sup>2</sup>Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA

<sup>3</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

<sup>5</sup>Division of Biostatistics, Institution for Health and Society, Medical College of Wisconsin, Milwaukee

<sup>6</sup>Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX

<sup>7</sup>Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

<sup>8</sup>Royal Marsden Hospital, Sutton, United Kingdom

<sup>9</sup>Mayo Clinic Arizona, Phoenix, AZ

<sup>10</sup>H. Lee Moffitt Cancer Center, Tampa, FL

<sup>11</sup>H. Lee Moffitt Cancer Center, Houston, TX

<sup>12</sup>Dana Farber Cancer Institute, Boston, MA

<sup>13</sup>Duke University Medical Center, Durham, NC

<sup>14</sup>Rogel Cancer Center, The University of Michigan - Michigan Medicine, Ann Arbor, MI

<sup>15</sup>The University of Michigan Health Systems, Ann Arbor, MI

<sup>16</sup>Department of Hematology/HCT, City of Hope Medical Center, Duarte, CA

<sup>17</sup>Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

<sup>18</sup>Harvard University, Cambridge, MA

<sup>19</sup>Medical College of Wisconsin, Milwaukee, WI

<sup>20</sup>Massachusetts General Hospital, Boston, MA

<sup>21</sup>Dept. of Medicine, Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

<sup>22</sup>Yale Smilow Cancer Center, New Haven, CT

<sup>23</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>24</sup>Washington University, St. Louis, MO

<sup>25</sup>Memorial Sloan Kettering Cancer Center, New York, NY

<sup>26</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

<sup>27</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>28</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>29</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

#### **4345 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, chemotherapy, Biological Processes, epigenetics

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Yihong Guan<sup>1</sup>, Anand D. Tiwari, PhD.<sup>1\*</sup>, Metis Hasipek, PhD<sup>2\*</sup>, Dale Grabowski, BS<sup>2\*</sup>, Yvonne Parker<sup>2\*</sup>, Cassandra M. Hirsch<sup>2\*</sup>, Amy C Graham, BS, MS<sup>2\*</sup>, Yasunobu Nagata<sup>2\*</sup>, Bartłomiej P. Przychodzen<sup>1\*</sup>, Aziz Nazha, MD<sup>2</sup>, Daniel Lindner, MD, PhD<sup>2\*</sup>, Tomas Radivoyevitch, PhD<sup>2,3\*</sup>, James G Phillips, PhD<sup>2\*</sup>, Jaroslaw P. Maciejewski<sup>2</sup> and Babal K. Jha<sup>1\*</sup>*

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

#### **4346 Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, chemical interactions

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Yihong Guan<sup>1\*</sup>, Edward F Greenberg, MD<sup>1</sup>, Metis Hasipek, PhD<sup>1\*</sup>, Cassandra M. Hirsch<sup>1\*</sup>, Amy C Graham, BS, MS<sup>1\*</sup>, Tomas Radivoyevitch, PhD<sup>1,2\*</sup>, Shi Chen<sup>3\*</sup>, Xiaochen Liu<sup>3\*</sup>, Valeria Visconte, PhD<sup>4</sup>, Dewen You, PhD<sup>1\*</sup>, Eiju Negoro, MD, PhD<sup>1\*</sup>, Bartłomiej P. Przychodzen<sup>5\*</sup>, Hideki Makishima, MD, PhD<sup>1,6</sup>, Aziz Nazha, MD<sup>1</sup>, Daniel Gackowski, PhD<sup>7\*</sup>, Ewelina Zarakowska<sup>7\*</sup>, Mridul Mukherji, D.Phil.<sup>8\*</sup>, Mikael A. Sekeres, MD, MS<sup>1</sup>, Mingjiang Xu, MD, PhD<sup>3</sup>, Ryszard Ölinski, Professor<sup>7\*</sup>, Jaroslaw P. Maciejewski<sup>1</sup> and Babal K. Jha<sup>1\*</sup>*

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Biochemistry and Molecular Biology & Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

<sup>7</sup>Department of Clinical Biochemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

<sup>8</sup>School of Pharmacy, University of Missouri - Kansas City, Kansas City, MO

### **4350 SKI Controls MDS-Associated Chronic TGFb Signaling, Aberrant Splicing, and Stem Cell Fitness**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Animal models, MDS, Biological Processes, Technology and Procedures, Study

Population, Myeloid Malignancies, genomics, hematopoiesis, flow cytometry, molecular testing, NGS,

RNA sequencing, pathogenesis

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*David Muench, BS<sup>1</sup>, Kyle Ferchen, BS<sup>2\*</sup>, Chinavenmeni S. Velu, PhD<sup>3,4\*</sup>, Kith Pradhan, PhD<sup>5\*</sup>, Kashish Chetal, MS<sup>6\*</sup>, Clemencia Colmenares, PhD<sup>7\*</sup>, Amit Verma, MD<sup>8</sup>, Nathan Salomonis, PhD<sup>6\*</sup> and H. Leighton Grimes, PhD<sup>9</sup>*

<sup>1</sup>Molecular and Developmental Biology Graduate Program, Cincinnati Children's Hospital Medical Center, Fort Wright, KY

<sup>2</sup>Department of Cancer Biology, University of Cincinnati, Cincinnati

<sup>3</sup>Cincinnati Children's Hosp. Med. Ctr., Cincinnati, OH

<sup>4</sup>Cincinnati Children's Hosp. Med. Ctr., Cincinnati

<sup>5</sup>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY

<sup>6</sup>Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

<sup>7</sup>Lerner Research Institute, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY

<sup>9</sup>Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

### **4351 Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, MDS, Biological Processes, genomics, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Yasunobu Nagata<sup>1\*</sup>, Satoshi Narumi, MD, PhD<sup>2\*</sup>, Yihong Guan<sup>1\*</sup>, Bartłomiej P. Przychodzen<sup>1\*</sup>, Cassandra M. Hirsch<sup>1\*</sup>, Hideki Makishima, MD, PhD<sup>3</sup>, Hirohito Shima<sup>2\*</sup>, Victor Pastor Loyola, MSc<sup>4\*</sup>, Teodora Kuzmanovic, BA<sup>1\*</sup>, Tomas Radivoyevitch, PhD<sup>5\*</sup>, Vera Adema, PhD<sup>1\*</sup>, Hassan Awada, MD<sup>1</sup>, Kenichi Yoshida, MD, PhD<sup>3\*</sup>, Francesc Sole, PhD<sup>6</sup>, Babal K. Jha<sup>1\*</sup>, Rabi Hanna, MD<sup>7</sup>, Thomas Laframboise, PhD<sup>8\*</sup>, Seishi Ogawa, MD, PhD<sup>9</sup>, Mikael A. Sekeres, MD, MS<sup>10</sup>, Marcin W. Włodarski, MD, PhD<sup>4,11</sup>, Jorg Cammenga, MD<sup>12\*</sup> and Jaroslaw P. Maciejewski<sup>1</sup>*

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan

<sup>3</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>4</sup>Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany

<sup>5</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

<sup>7</sup>Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

<sup>9</sup>Department of Pathology and Tumor Biology, Kyoto University, Sakyoku, Japan

<sup>10</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>11</sup>Hematology, St. Jude Children's Research Hospital, Memphis, TN

<sup>12</sup>Linköping University, Department of Hematology, Linköping, SWE

### **4352 BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Adult, Diseases, AML, MDS, Biological Processes, Technology and Procedures, DNA repair, Study

Population, cytogenetics, Clinically relevant, Myeloid Malignancies, genomics, NGS, pathogenesis

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Louis Williams, MD, MBA<sup>1</sup>, Teodora Kuzmanovic, BA<sup>2\*</sup>, Cassandra M. Hirsch<sup>2\*</sup>, Bartlomiej P.

Przychodzen<sup>2\*</sup>, Yogenthiran Saunthararajah, MD<sup>3</sup>, Hassan Awada, MD<sup>2</sup>, Vera Adema, PhD<sup>2\*</sup>, Amy C Graham, BS, MS<sup>2\*</sup>, Tomas Radivoyevitch, PhD<sup>2\*</sup>, Hetty E. Carraway, MD, MBA<sup>4,5</sup>, Aziz Nazha, MD<sup>4</sup>, Mikkael A. Sekeres, MD, MS<sup>6</sup> and Jaroslaw P. Maciejewski<sup>7</sup>

<sup>1</sup>NYU, New York, NY

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH

<sup>4</sup>Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>6</sup>Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>7</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

#### 4353 Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

AML, Diseases, CMML, MDS, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Teodora Kuzmanovic<sup>1\*</sup>, Bhumika J. Patel, MD<sup>2</sup>, Yasunobu Nagata<sup>3\*</sup>, Hassan Awada, MD<sup>4</sup>, Cassandra M.

Hirsch<sup>3\*</sup>, Bartlomiej P. Przychodzen<sup>1\*</sup>, Srinivasa Reddy Sanikommu, MD<sup>5</sup>, Louis Williams, MD, MBA<sup>6</sup>,

Sudipto Mukherjee, MD, PhD, MPH<sup>2</sup>, Anjali S. Advani, MD<sup>7</sup>, Aziz Nazha, MD<sup>8</sup>, Aaron T. Gerds, MD, MS<sup>9</sup>,

Tomas Radivoyevitch, PhD<sup>3\*</sup>, Hetty E. Carraway, MD, MBA<sup>7,10</sup>, Mikkael A. Sekeres, MD, MS<sup>11</sup> and

Jaroslaw P. Maciejewski<sup>3</sup>

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Fairview Park, OH

<sup>5</sup>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium health, Charlotte, NC

<sup>6</sup>NYU, New York, NY

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>8</sup>Cleveland Clinic, Cleveland, OH

<sup>9</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>10</sup>Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>11</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

#### 4362 Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Adult, Diseases, Non-Biological, Therapies, Biological Processes, chemotherapy, MDS, Study Population, epigenetics, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Michael K Keng, MD<sup>1</sup>, Samer K. Khaled, MD<sup>2</sup>, Brenda Cooper, MD<sup>3</sup>, Erica D. Warlick, MD<sup>4</sup>, David Ramies, MD<sup>5\*</sup>, Silvia Mappa, MD<sup>6\*</sup> and Ehab L. Atallah, MD<sup>7</sup>

<sup>1</sup>Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA

<sup>2</sup>Department of Hematology/HCT, City of Hope, Duarte, CA

<sup>3</sup>Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

<sup>4</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

<sup>5</sup>MEI Pharma, Inc., San Diego, CA

<sup>6</sup>Clinical Research and Development, Helsinn Healthcare, Lugano, Switzerland

<sup>7</sup>Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

#### 4370 Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Ling Zhang, MD<sup>1\*</sup>, Donald M Stablein, PhD<sup>2\*</sup>, Pearlie Epling-Burnette, PhD, PharmD<sup>3\*</sup>, Alexandra M. Harrington, MD, MT(ASCP)<sup>4</sup>, Lynn C. Moscinski, MD<sup>5</sup>, Steven Kroft, MD<sup>4\*</sup>, Amy E. DeZern, MD<sup>6</sup>, Tareq Al Baghdadi, MD<sup>7\*</sup>, Jane Jijun Liu, MD<sup>8\*</sup>, Matthew J. Walter, MD<sup>9</sup>, Rafael Bejar, MD, PhD<sup>10</sup>, Edward J. Gorak, DO, MBA, MS<sup>11</sup>, Rami S. Komrokji, MD<sup>12</sup>, Gregory A. Abel, MD, MPH<sup>13</sup>, Bart L Scott, MD<sup>14</sup>, Steven D. Gore, MD<sup>15</sup> and **Mikkael A. Sekeres, MD, MS**<sup>16</sup>

<sup>1</sup>University of South Florida, Moffitt Cancer Center, Tampa, FL

<sup>2</sup>The Emmes Corporation, Rockville, MD

<sup>3</sup>Moffitt Cancer Center & Research Institute/Immunology Program, Tampa, FL

<sup>4</sup>Medical College of Wisconsin, Milwaukee, WI

<sup>5</sup>H. Lee Moffitt Cancer Center, Tampa, FL

<sup>6</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>7</sup>IHA Hematology Oncology Consultants, Ypsilanti, MI

<sup>8</sup>Illinois Cancer Care, P.C., Peoria, IL

<sup>9</sup>Department of Medicine, Division of Oncology, Washington University In St. Louis, Saint Louis, MO

<sup>10</sup>Moores Cancer Center, University of California, San Diego, La Jolla, CA

<sup>11</sup>Baptist MD Anderson Cancer Center, Jacksonville, FL

<sup>12</sup>Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>13</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>14</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>15</sup>Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT

<sup>16</sup>Leukemia Program, Cleveland Clinic, Cleveland, OH

#### **4374 Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, MDS, Study Population, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David P. Steensma, MD<sup>1</sup>, Rami S. Komrokji, MD<sup>2</sup>, Amy E. DeZern, MD<sup>3</sup>, Gail J. Roboz, MD<sup>4</sup>, Andrew M. Brunner, MD<sup>5</sup>, Richard M. Stone, MD<sup>1</sup>, John Barnard, PhD<sup>6\*</sup> and **Mikkael A. Sekeres, MD, MS**<sup>7</sup>

<sup>1</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>2</sup>Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

<sup>3</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

<sup>4</sup>Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

<sup>5</sup>Massachusetts General Hospital, Boston, MA

<sup>6</sup>Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland

<sup>7</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

#### **4389 Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations**

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, AML, CML, MDS, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, NGS

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Vera Adema, PhD<sup>1\*</sup>, Cassandra M. Hirsch<sup>1\*</sup>, Bartlomiej Przychodzen<sup>1\*</sup>, Yasunobu Nagata<sup>1\*</sup>, **Tomas Radivoyevitch**<sup>2,3\*</sup>, **Thomas Laframboise, PhD**<sup>4\*</sup>, Amy C Graham, BS, MS<sup>1\*</sup>, Louis Williams, MD, MBA<sup>1</sup>, Hassan Awada, MD<sup>1</sup>, Aziz Nazha, MD<sup>5</sup>, Hetty E. Carraway, MD, MBA<sup>5,6</sup>, Valeria Santini<sup>7</sup>, Hrishikesh M

**Mehta, PhD<sup>1,8,9\*</sup>, Francesc Sole, PhD<sup>10</sup>, Mikkael A. Sekeres, MD, MS<sup>5</sup>, Valeria Visconte, PhD<sup>1</sup>, Rabi Hanna, MD<sup>9</sup>, Seth J. Corey, MD<sup>1,9,11</sup> and Jaroslaw P. Maciejewski<sup>12</sup>**

<sup>1</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

<sup>3</sup>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

<sup>5</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>MDS Unit, AOU Careggi, University of Florence, Florence, Italy

<sup>8</sup>Division of Hematology-Oncology, Department of Pediatrics, Virginia Commonwealth University, Richmond

<sup>9</sup>Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

<sup>10</sup>MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

<sup>11</sup>Departments of Pediatrics, Microbiology/Immunology, Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA

<sup>12</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

## **4410 Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings**

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Hematology Disease Topics & Pathways:

Adult, Biological, Leukemia, Diseases, Therapies, CLL, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement , TKI

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Lindsey E. Roeker, MD<sup>1</sup>, Christopher P. Fox, MD, PhD<sup>2\*</sup>, Toby A. Eyre<sup>3\*</sup>, John N. Allan, MD<sup>4</sup>, Stephen J. Schuster, MD<sup>5</sup>, Chadi Nabhan, MD<sup>6</sup>, Brian T. Hill, MD, PhD<sup>7,8</sup>, Nirav N Shah, MD<sup>9</sup>, Frederick Lansigan, MD<sup>10</sup>, Maryam Yazdy, MD<sup>11</sup>, Nicole Lamanna, MD<sup>12</sup>, Bruce Cheson, MD<sup>13</sup>, Arun K Singavi, MD<sup>9</sup>, Catherine C. Coombs, MD<sup>14</sup>, Paul Barr, MD<sup>15</sup>, Alan P Skarbnik, MD<sup>16</sup>, Mazyar Shadman, MD, MPH<sup>17</sup>, Hande H. Tuncer, MD<sup>18</sup>, Chaitra S. Ujjani, MD<sup>17</sup>, Allison M. Winter, MD<sup>19</sup>, Joanna Rhodes, MD<sup>5</sup>, Colleen Dorsey, BSN, RN<sup>1\*</sup>, Hannah Morse, BSN<sup>20\*</sup>, John M. Pagel, MD, PhD<sup>21</sup>, Annalynn M Williams, MS<sup>22</sup>, Ryan Jacobs, MD<sup>23</sup>, Andre Goy, MD<sup>24</sup>, Sivraj Muralikrishnan, MD<sup>10</sup>, Laurie Pearson, MD<sup>18\*</sup>, Andrea Sitlinger, MD<sup>25</sup>, Neil Bailey, MSc<sup>21\*</sup>, Anna Schuh, MD<sup>26</sup>, Danielle M. Brander, MD<sup>27</sup>, Amy A Kirkwood, MSc<sup>28\*</sup> and Anthony R Mato, MD<sup>20</sup>

<sup>1</sup>CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

<sup>2</sup>Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

<sup>3</sup>Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom

<sup>4</sup>Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

<sup>5</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

<sup>6</sup>Cardinal Health Specialty Solutions, Deerfield, IL

<sup>7</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>8</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI

<sup>10</sup>Dartmouth-Hitchcock Medical Center, Lebanon, NH

<sup>11</sup>Department of hematology and oncology, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

<sup>12</sup>Hematology/Oncology Division, Columbia University Medical Center, New York, NY

<sup>13</sup>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

<sup>14</sup>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

<sup>15</sup>University of Rochester, Rochester, NY

<sup>16</sup>John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ

<sup>17</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>18</sup>Tufts Medical Center, Boston, MA

<sup>19</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

<sup>20</sup>CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>21</sup>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

<sup>22</sup>University of Rochester Medical Center, Rochester, NY

<sup>23</sup>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

<sup>24</sup>John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

<sup>25</sup>Department of Medicine, Duke University Medical Center, Durham, NC

<sup>26</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

<sup>27</sup>Duke Cancer Institute, Duke University Health System, Durham, NC

<sup>28</sup>Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom

## 4414 Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Hematology Disease Topics & Pathways:

Leukemia, Diseases, CLL, Clinically relevant, Lymphoid Malignancies, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Brian Koffman, MDCM, DCFP, DABFM, MS Ed<sup>1\*</sup>, Betsy Dennison, MS, RN<sup>2\*</sup>, Kaitlin Kennard, RN, BSN<sup>3\*</sup>, John C. Byrd, MD<sup>4</sup>, Richard R. Furman, MD<sup>5</sup>, John M. Pagel, MD, PhD<sup>6</sup>, Matthew S Davids<sup>7</sup>, Chadi Nabhan, MD<sup>8</sup>, Neil E. Kay, MD<sup>9</sup>, Tanya Siddiqi, MD<sup>10</sup>, Danielle M. Brander, MD<sup>11</sup>, William G. Wierda, MD, PhD<sup>12</sup>, Deborah M. Stephens<sup>13</sup>, Brian T. Hill, MD, PhD<sup>14,15</sup>, Javier Pinilla Ibarz, MD<sup>16</sup>, Bruce Cheson, MD<sup>17</sup>, Steven T Rosen<sup>18</sup>, Farrukh T. Awan, MD<sup>19,20</sup>, Michael Y. Choi, MD<sup>21</sup>, Thomas E Henry, MBA, RPh, CPh<sup>16\*</sup>, Lindsey E. Roeker, MD<sup>22</sup> and Anthony R. Mato, MD MSCE<sup>22</sup>*

<sup>1</sup>CLL Society, Claremont, CA

<sup>2</sup>Clarity Communications, Pompton Lakes, NJ

<sup>3</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

<sup>4</sup>Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

<sup>5</sup>Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

<sup>6</sup>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

<sup>7</sup>Department of Medical Oncology, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA

<sup>8</sup>Cardinal Health Specialty Solutions, Dublin, OH

<sup>9</sup>Division of Hematology, Mayo Clinic, Rochester, MN

<sup>10</sup>City of Hope National Medical Center, Duarte, CA

<sup>11</sup>Duke Cancer Institute, Duke University Health System, Durham, NC

<sup>12</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

<sup>13</sup>University of Utah Huntsman Cancer Institute, Salt Lake City, UT

<sup>14</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>15</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>16</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

<sup>17</sup>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

<sup>18</sup>Beckman Research Institute, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA

<sup>19</sup>The Ohio State University, Dallas, TX

<sup>20</sup>Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX

<sup>21</sup>Moores Cancer Center, University of California San Diego, La Jolla, CA

<sup>22</sup>CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

## 4603 Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III

Hematology Disease Topics & Pathways:

Adult, Diseases, AML, Therapies, Non-Biological, chemotherapy, Biological Processes, Technology and Procedures, Study Population, cytogenetics, Clinically relevant, Myeloid Malignancies, immune mechanism, NGS

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Sagar S. Patel, MD<sup>1</sup>, Betty K. Hamilton, MD<sup>1</sup>, Lisa Rybicki, MS<sup>2\*</sup>, Dawn Thomas<sup>3\*</sup>, Arden Emrick<sup>1\*</sup>, Aziz Nazha, MD<sup>4</sup>, Sudipto Mukherjee, MD, PhD, MPH<sup>4</sup>, Anjali S. Advani, MD<sup>4</sup>, Hetty E. Carraway, MD, MBA<sup>4,5</sup>, Brad Pohlman, MD<sup>6</sup>, Brian J. Bolwell, MD<sup>1</sup>, Robert M. Dean, MD<sup>1</sup>, Aaron T. Gerds, MD, MS<sup>1</sup>, Rabi Hanna, MD<sup>7</sup>, Matt Kalaycio, MD<sup>1</sup>, Aiwen Zhang, PhD<sup>8\*</sup>, Mikael A. Sekeres, MD, MS<sup>4</sup>, Jaroslaw P. Maciejewski<sup>9</sup>, Navneet S. Majhail, MD, MS<sup>1</sup>, Medhat Askar, MD, PhD<sup>10\*</sup> and Ronald Sobecks, MD<sup>1</sup>*

<sup>1</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Allogen Laboratories, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>6</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Pediatric Blood and Marrow Transplant Program, Pediatrics Institute and Children's Hospital, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Department of Pathology and Laboratory Medicine, Baylor University Medical Center, Dallas, TX

## **4627 Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes**

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster III

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Najla H El Jurdi, MD<sup>1</sup>, Ali Filali, PhD<sup>2\*</sup>, Iman Salem, MD<sup>2\*</sup>, Mauricio Retuerto, MS<sup>2\*</sup>, Nina Dambrosio, CNP<sup>3\*</sup>, Hillard M Lazarus, MD<sup>4</sup>, Paolo F Caimi, MD<sup>5</sup>, Richard Creger, PharmD<sup>3\*</sup>, Brenda Cooper, MD<sup>6</sup>, Ben Tomlinson, MD<sup>7</sup>, Leland Metheny, MD<sup>7</sup>, Ehsan Malek, MD<sup>8</sup>, Folashade Otegbeye, MBBChir, MPH<sup>9</sup>, Rafick-Pierre Sekaly, PhD<sup>2\*</sup>, Mahmoud Ghannoum, PhD<sup>2\*</sup> and Marcos de Lima, MD<sup>7</sup>

<sup>1</sup>Hematology, Oncology and Transplantation, University of Minnesota, MINNEAPOLIS, MN

<sup>2</sup>Case Western Reserve University, Cleveland, OH

<sup>3</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>4</sup>Case Western Reserve University School of Medicine, Cleveland, OH

<sup>5</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

<sup>6</sup>Adult Hematologic Malignancies and Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>7</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>8</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

<sup>9</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

## **4695 National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014**

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Mohamed Mokhtar Bakr, MD<sup>1\*</sup>, Umar Zahid, MD, MPH<sup>2,3\*</sup>, Pavan Tenneti, MD<sup>4\*</sup>, Alsadiq Waleed Al-Hillan, MD<sup>5\*</sup> and Faiz Anwer, MD<sup>6,7</sup>

<sup>1</sup>Jersey Shore University Medical Center, New Jersey

<sup>2</sup>Jersey Shore University Medical Center, Neptune, NJ

<sup>3</sup>Johns Hopkins University, Baltimore, MD

<sup>4</sup>University of Arizona, Tucson, AZ

<sup>5</sup>Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ

<sup>6</sup>Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

<sup>7</sup>Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

## **4709 Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector**

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Atin Jindal, MD<sup>1\*</sup>, Jan Kover, BPharm<sup>2\*</sup>, Vanja Raduka, PharmD, R.Ph<sup>3\*</sup> and Timothy E. O'Brien, MD<sup>4</sup>

<sup>1</sup>Department of Medicine, Case Western Reserve University, MetroHealth Campus, Cleveland, OH

<sup>2</sup>MetroHealth Medical Center, Cleveland, OH

<sup>3</sup>MetroHealth Hospital, Cleveland, OH

<sup>4</sup>MetroHealth Medical Center/Case Western Reserve Univ School of Medicine, Cleveland, OH

## **4718 Identifying Neutropenic Fever Earlier: An Application of a Skin Patch for Continuous Temperature Monitoring**

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Nina Dambrosio, CNP<sup>1</sup>\*, Molly Porter, CNP<sup>2</sup>\*, Erica Bauer, RN<sup>2</sup>\*, Nathan Levitan, MD<sup>3</sup>\*, Deborah Liedtke, RN<sup>2</sup>\*, Marcos de Lima, MD<sup>4</sup> and Ehsan Malek, MD<sup>5</sup>***

<sup>1</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>2</sup>Seidman Cancer Center, Adult Stem Cell Transplant, Cleveland, OH

<sup>3</sup>University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>4</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>5</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

## **4731 Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect<sup>®</sup> MDS/AML Disease Registry**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Biological, Diseases, Therapies, Non-Biological, chemotherapy, MDS, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Christopher R. Cogle, MD<sup>1</sup>, Guillermo Garcia-Manero, MD<sup>2</sup>, David L. Grinblatt<sup>3</sup>, Rami S. Komrokji, MD<sup>4</sup>, Michael R. Savona, MD<sup>5</sup>, Bart L. Scott, MD<sup>6</sup>, Mikkael A. Sekeres, MD, MS<sup>7</sup>, Chrystal U. Louis<sup>8</sup>\*, E. Dawn Flick<sup>9</sup>\*, Melissa Nifenecker<sup>8</sup>\*, Pavel Kiselev<sup>8</sup>\*, Arlene S. Swern<sup>8</sup>\* and David P. Steensma<sup>10</sup>***

<sup>1</sup>University of Florida, Gainesville, FL

<sup>2</sup>MD Anderson Cancer Center, Houston, TX

<sup>3</sup>NorthShore University HealthSystem, Evanston, IL

<sup>4</sup>Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

<sup>5</sup>Vanderbilt-Ingram Cancer Center, Nashville, TN

<sup>6</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>7</sup>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>8</sup>Celgene Corporation, Summit, NJ

<sup>9</sup>Celgene Corporation, San Francisco, CA

<sup>10</sup>Dana-Farber Cancer Institute, Boston, MA

## **4736 Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect<sup>®</sup> MDS/AML Disease Registry**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Biological, AML, Diseases, Therapies, Myeloid Malignancies, transfusion

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Sudipto Mukherjee, MD, PhD, MPH<sup>1</sup>, Mehrdad Abedi, MD<sup>2</sup>, Harry P. Erba, MD, PhD<sup>3</sup>, Daniel A Polleyea, MD<sup>4</sup>, Gail J. Roboz, MD<sup>5</sup>, Michael A. Thompson, MD, PhD, FASCO<sup>6</sup>, Chrystal U. Louis<sup>7</sup>\*, E. Dawn Flick<sup>8</sup>\*, Melissa Nifenecker<sup>7</sup>\*, Pavel Kiselev<sup>7</sup>\*, Arlene S. Swern<sup>7</sup>\* and Christopher R. Cogle, MD<sup>9</sup>***

<sup>1</sup>Cleveland Clinic, Cleveland, OH

<sup>2</sup>University of California Davis Comprehensive Cancer Center, Sacramento, CA

<sup>3</sup>University of Alabama at Birmingham, Birmingham, AL

<sup>4</sup>University of Colorado, Denver, CO

<sup>5</sup>Weill Cornell Medical College, New York, NY

<sup>6</sup>Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI

<sup>7</sup>Celgene Corporation, Summit, NJ

<sup>8</sup>Celgene Corporation, San Francisco, CA  
<sup>9</sup>University of Florida, Gainesville, FL

## **4755 Early Infectious Complications after Autologous Hematopoietic Cell Transplantation (AHCT) for Lymphoma**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Lymphoma (any), Study Population, Lymphoid Malignancies, Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Shafia Rahman, MD<sup>1</sup>, Lisa Rybicki, MS<sup>2\*</sup>, Eric Cober, MD<sup>3\*</sup>, Robert M. Dean, MD<sup>4</sup>, Betty K. Hamilton, MD<sup>5</sup>, Deepa Jagadeesh, MD, MPH<sup>4</sup>, Brian T. Hill, MD, PhD<sup>6,7</sup>, Brad Pohlman, MD<sup>8</sup>, Ronald Sobecks, MD<sup>9</sup>, Matt Kalaycio, MD<sup>9</sup>, Sherif Mossad, MD<sup>3\*</sup> and Navneet S. Majhail, MD, MS<sup>9</sup>***

<sup>1</sup>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Department of Infectious Disease, Medicine Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

<sup>6</sup>Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>8</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>9</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

## **4759 Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study**

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Diseases, Leukemia, Therapies, Non-Biological, CLL, chemotherapy, Clinically relevant, Lymphoid Malignancies, pharmacology

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Anthony R Mato, MD<sup>1</sup>, Maryam Sarraf Yazdy, MD<sup>2\*</sup>, Brian T. Hill, MD, PhD<sup>3,4</sup>, Mazyar Shadman<sup>5\*</sup>, Hande Tuncer, MD<sup>6\*</sup>, Allison M. Winter, MD<sup>7</sup>, Kaitlin Kennard, RN, BSN<sup>8\*</sup>, John N. Allan, MD<sup>9</sup>, Chaitra S. Ujjani, MD<sup>10</sup>, Danielle M. Brander, MD<sup>11</sup>, Chadi Nabhan, MD<sup>12</sup>, Paul Barr, MD<sup>13</sup>, Jennifer R. Brown, MD, PhD<sup>14</sup>, Christopher P. Fox, MD, PhD<sup>15\*</sup>, Joanna Rhodes, MD<sup>16</sup>, Anna Schuh, MD<sup>17</sup>, Toby A. Eyre, MD<sup>18\*</sup>, Nicole Lamanna, MD<sup>19\*</sup>, Nitin Jain, MD<sup>20</sup>, William G. Wierda, MD, PhD<sup>21</sup>, Alan P Skarbnik, MD<sup>22</sup>, Lindsey E. Roeker, MD<sup>23</sup>, Rajat Bannerji, MD, PhD<sup>24</sup>, Andrew M. Evens, MD<sup>25\*</sup>, Frederick Lansigan, MD<sup>26</sup>, Jennifer C. Samp, MS, PharmD<sup>27\*</sup>, Jacqueline Nielsen, PhD<sup>28\*</sup>, James M. Pauff<sup>27\*</sup>, Thomas J. Kipps, MD, PhD<sup>29</sup>, Stephen J. Schuster, MD<sup>30</sup>, George A Follows, MD, PhD<sup>31\*</sup>, Bruce Cheson, MD<sup>32</sup> and Barbara Eichhorst<sup>33\*</sup>***

<sup>1</sup>CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>2</sup>Division of Hematology, Medstar Georgetown University Hospital, Washington, DC

<sup>3</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>6</sup>Tufts Medical Center, Boston, MA

<sup>7</sup>Cleveland Clinic, Cleveland, OH

<sup>8</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

<sup>9</sup>Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

<sup>10</sup>Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>11</sup>Duke Cancer Institute, Duke University Health System, Durham, NC

<sup>12</sup>Cardinal Health Specialty Solutions, Deerfield, IL

<sup>13</sup>University of Rochester, Rochester, NY

<sup>14</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>15</sup>Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

<sup>16</sup>Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA

<sup>17</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

<sup>18</sup>Churchill Hospital, Oxford University, Oxford, United Kingdom

<sup>19</sup>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY  
<sup>20</sup>Department of Leukemia, MD Anderson Cancer Center, Houston, TX  
<sup>21</sup>Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX  
<sup>22</sup>John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ  
<sup>23</sup>CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY  
<sup>24</sup>Cancer Institute of New Jersey, New Brunswick, NJ  
<sup>25</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
<sup>26</sup>Dartmouth-Hitchcock Medical Center, Lebanon, NH  
<sup>27</sup>AbbVie Inc., North Chicago, IL  
<sup>28</sup>AbbVie, Inc., North Chicago, IL  
<sup>29</sup>Moores Cancer Center, University of California School, San Diego, CA  
<sup>30</sup>Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA  
<sup>31</sup>Haematology, Cambridge University Hospitals NHS Foundation Trust (on behalf of the UK CLL forum), Cambridge, United Kingdom  
<sup>32</sup>Georgetown Univ. Hosp. Lombardi Cancer Ctr., Washington, DC  
<sup>33</sup>University Hospital Cologne, Cologne, Germany

#### 4768 Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Young Adult, Study Population

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Reema R Mathanda, MD<sup>1</sup>, Betty K. Hamilton, MD<sup>2</sup>, Lisa Rybicki, MS<sup>3</sup>, Anjali S. Advani, MD<sup>4</sup>, Brian J. Bolwell, MD<sup>4</sup>, Amy Colver, LISW<sup>4</sup>, Jane Dabney, LISW-S<sup>4</sup>, Christina Ferraro, CNP<sup>4</sup>, Aron Flagg, MD<sup>1</sup>, Rabi Hanna, MD<sup>5</sup>, Matt Kalaycio, MD<sup>4</sup>, Christine Lawrence, LISW-S<sup>4</sup>, Linda McLellan, LISW<sup>4</sup>, Ronald Sobecks, MD<sup>4</sup> and Navneet S. Majhail, MD, MS<sup>4</sup>

<sup>1</sup>Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>5</sup>Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

#### 4788 The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Adult, Study Population, Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Jason Tay, MD<sup>1</sup>, Ruta Brazauskas, PhD<sup>2,3</sup>, Naya He<sup>3</sup>, Sara Beattie<sup>4</sup>, Christopher Bredeson, MD, FRCPC, MSc<sup>5</sup>, Jignesh Dalal, MD<sup>6</sup>, Shahrukh K. Hashmi, MD, MPH<sup>7,8</sup>, Theresa E. Hahn, PhD<sup>9</sup>, Nandita Khera, MD<sup>10</sup>, William A. Wood, MD, MPH<sup>11</sup> and Wael Saber, MD, MS<sup>3</sup>

<sup>1</sup>Univ. of Ottawa/Ottawa Hosp., Calgary, AB, Canada

<sup>2</sup>Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

<sup>3</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

<sup>4</sup>Department of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, AB, Canada

<sup>5</sup>Ottawa General Hospital, Ottawa, ON, CAN

<sup>6</sup>Rainbow Babies & Children's Hospital, Cleveland, OH

<sup>7</sup>Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

<sup>8</sup>Department of Internal Medicine, Mayo Clinic, Rochester, MN

<sup>9</sup>Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>10</sup>Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

<sup>11</sup>Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC

#### 4802 Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Adult, antibodies, Biological, multiple myeloma, Diseases, Therapies, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sarah S Lee, MD, Nathaniel Rosko, PharmD\*, Pramod Pinnamaneni, MD, Craig Savage\*, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO and Jason Valent, MD

*Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*

**4804 Results from the ITP World IMPACT Survey (I-WISh): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives**

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

autoimmune disorders, Diseases, Bleeding and clotting, ITP, Immune Disorders

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Nichola Cooper, MRCP<sup>1</sup>, Alexandra Kruse<sup>2\*</sup>, Caroline Kruse<sup>2\*</sup>, Shirley Watson<sup>3\*</sup>, Mervyn Morgan<sup>3\*</sup>, James B. Bussel, MD<sup>4</sup>, Waleed Ghanima<sup>5</sup>, Donald M. Arnold, MD, MSc, FRCPC<sup>6</sup>, Cristina Santoro<sup>7\*</sup>, Ming Hou, MD<sup>8\*</sup>, Yoshiaki Tomiyama, MD<sup>9</sup>, Serge Laborde<sup>10\*</sup>, Barbara Lovrencic<sup>11\*</sup>, John Waller, PhD, BSc<sup>12\*</sup>, Tom Bailey<sup>12\*</sup>, Gavin Taylor-Stokes<sup>12\*</sup>, Miona Stankovic<sup>13\*</sup> and Andrew Provan<sup>14\*</sup>

<sup>1</sup>Hammersmith Hospital, Imperial College London, London, United Kingdom

<sup>2</sup>Platelet Disorder Support Association, Cleveland

<sup>3</sup>ITP Support Association, Bolnhurst, United Kingdom

<sup>4</sup>Division of Hematology/Oncology, Weill Cornell Medical College, New York

<sup>5</sup>Department of Medicine, Ostfold Hospital Trust, Kongsberg, Norway

<sup>6</sup>Department of Medicine, McMaster University, Hamilton, Canada

<sup>7</sup>Department of Cellular Biotechnologies & Haematology, 'Sapienza' University of Rome, Rome, Italy

<sup>8</sup>Department of Hematology, Shandong University, Jinan, China

<sup>9</sup>Osaka University Hospital, Osaka, Japan

<sup>10</sup>O'Cyto, Saint Loubes, France

<sup>11</sup>Italian Association Immune Thrombocytopenic Purpura, Caprino Veronese, Italy

<sup>12</sup>Bespoke Team, Adelphi Real World, Macclesfield, United Kingdom

<sup>13</sup>Novartis Pharma AG, Basel, Switzerland

<sup>14</sup>Barts and The London School of Medicine and Dentistry, London, United Kingdom

**4805 Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis**

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Madeline Waldron, PharmD<sup>1\*</sup>, Caitlin Siebenaller, PharmD<sup>2\*</sup>, Brian P. Hobbs, PhD<sup>3\*</sup>, Marc Earl, PharmD<sup>2\*</sup>, Mary Schleicher<sup>4\*</sup>, Hetty E. Carraway, MD, MBA<sup>5,6</sup>, Anjali S. Advani, MD<sup>7</sup>, Aziz Nazha, MD<sup>8</sup>, Aaron T. Gerds, MD, MS<sup>5</sup>, Betty K. Hamilton, MD<sup>5</sup>, Ronald Sobecks, MD<sup>9</sup>, Matt Kalaycio, MD<sup>9</sup>, Mikkael A. Sekeres, MD, MS<sup>10</sup> and Sudipto Mukherjee, MD, PhD, MPH<sup>10</sup>

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Pharmacy, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Medical Library Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

<sup>5</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>6</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>7</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>8</sup>Cleveland Clinic, Cleveland, OH

<sup>9</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## 4806 Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia

### Patients on Duration of Hospital Stay

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Madeline Waldron, PharmD<sup>1\*</sup>, Caitlin Siebenaller, PharmD<sup>2\*</sup>, Marc Earl, PharmD<sup>2\*</sup>, Xuefei Jia, MS<sup>3\*</sup>, Hetty E. Carraway, MD, MBA<sup>4,5</sup>, Anjali S. Advani, MD<sup>6</sup>, Aziz Nazha, MD<sup>7</sup>, Aaron T. Gerds, MD, MS<sup>8</sup>, Betty K. Hamilton, MD<sup>4</sup>, Ronald Sobecks, MD<sup>9</sup>, Matt Kalaycio, MD<sup>9</sup>, Barb Tripp, CNS<sup>10\*</sup>, Brian P. Hobbs, PhD<sup>3\*</sup>, Mikael A. Sekeres, MD, MS<sup>11</sup> and Sudipto Mukherjee, MD, PhD, MPH<sup>11</sup>**

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Department of Pharmacy, Cleveland Clinic, Cleveland, OH

<sup>3</sup>Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>4</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>5</sup>Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

<sup>6</sup>Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>7</sup>Cleveland Clinic, Cleveland, OH

<sup>8</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

<sup>9</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

<sup>10</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>11</sup>Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## 4809 Clinical Outcomes of Isolated Distal Deep Vein Thrombosis Associated with Cancer: The Cleveland Clinic Experience

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bleeding and clotting, Clinically relevant, VTE

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Shyam K. Poudel, MD<sup>1\*</sup>, Xuefei Jia, MS<sup>2\*</sup>, Deborah Y. Park, BS<sup>3\*</sup>, Mailey Lynn Wilks, CNP, MSN, APRN<sup>1\*</sup>, Vicki Pinkava, MSBS, PA-C<sup>1\*</sup>, Meghan O'Brien, MS, ANP-BC<sup>1\*</sup>, Barbara Tripp, CNS, AOCN<sup>1\*</sup>, Jung-Min Song, RN, CNS<sup>1\*</sup>, Keith R. McCrae, MD<sup>4</sup>, Alok A. Khorana<sup>1</sup> and Dana E. Angelini, MD<sup>1</sup>**

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

<sup>2</sup>Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH

<sup>4</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

## 4832 Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Rajshekhar Chakraborty, MBBS<sup>1</sup>, Lisa Rybicki, MS<sup>2\*</sup>, Christy J. Samaras, DO<sup>3</sup>, Beth M. Faiman, PhD, CNP<sup>3</sup>, Jason Valent, MD<sup>1</sup> and Navneet S. Majhail, MD, MS<sup>4</sup>**

<sup>1</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>Cleveland Clinic Foundation, Cleveland, OH

<sup>3</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>4</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

## 4834 Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Megan Sturdy, MD<sup>1</sup>, Rebecca Ye, BA<sup>2</sup>, Trevor L Jenkins, MD<sup>3</sup>, James Driscoll, MD, PhD<sup>4</sup>, Paolo Caimi, MD<sup>5</sup>, Leland Metheny, MD<sup>6</sup>, Rachel Zebrowski, RN<sup>7</sup>, Nicole Ferrari<sup>8</sup>, Merle Kolk<sup>9</sup>, Marcos de Lima, MD<sup>9</sup> and Ehsan Malek, MD<sup>10</sup>*

<sup>1</sup>University Hospitals Richmond Medical Center, Cleveland, OH

<sup>2</sup>New York University, Cleveland, OH

<sup>3</sup>Harrington Heart & Vascular Institute, University Hospital Cleveland Medical Center, Cleveland, OH

<sup>4</sup>Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

<sup>5</sup>University Hospitals of Cleveland, Cleveland, OH

<sup>6</sup>Stem Cell Transplant Program, University Hospitals Cleveland Medical Center, Cleveland, OH

<sup>7</sup>University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>8</sup>University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>9</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

<sup>10</sup>Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

#### **4835 Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis**

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, multiple myeloma, Plasma Cell Disorders, Study Population, Lymphoid Malignancies,

Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

*Rajshekhar Chakraborty, MBBS<sup>1</sup>, Saad Ullah Malik<sup>2</sup>, Naimisha Marneni<sup>3</sup>, Alex V. Mejia Garcia, MD<sup>3</sup>, Faiz Anwer, MD<sup>4,5</sup>, Alok A. Khorana<sup>6</sup> and Navneet S. Majhail, MD, MS<sup>7</sup>*

<sup>1</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>2</sup>University of Arizona, Tucson

<sup>3</sup>Cleveland Clinic, Cleveland

<sup>4</sup>Taussig Cancer Institute, Cleveland Clinic, Cleveland

<sup>5</sup>University of Arizona, Tucson, AZ

<sup>6</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

<sup>7</sup>Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH